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YOHANNES TSEGAI GHEBREMARIAM (August 2006) 
THESIS TITLE: EVALUATION OF THE IN VIVO ROLE OF VACCINIA VIRUS COMPLEMENT 
CONTROL PROTEIN (VCP) FOLLOWING RENAL ISCHEMWREPERFUSION INJURY 
ABSTRACT: In transplantation, vascularized organs often suffer the consequences of ischemic 
damage as well as reperfusion injury following the reestablishment of blood flow. The induced 
ischemialreperfusion (I/R) damage is usually associated with the accumulation of injurious 
complement components. The vaccinia virus complement control protein (VCP) has the ability 
to simultaneously inhibit the classical and the alternative complement pathways by binding to 
the early components C3b and C4b. The complement component C3 is known to be the central 
route to all of the known complement activation pathways. As a result, it is involved in a 
number of complement-mediated ailments including renal ischemialreperfusion injury. 
The objectives of this study were to initially evaluate the in vitro roles of the natural VCP and 
the humanized recombinant VCP (hrVCP), and then to establish their in vivo roles in a renal 
I/R injury model. 
The recombinant VCP was produced both in flasks and the fermentor, while the natural VCP 
was produced in tissue culture. The in vitro activities of the proteins were tested for their 
ability to inhibit the classical and the alternative complement pathways using a hemolysis 
assay, and the production of pathway-specific fragment (Bb) respectively. The proteins were 
found to be biologically active in inhibiting complement activation at various concentrations. 
The in vivo role ofVCPlhrVCP was investigated by subjecting Long Evans rats to bilateral IIR 
injury by clamping both the renal arteries for 60 minutes followed by 24 hours of reperfusion. 
The animals were randomly allocated to receive VCPlhrVCP, phosphate buffered saline (PBS) 
or sham groups. Blood samples were collected and the kidneys removed for histopathological 
and immunohistochemical studies. The biochemical studies showed that the PBS group (n = 4) 
displayed 2.7-fold and lO-fold increases in the serum urea and creatinine concentrations 
respectively compared to the VCPlhrVCP groups. Moreover, the histopathological study 
revealed severe tubular damage in the PBS group compared to the focal tubular injury in the 
VCP (n = 3) and hrVCP (n = 3) treated animals. The immunohistochemical study displayed 
marked deposition of C3 in the renal tubules of the PBS group compared to the focal C3 
staining in the VCPlhrVCP groups suggesting the ability of VCPlhrVCP to ameliorate renal 
IIR injury by inhibiting the local biosynthesis ofC3. 
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LITERATURE REVIEW: 
CHAPTER 1: COIvIPLEMENT INHIBITORY PROTEINS 
1.1 Poxviruses 
The genus Orthopoxvirus, is one of the eight genera, which constitute vertebrate poxviruses, 

and belongs to the family of Poxviridae, Chordopoxvirinae subfamily. The genus includes a 

number of poxviruses, which are large cytoplasmic DNA viruses with an average genome size 

of200kbp (above 10-fold larger than HIV genome). Some ofthe better known members of this 

genus are the camelpox, cowpox, vaccinia, monkeypox and variola (commonly known as 

smallpox virus) viruses (Smith and Kotwal, 2002). The latter two members have been shown to 

establish serious infection in humans. The variola virus is the only member known to only 

, infect humans and has claimed thousands oflives before its successful eradication following an 

efficient vaccination program launched by the World Health Organization (WHO) 

(Henderson i , 1999; Henderson2, 1999; Henderson et ai, 1999; Henderson and Fenner, 2001; 

Wittek, 2006) 
1.2 Complement Inhibitors Encoded by Poxviruses 
Besides the molecules for viral replication, poxviruses also encode a stock of proteins that 
nullify the host immune defense mechanism. Some of the defense molecules engaged in 
clearing viral infection include cytokines, chemokines and complement (Alcami et ai, 2000; 
Kotwal, 2000; Smith and Kotwal, 2002). Poxviruses possess more than one defense 
mechanism for the same antiviral molecule encoded by the host. For example, the viruses 
encode proteins (known as "immunomodulatory proteins") that block the synthesis of 
cytokines as well as proteins that bind, and therefore inhibit, already synthesized cytokine 
molecules (Kotwal, 2000). These lines ofdefense encoded by poxviruses not only enable them 
to successfully subvert destruction but also suggest that the viruses have salvage mechanisms 
to challenge the host defense. Members of poxviruses which encode complement inhibitory 
proteins (known as "virokines" [Kotwal, 2000; Smith and Kotwal, 2001]) include variola, 
vaccinia, cowpox and monkeypox viruses. The encoded proteins enable the viruses to 
persistently infect target cells despite the immune challenges from the host. Although this 
appears to be a common in vivo role played by the viral complement inhibitors, there is 
significant difference in their ability and preference to inhibit host complement. Some of the 
well-studied complement inhibitors are described below. 
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1.2.1 Smallpox Inhibitor of Complement Enzymes (SPICE) 
The variola (smallpox) virus is known for its virulence. Despite its eradication, the genome of 
the virus, its mechanisms of disease causation and host discrimination are still being kept under 
close scrutiny (Dunlop et aI, 2003). Understanding the variola genome and its subsequent 
proteins not only help researchers to prepare for any eventuality of its reemergence (De Clercq, 
2001), but also provide the opportunity to use some of its proteins, such as those engaged in 
inhibiting human complement during infection, for therapeutic purposes in patients suffering 
from uncontrolled complement disorders such as autoimmune diseases. One of such potentially 
therapeutic proteins encoded by smallpox virus is SPICE. 
SPICE, a potent complement inhibitor encoded by variola virus in the left terminal region of its 
genome, is a 28.158 kDa (Sfyroera et aI, 2005) protein composed of four short consensus 
repeats (SCRs; usually composed of 60-70 amino acids) of 61 amino acids each. The SCRs are 
interlinked by disulphide bonds (Zhang and Morikis, 2006). 
Although its crystal structure has not yet been determined, both its remarkable amino acid 
homology (95% identity) and modeling studies suggest that SPICE is structurally similar to the 
crystallized (Murthy et ai, 2001) vaccinia virus encoded complement inhibitor, the vaccinia 
virus complement control protein (VCP) (Rosengard et aI, 2002; Dunlop et aI, 2003). 
Functionally, in addition to its similarity to poxviral proteins such as VCP, the cowpox 
encoded inflammation modulatory protein (IMP) and the recently characterized monkeypox 
encoded inhibitor of complement enzymes termed by the authors as MOPICE (Liszewski et aI, 
2006), SPICE is similar to the cellular complement control proteins (CCPs) (Dunlop et aI, 
2003) such as decay-accelerating factor (DAF; CD55), Factor H, membrane cofactor protein 
(MCP; CD46), complement-4b-binding protein (C4b-BP) and soluble complement receptor 
type 1 (sCR1), which are collectively known as the regulators of complement activation 
(Liszewski et ai, 2000; Smith et aI, 2000). In vitro studies have demonstrated that SPICE 
inhibits both the classical and the alternative pathways of human complement more efficiently 
than its viral homologs, VCP (Rosengard et aI, 2002; Sfyroera et aI, 2005) and MOPICE 
(Liszewski et aI, 2006). 
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In vivo, following entry to its host via the respiratory route (Smith and Kotwal, 2002), the 
variola virus strives to replicate to higher titers in infected cells in order to establish infection. 
However, it is a prerequisite for the virus to overwhelm the host complement and protect the 
infected cells by secreting complement inhibitors and shifting the balance to its advantage. 
Therefore, SPICE, an efficient complement inhibitor, is thought to be the ultimate mechanism 
by which the virus attenuates its host (Lachmann, 2002; Dunlop et ai, 2003). The role of 
SPICE in smallpox infection appears to be critical in leading to the speculation that 
immunizing humans with SPICE might be protective against possibly emerging smallpox 
infection (Lachmann, 2002). Meanwhile, the anti-complement therapeutic potential of SPICE 
might be further elucidated by developing animal models of different ailments that mimic the 
clinical scenario, such as head injury, spinal cord injury, xenorejection, sepsis, 
ischemiaireperfusion injury and arthritis where complement has been shown to play an 
important role. 
1.2.2 Inflammation Modulatory Protein (IMP) 
IMP, a homolog of SPICE, MOPICE and VCP, is an anti-inflammatory protein encoded by 
cowpox virus (CPV), a virus used by Edward Jenner to successfully vaccinate people against 
smallpox (Moss, 1996; Kotwal, 2000; Viera and Chies, 2005). CPV, in contrast to variola virus 
which only infects humans, is able to infect wild (rodents, lions, elephants), domestic animals 
(cattle, cats), and humans (Smith and Kotwal, 2002). Wild type CPV infection manifests less 
pathologic changes than infection with the mutant CPV lacking the gene that encodes the 
inflammation modulatory protein (CPV-IMP). For example, Miller et al (1997) demonstrated 
that both wild-type and C5-deficient BALB/c mice inoculated with the mutant virus displayed 
severe footpad swelling and aggregation of inflammatory cells compared to the wild-type CPV 
infected mice suggesting the beneficial role of IMP in the containment of inflammation 
(Howard et aI, 1998). 
In vitro studies have shown that IMP possesses four SCRs and retains the ability to inhibit the 
classical pathway of complement activation. It also binds to heparin (Smith et ai, 2000). 
Moreover, comparative phylogenetic analysis has indicated that IMP together with SPICE and 
VCP might have emerged from a common ancestral complement inhibitor (Ciulla et aI, 2005). 
However, there are very limited in vitro studies on IMP, and the crystal structure and the 
pharmacological value of purified IMP in curbing complement-mediated diseases remain to be 
determined. 
4 
1.2.3 Monkeypox Inhibitor of Complement Enzymes (MOPICE) 
After the successful eradication of smallpoX:, monkeypox infection has emerged as the most 
devastating and perhaps life-threatening orthopoxviral disease, with symptoms resembling that 
of smallpox (Douglass and Dumbell, 1992). Humans (mostly hunters) are primarily infected 
through contact with infected monkeys (zoonosis) and can secondarily infect other individuals. 
For example, the two independent outbursts of monkeypox infection in the Democratic 
Republic of the Congo (DRC) in 1970, and more than three decades later in the United States 
suggest that monkeypox infection is a relapsing biological threat (Liszewski et ai, 2006). The 
presence of MOPICE in the genome of the DRC-strain appears to have enhanced the virulence 
of the virus compared to the milder form ofmonkeypox infection which occurred in the United 
States (Liszewski et ai, 2006). 
MOPICE, a recently characterized potent complement inhibitor, is structurally and functionally 
similar to SPICE, IMP and VCP, with the exception of possessing a truncated 4th SCR as a 
result of premature stop codon in the carboxy terminal of the protein (Uvarova and 
Shchelkunov, 2001; Liszewski et ai, 2006). Despite the fact that the truncation has reduced the 
number of putative heparin binding sites from four (SPICE, IMP and VCP) to three (Smith et 
ai, 2000), MOP ICE binds heparin as strongly as VCP and SPICE (Liszewski et ai, 2006), 
suggesting that the overall positive charge might be more influential in determining the affinity 
to the negatively charged heparin column. Interestingly, MOPICE has been shown to bind C3b, 
a critical complement component (refer "CHAPTER 4" of the thesis), more efficiently than VCP, 
suggesting its preferential application in treating complement-mediated diseases where C3 
plays a damaging role, such as renal ischemiaJreperfusion injury (Zhou et ai, 2000; "CHAPTER 
4" of the thesis), traumatic brain injury (Keeling et ai, 2000) and guinea pig-to-rat heart 
transplantation (Anderson et ai, 2003). 
1.2.4 Vaccinia Virus Complement Control Protein (VCP) 
Historically, VCP was the first viral complement inhibitor to be identified from vaccinia virus. 
It was identified during sequencing of the terminally located "nonessentiaf' genes (Kotwal and 
Moss, 1988). The vaccinia virus, known for representing candidate vaccine strains (Smith and 
Kotwal, 2002), encodes VCP in the left terminus of its genome in order to evade the host 
immune defense mechanisms. VCP migrates as a ~28 kDa (in a 12% SDS-PAGE gel) (Smith 
et ai, 2000) and ~35kDa protein (in a 10% SDS-PAGE gel) (Kotwal and Moss, 1988; Kotwal 
et ai, 1990), and is composed of four SCRs, sharing significant structural homology to the host 
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complement-4b-binding protein (C4b-BP). Functionally, VCP blocks both the classical and the 
alternative pathways of complement activation (Kotwal et aI, 1990; Isaacs et ai, 2003) and 
subsequently protects the vaccinia virus from neutralization, and prolongs the survival of 
infected cells in order to generate more viruses before their death (Isaacs et ai, 1992; Kotwal, 
2000; Dunlop et aI, 2003; Kotwal and Abrahams, 2004). In order to further elucidate the 
potential benefits of complement inhibition, the VCP gene was amplified from the vaccinia 
virus Western Reserve (WR) strain genomic DNA and cloned into yeast cells for large-scale 
production and ease of characterization (Smith et ai, 2000). This full length recombinant VCP 
(rVCP) is probably the most studied recombinant viral complement inhibitor, extending from 
its ligand binding ability (Smith et aI, 2000; Ganesh et aI, 2004; Ganesh et ai, 2005), 
crystallization (Murthy et ai, 2001), and physicochemical property (Smith et ai, 2002), to its 
multitude of therapeutic potentials (Daly and Kotwal, 1998; Anderson! et ai, 2002; Anderson2 
et ai, 2002; Hicks et aI, 2002; Anderson et ai, 2003; Jha and Kotwal, 2003; Scott et ai, 2003; 
Kahn et ai, 2003; Reynolds et ai, 2004; Jha et ai, 2005; Thorbjornsdottirl et ai, 2005; 
Ghebremariam et ai, 2006). 
The recombinant VCP is predominantly a monomer which exists as a 28kDa protein that can 
tolerate extremes of temperature, pH, and storage (Smith et ai, 2002; Liszewski et aI, 2006). 
However, recent studies have shown that the natural VCP secreted from infected mammalian 
cells has a different oligomerization pattern, which partially accounts for its enhanced 
functional activity (Liszewski et ai, 2006). We have shown that the VCP secreted from 
vaccinia virus Lister strain is the only glycosylated (N-X-S form) poxviral complement 
inhibitor and that this glycosylation appears to have affected its functional properties (Odunuga 
et aI, 2005). 
Functionally, VCP and rVCP have been shown to modulate a number of complement-mediated 
ailments. For example, the loop of complement activation by the amyloid-beta (A[3) peptide, a 
reactive molecule known to be progressively deposited in Alzheimer's disease, has been 
completely abolished using VCP (Daly and Kotwal, 1998). Moreover, intracranial 
administration of VCP has been shown to improve memory following fluid percussion injury 
in rats (Hicks et ai, 2002). Furthermore, Scott et at (2003) demonstrated that the intravenous 
administration of rVCP in mice increased the ability of neutrophils to reduce bacterial load 
following intestinal infection. Moreover, we, in collaboration with Dr. Tom E. Mollnes's 
laboratory in Norway, have recently shown (Thorgersen et ai, manuscript in preparation) that 
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VCP is a potent inhibitor of pig complement following selective activation of the alternative 
pathway with zymosan, heat aggregated IgG (HAIGG) and E. coli in swine sera and whole 
blood, as evaluated by measuring tumor necrosis factor (lNF-a.), interleukin (IL-1j3) and IL-8. 
This work suggests a therapeutic potential for VCP in conditions predominantly driven by the 
alternative pathway of complement activation such as renal ischemiaireperfusion injury. 
Other studies have investigated the therapeutic values of VCP/rVCP in transplantation. AI­
Mohanna et al (2001) have demonstrated the ability ofVCP to competitively block the binding 
of the preformed anti-galactosyl-a. 1,3 galactosyl transferase xenoantibodies to their natural 
receptors on the surface of non-primate endothelial cells, as well as its additional ability to 
inhibit the destruction of pig endothelial cells by human inflammatory cells, suggesting its 
pharmacologic potential in xenotransplantation research. This in vitro evidence was supported 
by the ability of rVCP to significantly prolong the survival of xenografted organs following 
mouse-to-sensitized rat (Anderson! et aI, 2002) and guinea pig-to-rat (Anderson et aI, 2003) 
heart xenotransplantations. Moreover, Kahn et al (2003) have demonstrated the ability of rVCP 
to increasingly downmodulate complement activation following its administration in primates, 
supporting its therapeutic potential in xenotransplantation. Recently, we reviewed the ethical, 
psychosocial, biosafety and molecular barriers confounding xenotransplantation research, and 
discussed various therapeutic approaches towards clinical xenotransplantation (Ghebremariam1 
et aI, 2005; Ghebremariam2 et aI, 2005). 
Based on the aforementioned therapeutic promise of the recombinant VCP, its remarkable 
homology to SPICE (95-95.4% identity depending on the strains; Rosengard et aI, 2002; 
Lachmann, 2002; Dunlop et aI, 2003), the extreme potency of SPICE extending from 100 
(Rosengard et aI, 2002) to lOOO-fold (Sfyroera et aI, 2005) than rVCP, computer modeling 
predictions on surface exposure and ligand binding efficiency, and its homology to host 
complement control proteins, specific amino acids were substituted in rVCP in the hope of 
enhancing its activity (Ghebremariam3 et aI, 2005; Sfyroera et aI, 2005). 
The novel work by Sfyroera et al (2005) demonstrated the generation of 12 independent rVCP 
mutants with single, double or multiple amino acid substitution(s) towards their SPICE 
analoglhomologs. The surface plasmon resonance (SPR)-based binding assay and ELISA­
based functional assays revealed that all the generated mutant proteins acquired greater ability 
in regulating complement activation (Sfyroera et aI, 2005). 
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For example, the single amino acid substitution of glutamic acid (E) at position 120 to its 
SPICE analog (EI20K) has immensely upregulated the alternative pathway activity of the 
protein by about 87-fold (Sfyroera et aI, 2005). Furthermore, the authors have demonstrated 
that not all the amino acid differences between VCP and SPICE (Figure 1) are equally critical, 
and only few specific amino acid changes are required in order to make rVCP as potent as 
SPICE. 
In the authors own words, the combined two amino acid substitutions in rVCP at positions 108 
and 120 ofthe second SCR (SCR-2) to their SPICE analogs (E108K, E120K) is described to be 
" ••. THE MINIMAL AMINO ACID SUBSTITUTIONS REQUIRED ON VCP TO BRING ITS ACTIVITY CLOSE 
TO THE ACTIVITY OF SPICE." (Sfyroera et aI, 2005). Our findings (In vitro, "CHAPTER 3" and in 
vivo "CHAPTER 4" ofthe thesis) supported the work by Sfyroera el al (2005), and demonstrated 
that SCR-2, a module that displays above 40% of the amino acid differences, is a critical 
domain that significantly interacts with both the classical and the alternative pathways of 
complement activation (Ghebremariam3 et aI, 2005). Most researchers appear to have been 
exclusively engaged in identifying critical amino acid(s) in rVCP, and the interaction of these 
modified protein(s) with complement components, heparin and other ligands (Smith et aI, 
2000; Murthy et ai, 2001; Rosengard et ai, 2002; Smith et ai, 2003; Ganesh et ai, 2004; Ganesh 
et ai, 2005; Ghebremariam3 et aI, 2005; Sfyroera et aI, 2005). Very little (if any) attention has 
been given to basic and essential immunogenicity studies of rVCP, SPICE and any of the 
derivative poxviral complement inhibitors, which we regard as potential anti-complement 
therapies (Mollnes and Kirschfink, 2006). 
1.3 Natural Human Complement Regulators 
The human complement regulatory proteins (CRPs) are a subset of proteins that exist in either 
a soluble form or bound to cell membrane (Lachmann, 2002; Liszewski et aI, 2006). They have 
significant amino acid identity with the poxviral complement inhibitors described above. The 
physiological role of the human complement regulators is to protect endogenous cells from 
excessive complement driven self-attack (Mollnes et ai, 2002; Dunlop et aI, 2003). These 
proteins are encoded by genes located on the long arm of chromosome 1 (Lachmann, 2002; 
Liszewski et aI, 2006), and belong to the regulators of complement activation (RCA) family 
(Liszewski et aI, 2000; Smith et aI, 2000; Ganesh et aI, 2004). 
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The family includes complement-4b-binding protein (C4b-BP), complement receptor type 1 
(CR1), membrane cofactor protein (MCP), decay-accelerating factor (DAF), CD59 and Factor 
H (Cozzi and White, 1995; Smith et ai, 2000). A brief description of each of these members of 
the RCA family is described below. 
1.3.1 Complement-4b-Binding Protein (C4b-BP) 
As its name implies, this protein binds to the complement component C4b (Kotwal et ai, 1990) 
and inhibits the classical pathway C3 (C4b2a) and C5 (C3bC4b2a) convertases (Kotwal, 1997; 
Lachmann, 2002; Mollnes and Kirschfink, 2006). C4b-BP exists naturally as a soluble plasma 
glycoprotein bound to protein S (Wiesel et ai, 1990; Lachmann, 2002; Ganesh et ai, 2004; 
Liszewski et ai, 2006). A chimeric membrane bound form of C4b-BP has been engineered on 
the surface of pig endothelial cells, and used in pig-to-human xenotransplantation research 
(Mikata1 et ai, 1998; Mikata2 et ai, 1998). C4b-BP is the largest of all the members of the RCA 
family containing 56 SCRs and has the highest structural homology to VCP with an average 
amino acid identity of 32% (extending from 28% to 38% within the first 4 SCRs) (Kotwal and 
Moss, 1988; Kotwal, 2000; Dunlop et ai, 2003). C4b-BP (550kDa) is a very potent 
complement regulatory glycoprotein with both cofactor (for Factor I to degrade C4b) and 
decay-accelerating (accelerates the decay of the classical pathway C3 and C5 convertases) 
activities (Kotwal et ai, 1990), making it a good candidate as anti-complement therapy. 
However, the exploitation of C4b-BP's protective role by some microbes in order to escape 
immune surveillance (Lachmann, 2002) may affect its chances of proceeding to the clinic. 
1.3.2 Complement Receptor Type 1 (CR1) 
CR is a membrane-anchored protein that exists in two types namely CRI (CD35) and CR2 
(CD21) (Lachmann, 2002). Of the two, CRI is by far the most studied protein in complement 
research, not only because CR2 does not possess any significant complement regulatory 
activity (Mollnes and Kirschfink, 2006) but also because it serves as a receptor for Epstein­
Barr virus (Kotwal, 1997; Dunlop et ai, 2003), a herpesvirus known to cause Burkitt's 
lymphoma and infectious mononucleosis in children. CR1, on the other hand, possesses 
complement regulatory activity similar to that ofVCP (Kotwal, 2000). 
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CRt, composed of 30 SCRs, is the most efficient complement regulator in the RCA family, 
with cofactor and decay-accelerating activities in the classical and alternative pathways of 
complement activation (Rosengard et aI, 2002; Mollnes and Kirschfink, 2006) making it a 
candidate protein for therapeutic purposes. Weisman et al (1990) have engineered a soluble 
form of CRI (sCRI), and showed its ability to reduce myocardial infarction in rats. Soluble 
CRl (sCRl) has a unique ability to inhibit all the three known routes of complement activation 
namely the classical, alternative and the lectin pathway (Sacks et aI, 2003). Subsequently, 
sCRl (120kDa) has proven its strong potential in higher-order animal xenotransplantation 
(Pruitt et aI, 1994) and has reached different stages of clinical trials with some promises in 
vascular surgery (Sacks et aI, 2003; Mollnes and Kirschfink, 2006). Mollnes and Kirschfink 
(2006) have reviewed more than a decade work on sCRI. 
1.3.3 Membrane Cofactor Protein (MCP) 
MCP, also known as CD46, is expressed on the surface of Band T lymphocytes (Sacks et aI, 
2003) and is one of the two smallest (4 SCRs) members of the RCA family (Dunlop et aI, 
2003). It shares significant amino acid homology (35%) and functional identity with VCP 
(Smith et aI, 2000; Sfyroera et aI, 2005). As its name indicates, MCP serves as a cofactor in 
assisting Factor I in order to degrade activated C3 (C3b) and C4 (C4b) complement 
components (Liszewski et aI, 2000). The molecular significance of the different SCRs in MCP 
have been meticulously elucidated (Liszewski et aI, 2000) and shed light on other complement 
inhibitors (Rosengard et aI, 2002; Ghebremariam3 et aI, 2005). Despite its small size and 
modest complement inhibitory activity, its chances of progressing to the clinic may be 
hampered by the fact that it is used by many bacteria and viruses as a convenient route of entry 
into cells (lymphocytes, monocytes and keratinocytes) which express MCP (Kotwal, 1997; 
Liszewski et aI, 2000), which undoubtedly increases the chances of subsequent infection(s) if 
used clinically. 
1.3.4 Decay-accelerating Factor (DAF) 
DAF (CD55) is a four-SCR protein expressed on the surface of erythrocytes, lymphocytes and 
antigen-presenting cells (Mollnes et aI, 2002; Sacks et aI, 2003). It shares 31 % amino acid 
homology to VCP (Sfyroera et ai, 2005) and has efficient decay-accelerating activity (Dunlop 
et ai, 2003). 
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In vivo studies have shown that the deletion ofDAF gene in mice increases the susceptibility to 
ischemia (Yamada et ai, 2004) and immune-complex disorders (Mollnes et ai, 2002), 
suggesting its indispensable role. Numerous studies involving the expression of DAF on the 
endothelial surface of pig organs (Langford et ai, 1994; Cozzi and White, 1995; Rosengard et 
ai, 1995) have reported its potential in abolishing hyperacute xenorejection (McCurry et ai, 
1995; Schmoeckel et ai, 1997; Ramirez et ai, 2002; Brandl et ai, 2003). 
However, other researchers are sceptical about the therapeutic promise of DAF, not only 
because it fails to effectively inhibit complement (Koike et aI, 1996; Kotwal, 1997; Van 
Denderen et ai, 1997) but also because it is used as a receptor by enteroviruses and as a shield 
by HIV in order to evade immune surveillance (Kotwal, 1997). Therefore, its chances of 
advancing to the clinic might be extremely minimal. 
1.3.5 CD59 

It is not clear whether CD59 belongs to the RCA family (Cozzi and White, 1995) as the 

literature has exclusively ignored it (Murthy et aI, 2001; Lachmann, 2002; Sfyroera et aI, 2005; 

Mollnes and Kirschfink, 2006). CD59 is expressed on the surface of many cells and is used to 

inhibit the alternative complement pathway by preventing the formation of membrane attack 

complex (MAC; C5b-9) (Anderson et ai, 2003; Yamada et aI, 2004). Failure of CD 59 to inhibit 

the detrimental MAC formation has been described as a primary cause of hyperacute rejection 

in guinea pig-to-rat heart transplantation (Anderson et ai, 2003). Moreover, Mollnes et al 

(2002) have documented the fragile nature of erythrocytes isolated from CD59-deficient mice 

indicating the importance of its natural expression. Moreover, other studies have demonstrated 

the cooperative role of CD59 with DAF in renal ischemiaJreperfusion injury (Yamada et ai, 

2004) and experimental xenotransplantation (McCurry et ai, 1995). However, its failure to 

regulate the classical complement pathway and other biosafety concerns (Kotwal, 1997) may 

diminish its chances of proceeding to the clinic. 

1.3.6 Factor H 

Factor H is a soluble protein composed of20 SCRs (Dunlop et aI, 2003) and has the ability to 

regulate the alternative pathway C3 (C3bBbP) and C5 (C3b2BbP) convertases (Kotwal, 1997; 

Mollnes and Kirschfink, 2006). 
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Interestingly, Factor H is the only heparin binding protein among the members of the RCA 
family. This heparin binding ability allows Factor H to possesses multifunctional activities, 
such as the inhibition of antibodies and inflammatory cells from binding to the surface of 
endothelial cells, thus, preventing cytotoxicity (Kotwal, 2000). 
Deficiency of Factor H is associated with a detrimental genetic disorder, hemolytic uremic 
syndrome, indicating its critical role in the pathophysiology of complement regulation (Ganesh 
et aI, 2004; Zipfel et aI, 2006). Despite its essential role in complement regulation and 
cytoprotection, its chances of progressing towards clinical trials may be impeded due to 
biosafety concerns (Kotwal, 1997; Lachmann, 2002). 
To efficiently and safely regulate excessive complement activation, all the potential 
complement inhibitory proteins need to be well characterized and any putative microbial 
binding site(s) need to be modified or else eliminated. One such key approach in characterizing 
and refining potentially therapeutic proteins is their molecular recombination in various 
expression systems (He et aI, 1997; Smith et aI, 2000; Rosengard et aI, 2002; Sfyroera et aI, 
2005; Liszewski et aI, 2006). 
1.4 Expression of Recombinant Proteins 
Protein biotechnology is being enjoying the extraordinary advances in molecular biology. The 
engineering of foreign proteins in mUltiple expression systems has become increasingly 
simplified. Although Escherichia coli was among one of the protein expression systems, its 
inability to secret the proteins of interest (Files et aI, 2001; Liu et aI, 2001), and the folding 
problems often encountered (Lange et aI, 2001; Ouyang et aI, 2003), have resulted in the 
search for other expression systems. The expression of recombinant proteins in eukaryotic 
systems, such as the yeast and mammalian cells have made major differences in the folding 
and other posttranslational properties of the expressed proteins (Chen et aI, 1997; Lange et aI, 
2001; Ouyang et aI, 2003). However, because of the need for expensive growth and 
maintenance media, as well as the risk of infectious contaminants, the mammalian cell-based 
tissue culture expression system is used sparingly (Sudbery, 1996; Chen et aI, 1997). 
The transformation of yeast cells for the expression of foreign genes has become a widely 
accepted approach for over two decades (Sudbery, 1996; Chen et aI, 1997; Sreekrishna et aI, 
1997; Cereghino et aI, 2002). 
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A number of yeast strains have been used as vehicles for protein production. Saccharomyces 
cerevisiae, Pichia pastoris (P. pastoris) and Hansenula polymorpha have been successfully 
used to express one or more potentially therapeutic proteins (Sudbery, 1996). However, the 
methylotrophic yeast P. pastoris has been found to be the most affordable and optimal 
expression system for diverse proteins (Zhu et aI, 1995; Sudbery, ·1996; Chen et ai, 1997; He et 
ai, 1997; Kobayashi et ai, 2000; Files et ai, 2001; Lange et ai, 2001; Liu et ai, 2001; Cereghino 
et aI, 2002; Koganesawa et aI, 2002; Ouyang et ai, 2003). For example, different modules of 
the VCP gene were expressed in P. pastoris (Smith et ai, 2000) and the recombinant proteins 
have been successfully produced ever since (Smith et ai, 2000; Hicks et aI, 2002; Anderson l et 
ai, 2002; Anderson et ai, 2003; Reynolds et ai, 2004; Ghebremariam3 et ai, 2005; Jha et ai, 
2005; Ghebremariam et ai, 2006). 
Similarly, researchers have reported over 40% increase in the production of the free radical 
scavenger, thioredoxin, by simply switching the expression system to P. pastoris (Anna et aI, 
2003). Other researchers have demonstrated satisfactory yield of their respective recombinant 
proteins ranging from 300 to 900mgllt when expressed in P. pastoris (Chen et ai, 1997; 
Kobayashi et ai, 2000; Liu et aI, 2001; Lee et aI, 2003; Ouyang et ai, 2003). 
The cloning of foreign genes into shuttle vectors (such as pPIC9) downstream to the well­
characterized and engineered alcohol oxidase 1 (AOX1) promotor of P. pastoris, allows the 
constitutively inducible promotor to be upregulated upon the addition of methanol during 
induction phase of the protein production (Chen et ai, 1997). The pseudo regulation of the 
AOXI gene, in order to facilitate the interaction between oxygen and methanol, is the basis for 
the molecular exploitation of the cloning site (Lee et ai, 2003). In addition to the optimal yield, 
P. pastoris has the added advantages of minimal glycosylation and endotoxin related problems 
which often hamper the clinical applications of recombinant proteins (Sudbery, 1996; Chen et 
ai, 1997; Cereghino et ai, 2002). 
The success of laboratory scale production of proteins using P. pastoris, has encouraged 
scientists to expand the amount of protein production to an industrial scale. The use of 
fermentors for the production of recombinant proteins has significantly increased the amount 
of protein produced compared to the flask-based small-scale production (Koganesawa et ai, 
2002). 
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A fennentor is a bioreactor-like device which incorporates a vessel, an agitator, a condenser, 
heat blanket, pH and oxygen probes, a thennometer and a primary control unit which can be 
connected to an external computer to monitor the progress of the different parameters. It is 
usually connected to an external pump for delivering acidibase, oxygen and sources of 
antifoam and other solutions necessary during the process of fennentation. 
The tight regulation of temperature, agitation, pH and dissolved oxygen levels in fennentors 
creates a suitable atmosphere for the yeast cells to grow to high density (Chen et aI, 1997; Files 
et aI, 2001; Cereghino et ai, 2002; Thiry and Cingolani, 2002; Lee et ai, 2003). For example, 
Zhu et al (1995) demonstrated remarkable differences in the enzymatic activity of the 
recombinant a-galactosidase following subtle changes in pH, suggesting the crucial role of the 
acidity/alkalinity of the media used for protein production. The activity of proteases appear to 
be pH dependent and their proteolytic activity can generally be decreased by lowering the pH 
of the media (Sreekrishna et ai, 1997; Koganesawa et ai, 2002; Thiry and Cingolani, 2002); 
although it seems to be the converse for other proteases (Kobayashi et ai, 2000). 
Furthermore, the supply of additional source of oxygen (medical or industrial grade) to the 
recombinant cells appears to positively influence the amount of protein secreted (Chen et ai, 
1997; Lee et ai, 2003). 
The in vitro and in vivo authenticity of the secreted proteins needs to be monitored, as 
incorrectly folded or hyperglycosylated proteins may be immunogenic and may induce 
complex reactions when administered clinically for the treatment of various diseases (Sudbery, 
1996). 
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CHAPTER 2: ISCHEMIAIREPERFUSION INillRY 
2.1 The Renal System 
The renal system includes the kidneys, collecting ducts, urinary bladder, ureters and the 
urethra. Each of the components performs an important function in order to clear metabolic 
wastes from circulation. A brief description of the anatomy including blood supply and 
innervation, histology (microscopic and macroscopic structures), physiology (function), and 
clinical investigations of the renal system follow. 
2.1.1 Anatomy 
The kidneys are located in the abdomen, in the retroperitoneum on either side of the vertebral 
column (Bulgar and Hebert, 1979; Ross, 1972). This anatomical location appears to be uniform 
across species from man to small laboratory animals including rats (Ross, 1972). The blood 
vessels (renal artery and vein), the ureter and nerve supply enter the kidney in the hilum. The 
blood vessels ensure the supply of oxygenated (arterial) blood and the exit of deoxygenated 
(venous) blood. The ureter drains the urine into the urinary bladder and the sympathetic 
nervous system innervates the renal artery (Ross, 1972). 
2.1.2 Histology 
Microscopically, the renal tubules are composed of the functional unit (nephron) and parts of 
the collecting ducts (Bulger and Hebert, 1979). Moreover, the nephron is further composed of 
various segmented structures that ultimately contribute to the histologic appearance of the 
kidney. In summary, the various structures that are distinctively visible under the microscope 
include (Bulger and Hebert, 1979): the nephron, made up of the following structures: the 
glomeruli, which is made of Bowman's capsule, the glomerular capillaries and the specialized 
phagocytic cells known as mesangial cells; the proximal tubule (convoluted and straight 
portions); loop of Henle (descending and ascending parts); distal tubule (includes the cortex 
and the medulla-containing straight portion and the convoluted region); and the collecting duct 
which comprise the cortical, outer medullary and the inner medullary collecting ducts. 
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2.1.3 Physiology 

The kidneys are involved in the excretion of metabolic wastes such as urea and creatinine , 

acid-base balance as a compensatory mechanism following respiratory acidosis/alkalosis, 

activation of vitamin D, and synthesis of hormones such as erythropoietin, a hormone which is 

necessary for red blood cell maturation (Zilva et aI, 1988; Ghebremariam' et ai, 2005; 

Ghebremariam
2 
et ai, 2005), and renin, a proteolytic enzyme involved in maintaining blood 

pressure through the renin-angiotensin system (Zilva et aI, 1988). 

Between 180 to 200 liters (125 to 139 mllmin) of fluid gets filtered by the glomeruli per day 
and about 99% of the filtrate gets reabsorbed through the proximal convoluted tubule (Bulger 
and Hebert, 1979; Zilva et aI, 1988). The loop of Henle is involved in concentrating the 40 to 
60 liters of water received, by 20 to 30-fold. The distal convoluted tubule and the collecting 
duct are involved either in urine dilution, in the absence of the antidiuretic hormone (ADH), or 
in the concentration of urine in the presence of ADH by reabsorbing water into the ascending 
vasa recta (Zilva et ai, 1988). Finally, the ureters are used as passage routes for the urine to be 
temporarHy stored in the urinary bladder before excretion through the urethra. 
2.1.4 Laboratory Investigation of Renal Diseases 
The following tests are used to assess renal function: 
2.1.4.1 Urea and Creatinine 
Urea and creatinine are the two major nitrogenous metabolic waste products. These markers 
can be clinically used to assess renal function, with the upper limits of 42 mgldl (urea) and 
1.2mg/dJ (creatinine). However, each of them is susceptible to exogenous influences such as 
diet, extrarenal injury (for example, injury to the muscle) and biochemical reagents, when 
assessed using manual or semi-automated techniques. It is therefore advisable to request the 
two tests simultaneously to assess renal function. Alternatively, the rate of creatinine clearance 
can be measured by quantifying the level of creatinine in urine and its concentration in plasma 
(Zilva et ai, 1988). In general, increases in urea and creatinine are sugge~five of renal 
disease(s) that compromise the integrity of the nephrons. 
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2.1.4.2 Electrolytes 
It is clinically advisable to measure the plasma or serum levels of some electrolytes when 
tubular dysfunction is suspected. For example, the concentration of bicarbonate [HC0 1 and
3
potassium [K+] usually decrease as a result of proximal or distal tubule dysfunction as they are 
involved in reabsorption and electrolyte balance respectively. In addition to the estimation of 
these electrolytes, the concentrations of phosphate [P0431, magnesium [Mg2+], and uric acid 
need to be included as they, together with the urinary presence of amino acids, phosphate and 
glucose, are indicative of injury to the proximal tubule and therefore may help rule out failure 
in the distal convoluted tubule (Zilva et ai, 1988). 
2.1.4.3 pH 
Urine pH (the level of hydrogen ion concentration [W]) can be semiquantified using dipsticks 
or precisely quantified using pH meter. The hydrogen ion [H+] is mainly excreted by 
conjugating with ammonia [NH/] in the form of ammonium [NH/]. The physiological urine 
pH is 7. A pH of less than 7 is indicative of acidic urine and alkaline urine has pH above 7. 
Measurement of urine pH is additional yet important clinical information in the accurate 
diagnosis and nature of kidney stone (calculi). For example, urine pH displays strong acidity 
(very low pH) in kidney stone patients where the calculi are mainly composed of uric acid. 
Meanwhile, alkaline urine pH is displayed in patients where the calculi are predominantly 
composed of calcium and also in patients suffering from infection stones (Fairley, 1979). 
Furthermore, urine pH can be monitored regularly in such patients following treatment to 
reverse the acidosis or alkalosis. 
2.1.4.4 Protein 
Under physiological conditions, every filtered protein must be reabsorbed. However, the 
presence of protein in urine is not necessarily an indication of renal disease as temporary 
circumstances such as strenuous exercise and emotional stress (Kassirer and Harrington, 1979) 
may lead to proteinuria. Yet, the persistent presence of protein (mainly albumin) in urine is a 
pathologic feature usually suggesting renal dysfunction and therefore should be integrated with 
other tests suggestive of renal pathology. 
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2.1.4.5 Renal biopsy (Histology) 
Despite its invasiveness, renal biopsy is the definitive diagnostic procedure to diagnose 
diseases involving different compartments of the kidney. The renal biopsy can be stained with 
hematoxylin and eosin (H&E) stain and the integrity of the glomeruli, Bowman's capsule, 
tubules and blood vessels can be assessed (Tisher and Croker, 1979). 
Histologic evaluation of kidney biopsy is a reflection of the architecture of the various 
components of the kidney and unlike most other laboratory tests that use blood, urine, serum or 
plasma as specimens, it is less susceptible (if at all) to exogenous factors. Moreover, it is 
particularly useful in patients with sub-clinical changes. 
2.1.4.6 Immunohistochemistry 
Immunostaining of frozen or paraffin-embedded kidney biopsy is essential in a number of 
immune complex diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus 
(SLE) in order to evaluate the effect of auto-antibodies (Tisher and Croker, 1979; Wen et ai, 
2004). It is also useful in non-autoimmune diseases to look for possible mechanisms of tissue 
injury. For example, the immunostaining for complement component C3 in renal 
ischemiaireperfusion injury· is crucially important in understanding the mechanism of tissue 
damage following IIR injury in rats. In addition to the semiquantitative immunohistochemical 
complement scoring, the degree of complement activation in biological fluids can be accurately 
and specifically quantified using pathway specific (classical, alternative or lectin pathway) 
diagnostic kits (Wen et aI, 2004). 
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The Immune System 
The immune system is broadly categorized into innate and adaptive (acquired) immunity. The 
innate immunity is the rapid and non-specific defense mechanism against microbial infections. 
The skin (as a mechanical barrier), the respiratory system (through the expression and secretion 
of cilia, mucus and surfactants) and the gastrointestinal system (due to gastric acid secretion) 
are the main physical defense barriers (Nairn and Helbert, 2002). The innate immunity also 
possesses extracellular molecules in order to rapidly clear microbial infections. These 
molecules include interferons, C reactive protein (CRP) and complement. 
Interferons, type I a and r,3, inhibit the replication of double-stranded RNA viruses (by directly 
interfering the process of transcription), activate natural kiHer cells and amplify the killing 
action of CDS+ cytotoxic T cells. CRP is among the many molecules that respond during early 
(acute phase) infection by binding to the bacterial cell wall to induce phagocytosis. Other 
molecules that are released during the "acute phase response" are interleukins (lL-l & 6) and 
tumor necrosis factor (TNF) (Nairn and Helbert, 2002). Complement is another, yet important, 
component of the innate immunity that is involved in speeding up the clearance of microbial 
infections in various orchestrated ways as described below. 
The innate immunity is short lasting, and if the infection is not cleared soon enough, it alerts 
the adaptive immunity to deal with the established infection (Nairn and Helbert, 2002). The 
adaptive immunity, though slow to kick in, is highly specific and relatively long lasting (Nairn 
and Helbert, 2002). 
2.2 The Complement System 
Although the history of complement dates back to the times of Robert Koch and Louis Pasteur 
in the 1880s, the term "complement' was coined by Ehrlich and colleagues in 1899 
(Lachmann, 2006). Following this description, four complement components have been 
identified between 1907 (C 1) and 1926 (C4) (Lachmann, 2006). Between the two arms of the 
immune system, acquired and innate, the complement cascade is an integral component of the 
innate immunity and through its remarkable ability to distinguish self from non-self (Mollnes 
and Fiane, 2003), it serves as an essential defense tool against invading microorganisms 
(Girardi et aI, 2006). However, failure of the system to differentiate self from non-self could 
well trigger and/or complicate a number of autoimmune diseases including rheumatoid arthritis 
(RA) and systemic lupus erythematosus (SLE) (Mollnes and Kirschfink, 2006). 
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Despite the pioneering advances in immunobiology research, the complement system is still 
not fully understood. So far, about 40 different molecules have been identified as complement 
components. These molecules exist in different forms and have immensely unique roles in 
enabling the complement system as a defense mechanism. The system can be activated and 
regulated by any of the three independent yet interlinked pathways (Zipfel et ai, 2006) namely 
the classical, alternative or lectin pathway ofcomplement activation (Sacks et ai, 2003). 
Tight regulation of complement is critically important, a lack of complement regulation can 
result in deleterious deficiency conditions such as the hemolytic uremic syndrome (HUS), and 
macular degeneration (MD) (Ganesh et ai, 2004; Zipfel et ai, 2006), and excessive complement 
activation results in inflammatory conditions such as spinal cord injury (Reynolds et ai, 2004), 
traumatic brain injury (Hicks et aI, 2002), xenorejection (Anderson et ai, 2003; Ghebremariam l 
et ai, 2005; Ghebremariam2 et ai, 2005), ischemia reperfusion injury (Zhou et ai, 2000; 
Thurman et ai, 2003; Thurman et ai, 2005; Ghebremariam et ai, 2006), arteriosclerosis 
(Thorbjornsdottir l et ai, 2006), recurrent miscarriage (Girardi et ai, 2006), Alzheimer's disease 
(Daly and Kotwal, 1998), collagen-induced arthritis (Jha et ai, 2005), acute respiratory distress 
syndrome (ARDS), acid-aspiration to the lungs, sepsis, and systemic inflammatory response 
syndrome (Mollnes and Kirschfink, 2006). 
Although, complement in general plays a damaging role in all these ailments, any given 
condition is primarily driven by either of the pathways of complement activation. A brief 
description ofeach of the three pathways and the mechanisms oftissue injury follow. 
2.2.1 The Classical Pathway and Disorders Associated 
The classical pathway (CP) was named to reflect its first and classic discovery following the 
differential understanding of the complement system (Nairn and Helbert, 2002). The CP is 
composed of five pathway-specific complement components namely the CIq, Clr, CIs, C4 
and C2, and the non-specific critical component, C3. In this chain reaction, Cl interacts with 
IgG (Gl, G2 or G3 subunits) or IgM antibodies resulting in direct activation of C2 and C4 
components and this results in the formation of classical pathway C3 convertase (C4b2a) 
(Figure I). The C3 convertase then catalyses the cleavage of C3 to its active components C3a 
and C3b (Tosi, 2005). 
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Being a component of the innate immunity, the CP is physiologically involved in the clearance 
of invading microorganisms (opsonization) and stimulation of the B cells for antibody 
production (Whaley, 1985; Nairn and Helbert, 2002). The CP is activated by antigen-antibody 
interaction, which involves the recognition of an antigen by the Fc receptor(s) of an 
immunoglobulin and a further complexed interaction with the different components (Whaley, 
1985). However, when the CP is defective, it results in a number of genetic diseases including 
systemic lupus erythematosus (SLE) and hereditary angioedema (RAE), as well as infectious 
diseases such as streptococcal infection (Rynes and Pickering, 1985). In contrast, excessive 
activation of the CP results in ischemiaireperfusion (IIR) injury of the skeletal muscle, heart, 
lung and intestine (Sacks et ai, 2003). Brief descriptions of these ailments follow. 
2.2.1.1 Systemic Lupus Erythematosus (SLE) 

SLE is an autoimmune disease that occurs commonly in patients with complement deficiency. 

Depending on which classical complement component is defective, the probability of 

developing SLE varies from about 15% (C2 deficiency) to 90% (Clq deficiency) (Wen et ai, 

2004). The hallmarks of SLE include juvenile onset, increased susceptibility to light, low white 

blood cell (WBC) and platelet counts, rash, arthritis and cardiac complications (Rynes and 

Pickering, 1985; Wen et ai, 2004; Abou-Raya and Abou-Raya, 2006). 

2.2.1.2 Hereditary Angioedema (RAE) 

HAE is non sex-linked (autosomal) disorder that manifests in a heterozygous state as a result of 

mutation(s) in the CI-Inh gene (Nairn and Helbert, 2002). CI-Inh is a CP regulatory protein for 

Clr and its natural substrate (CIs) as well as the coagulation cascade molecules such as factor 

XI, the fibrinogen activator (plasmin) and kallikrein (Wen et aI, 2004). 

Thus, deficiency of CI-Inh affects three distinct pathways, namely the coagulation, 

complement and the kinin-kallikrein pathways. 

Biochemically, RAE exists in two forms. Type I RAE is characterized by low levels ofCI-Inh 
due to decreased production of antigenic levels and manifests (penetrance rate) in 85% of 
children with CI-Inh mutation (Wen et ai, 2004). Type II RAE is distinguished from type I by 
its normal or high antigenic levels ofCI-Inh (Wen et ai, 2004). However, the protein produced 
is not biologically active probably due to mutation (s) that affect the folding of the protein or 
other posttranslational properties. 
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In general, advanced RAE symptoms include edematous swelling in the face and extremities, 
increased capillary permeability, upper respiratory tract obstruction, and vomiting as a result of 
bowel wall edema (Nairn and Helbert, 2002; Wen et ai, 2004; BorkJ et ai, 2006; Bork2 et ai, 
2006). The possible treatment for type I HAE is the administration of purified C I-Inh to 
normalize the antigenic levels (Asghar, 1996; Nairn and Helbert, 2002). 
The other, probably rare, form of angioedema is the non-hereditary one, known as acquired 
angioedema (AAE). Here, the antigenic level of CI-Inh produced is normal but the protein is 
cleared prior to the fulfillment of its physiological duty (Wen et ai, 2004). 
2.2.1.3 Microbial Infection 
Until the development of a fully functional adaptive immunity, the innate immunity is 
responsible for the defense against microbial infections. Because the adaptive immunity takes 
over during adolescence, the inability to clear microbial infection as a result of classical 
complement component deficiency is only noticed during childhood. For example, the lack of 
functional C2 increases the susceptibility to encapsulated bacterial infection in children (Wen 
et ai, 2004; Sjoholm et ai, 2006). One of the infections that occur as a result of a defective 
classical pathway is pneumonia caused by the gram-positive cocci, Streptococcus pneumoniae 
(Mold et ai, 2002; Sjoholm et ai, 2006). 
2.2.2 The Lectin Pathway (LP) 
The lectin pathway (LP) is the most recently identified pathway of complement activation 
(Tosi, 2005). The LP possesses significant resemblance to the classical pathway (CP). 
However, unlike the CP, there is no participation of antibodies. This component of the innate 
immunity contributes to defense against microbial infection by the interaction of its mannose 
binding lectin (MBL) to saccharide molecules on bacterial surface (Trouw et aI, 2005). This 
interaction activates serine protease enzymes that are homologous to Clr and CIs components 
of the classical pathway as described earlier. The activated molecules further activate C2 and 
C4 in order to form the classical pathway C3 convertase (C4b2a) (Figure I). This results in 
direct activation of C3, a complement component where all the currently known complement 
activation pathways converge (Tosi, 2005). 
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Any aberration or mutation in the coding or promotor region of the MBL gene could deviate 
the physiology of the aforementioned process of LP activation and may result in decreased 
levels of MBL in serum that subsequently results in a number of diseases including recurrent 
bacterial infections, cystic fibrosis, sepsis, spontaneous abortion and SLE (Wen et ai, 2004; 
Trouw et aI, 2005). On the other end, an excessive level of MBL is associated with various 
kidney diseases such as IgA nephropathy and lupus nephritis (Trouw et ai, 2005) as well as 
cardiac ischemia/reperfusion injury (Sacks et ai, 2003). 
2.2.3 The Alternative Pathway (AP) and Disorders Associated 
The AP, a component ofthe innate immunity, is one of the earliest pathways to be identified. 
The name was probably coined to indicate the separate (alternative) way of complement 
activation independent of antibodies (classical pathway) as demonstrated by Ritz in 1912 
(Lachmann, 2006). Peter Lachmann, in his recently published extensive review article on the 
genesis of complement, described H. Ritz as the first researcher to have activated a 
complement component independent of antibodies by the use of cobra venom. Two years later, 
Ritz's work was supported by Coca who activated the now called alternative pathway (AP) 
using the yeast cell wall, zymosan (Lachmann, 2006). More than four decades later, in 1954, 
Pillimer identified a factor necessary for the alternative pathway activation; he named this 
factor Properdin (Lachmann, 2006). Sixteen years after revealing Properdin, in 1970, one of 
the key components of the AP was identified by Boenisch and Alper, and was named as Factor 
B by Goodkofsky and Lepow in 1972 (Lachmann, 2006). In the same year, Hans Muller­
Eberhard and Gotze nomenclatured the complement component C3 and finally, to complete the 
picture, the last component of the AP was identified and named as Factor D (Lachmann, 2006). 
Under physiological conditions, the AP is initiated by the cleavage of C3 into its active form 
C3b, which then binds to a cleavage product ofFactor B, Bb. The zymogen factor B (93kDa) is 
cleaved by factor D into Ba (33kDa) and the proteolytic enzyme Bb (60kDa) (Quidel 
corporation, 2004; Ghebremariam3 et ai, 2005). Bb interacts with C3b and forms the complex 
C3bBb (Quidel corporation, 2004), which is also known as the alternative pathway C3 
convertase. The Bb fragment further cleaves C3 to the anaphylatoxin peptide C3a and the C3b 
fragments. The cleaved C3, C3b, interacts with the complex C3bBb to form C3bBbC3b 
complex also known as the alternative pathway C5 convertase. This proteolytic enzyme then 
cleaves C5 to the anaphylatoxin peptide C5a and the C5b fragments (Quidel corporation, 
2004). 
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Finally, the two convertases, C3 and C5, are stabilized by Properdin (Factor P) and this 
stability favors the amplification loop of the AP (Figure 1) to continuously produce C3b (Tosi, 
2005). The peptides generated during AP activation, C3a and C5a together with the classical 
pathway derived C4a act as chemotaxic factors and hence attract inflammatory cells such as 
neutrophils to a site of injury and also trigger the release ofvasodilators such as histamine from 
mast cells (Tosi, 2005). However, when the peptides are generated in excessive amount, they 
can lead to inflammatory reactions and other severe consequences. Meanwhile, the C5b 
associates with the complement components C6, C7, C8 and many C9 molecules to form C5b­
9n, mainly known as membrane attack complex (MAC) (Figure 1). Because the assembly of 
the complex happens on the surface of target cells, MAC attacks the target cells by penetrating 
their surface and can kill some internalized bacteria and certain enveloped viruses to prevent 
the spread of the microbes into uninfected cells (Tosi, 2005). 
ta) Cmssicatpathway (b) Lectin pathway (Q) Alternative pathway 
Ag-Ab complexes 
and O1hers (e.g. CRP) 
Mk:fobial surfa<:es (mannose) 
and olhers (e.g. IgA) 
Spontaneous and 
foreign surfa<.:es 
Figure-I: Activation sequence of the 3 independent complement pathways and the possible 
intervention using target specific complement regulatory molecules (Figure reproduced from 
Mollnes et ai, 2002. TRENDS in Immunology 23(2) page 62 for the SOLE PURPOSE OF 
SUMMARIZATION). 
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If the alternative pathway is defective as a result of mutation or autoantibodies, or excessively 
activated as a result of injury, it can lead to a myriad of pathogenic infections and debilitating 
conditions such as rheumatoid arthritis (RA), hemolytic uremic syndrome (HUS), lupus 
nephritis, membranoproliferative glomerulonephritis (MPGN), anti-phospholipid syndrome 
(APS), asthma, neurological ailments such as multiple sclerosis, age-related macular 
degeneration (ARMD), and renal ischemiaJreperfusion injury (Holers et aI, 2004; Zipfel et aI, 
2006). A brief description of these conditions and an overview of the mechanisms of disease 
causation follow. 
2.2.3.1 Hemolytic Uremic Syndrome (HUS) 
HUS is a syndrome of diseases broadly classified into: 
1) Typical HUS is a non-genetic form caused by members of the gram-negative bacteria 
capable of releasing shiga toxin to the blood stream (toxemia). For example, members of the 
Enterobacteriacae family such as Shigella dysentery subtype I and Escherichia coli subtypes 
0-26, 0-111 and 0-157 (Zipfel et ai, 2006). Typical HUS occurs almost exclusively in 
children and is characterized by diarrhea (Ganesh et aI, 2004), self- limiting and non-recurrent 
infection that can be cured in majority ofthe patients (Zipfel et aI, 2006). 
2) Atypical or adult form HUS is a genetic disorder caused by point mutations or deletions in 
the genes that code for alternative pathway C3 convertase regulatory proteins. 
Most of these mutations were detected in Factor H and some in membrane cofactor protein 
(MCP, CD46) and Factor I (Ganesh et aI, 2004; Zipfel et aI, 2006). These mutations result in 
low levels of the mutated complement control protein such as Factor H and therefore unable to 
effectively bind to C3b and hence fail to regulate complement activation (Ganesh et aI, 2004; 
Zipfel et aI, 2006). 
Hyperactivation of the C3 convertase in this circumstance leads to the depletion of the basal 
circulating complement as manifested by low levels of the classical and the alternative 
complement activity in vitro (Zipfel et aI, 2006). This form of HUS is characterized by 
hemolytic anemia, low platelet count and seeding of platelet thrombi into the kidneys usually 
causing renal failure. Consequently, patients with atypical HUS usually have poor prognosis 
(Zipfel et ai, 2006). 
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2.2.3.2 Rheumatoid Arthritis (RA) 
RA is an autoimmune disease characterized by joint inflammation, caused by hyperactivation 
of the alternative pathway. The hallmarks of the disease include decreased AP activity, 
accumulation of AP breakdown products in the joint fluid, and increased complement activity 
in the peripheral blood (Holers et aI, 2004). The predominant role of AP in RA was 
demonstrated by the induced resistance of Factor B deficient DBAlIj mice to anti-glucose-6­
phosphate isomerase (GPI) antibody-induced arthritis and to collagen induced arthritis (CIA) 
(Holers et aI, 2004). Meanwhile, the beneficial role of anti-complement proteins such VCP 
further confirmed the role of complement in RA using the CIA mice model (Jha et ai, 2005). 
2.2.3.3 Lupus nephritis (LN) 
LN is an autoimmune disease associated with SLE, which primarily affects the glomerulus 
causing excretion of protein in urine, deposition of IgG antibodies, and other renal 
abnormalities (Holers et aI, 2004; Li et aI, 2006). The role of complement in LN has been 
implicated through the inhibition of disease progression by the use of soluble and membrane­
bound complement inhibitors such as Crry and anti-C5 monoclonal antibody. The predominant 
role of the alternative complement pathway was demonstrated from the observed protection of 
Factor B deficient mice and through inhibition of the complement component C5, a building 
block of MAC (Holers et aI, 2004). The anti-inflammatory drug prednisone and the 
immunosuppressive regimens of cyclophosphamide and mycophenolate mofetil are clinically 
accepted therapeutic options for LN (Flores-Suarez, 2006). 
2.2.3.4 Membranoproliferative Glomerulonephritis (MPGN) 
Histologically, there are two types of MPGN, namely MPGN I and II. The deposition of 
complement in the subendothelial layer distinguishes type I MPGN from type II, where 
complement is densely deposited in the basement membrane of the glomerular capillary wall 
(pickering et aI, 2006; Zipfel et aI, 2006). Common molecular defects in both forms of MPGN 
are the significant reduction or absence ofthe complement regulatory protein Factor H and low 
levels .of circulating complement due to their local consumption usually caused by 
hyperactivation of the alternative pathway C3 convertase (Dragon-Durey et aI, 2004; Zipfel et 
aI, 2006). The severity of the disease may vary based on the number, site and type of mutation 
(heterozygous, compound heterozygous, homozygous) in Factor H and the presence of 
autoantibodies in the basement membrane of the glomerulus (Zipfel et ai, 2006). 
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Under physiological conditions Factor H regulates complement activation and contributes to 
the maintenance of glomerular function. However, due to a single, double or multiple mutation 
(s) in the active site of the Factor H gene, the encoded protein becomes defective or even 

absent and hence unavailable to regulate complement activation in the glomerulus (Dragon­

Dureyet aI, 2004; Zipfel et aI, 2006). Interestingly, in some MPGN patients, the secretion of 

Factor H is intact. However, the production of autoantibodies that block the secreted Factor H 

encourage deregulation of complement activation (Zipfel et aI, 2006). 

2.2.3.5 Anti-phospholipid Syndrome (APS) 

APS is a complication triggered by antiphospholipid (aPL) autoantibodies against placenta 

during gestation. APS is associated with spontaneous abortion, fetal growth limitation and 

coagulation cascade disruption (Holers et aI, 2004; Velayuthaprabhu and Archunan, 2005; 

Girardi et aI, 2006). 

There is direct and indirect evidence that suggests the damaging role of complement in APS, 
and thus complications during pregnancy. For example, the inhibition of complement in 
pregnant mice using the complement inhibitor, complement receptor type 1 (CR-l)-related 
gene y (Crry), ameliorated spontaneous abortion (Holers et aI, 2004; Girardi et aI, 2006). 
Moreover, the absence of Crry endogenous expression induced fetal loss, suggesting the 
significant role of complement (Holers et ai, 2004). Furthermore, applying the principles of 
knockout technology, several studies (Holers et aI, 2002; Girardi et aI, 2003; Pierangeli et aI, 
2005) have demonstrated the crucial roles of Factor B, C3, C4 and C5 complement 
components in APS, supporting the contributions of the lectin, classical and the alternative 
pathways ofcomplement activation. 
Moreover, by the use of neutrophil depleting monoclonal antibodies, the role of these 
inflammatory cells (Girardi et aI, 2003) and the suggestive role of lethal inflammatory 
chemicals such as free radicals, cytokines and chemokines in aggravating APS was proposed 
and the study speculated effective intervention in APS-related fetal loss and growth defects in 
the clinic (Girardi et aI, 2006). 
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2.2.3.6 Asthma 
Asthma is a hypersensitivity reaction induced by allergens resulting in airway inflammation 
and obstruction (Nairn and Helbert, 2002). The allergens trigger cell-mediated immune 
responses that involve CD4+ T -helper memory cells and the subsequent production of cytokine 
molecules to participate in airway inflammation (Holt et aI, 1999). Although the role of cell 
mediated response in this pulmonary disease is relatively well realized, the understanding of 
the involvement of complement system in asthma is still in its infancy. However, preliminary 
studies have demonstrated the elevation of the inflammatory complement components C3a and 
C5a in bronchial washings from asthmatic patients (Krug et aI, 2001; Holers et aI, 2004). 
Moreover, the lack of the anaphylatoxin peptide C3a receptor in experimental animals had 
been shown to correlate with reduction in disease progression. Furthermore, inhibition of 
complement using Crry-Ig or anti-factor B monoclonal antibody in sensitized mice as well as 
the use of Factor B deficient mice supported the role of complement in experimental asthma 
and suggested the potential benefits of complement inhibition in clinical asthma (Holers et aI, 
2004; Taube et aI, 2006). 
2.2.3.7 Neurological Ailments 
There are several reasons to believe that inflammatory chemicals and complement playa role 
in many diseases of the nervous system. Examples include Alzheimer's disease, Parkinson's 
disease, head injury, traumatic brain injury, multiple sclerosis and age-related macular 
degeneration. For example, the use of nonsteroidal anti-inflammatory drugs (NSAIDs) has 
been shown to reduce the risk of developing Alzheimer's and Parkinson's diseases, multiple 
sclerosis, and age-related macular degeneration suggesting the damaging role of inflammation 
in the development of these neurological ailments (McGeer et ai, 2005). A key component that 
gets excessively activated in the process of neuroinflammation is the complement cascade 
(Kulkarni et ai, 2004). Once complement is activated, it in tum amplifies inflammation through 
the secretion of the inflammatory C3a, C4a and C5a peptides (Kulkarni et ai, 2004; McGeer et 
al,2005). 
For example, in Alzheimer's disease (AD), complement is activated by the direct interaction of 
the ~-amyloid plaques to the classical pathway component Clq (Daly and Kotwal, 1997; 
McGeer et ai, 2005) suggesting the role of complement in AD. Moreover, complement 
inhibition using Crry-Ig has been shown to be neuroprotective in head injury mice model 
(Rancan et ai, 2003; Leinhase, 2006). 
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Therefore, in addition to antiwinflammatory drugs, the use of effective complement inhibitors 
may also provide promising insights towards neuroprotection (Kulkarni et ai, 2004). 
Multiple sclerosis is another neurodegenerative disorder where complement in general and the 
alternative complement pathway in particular are believed to be involved in the destruction of 
neurons. Indirect evidence of this hypothesis is the significant reduction in disease progression 
in Factor B deficient mice (Nataf et ai, 2000; Holers et ai, 2004). 
In age-related macular degeneration (ARMD), a progressive degeneration of the macular densa 
of the eye which results in blindness, the alternative pathway of complement activation 
regulator, Factor H, has been strongly implicated (Tuo et ai, 2006). The point mutation in the 
short consensus repeat 7 (SCR 7) substitutes histidine for tyrosine (H402Y) rendering Factor H 
unable to effectively regulate the alternative pathway (Zipfel et ai, 2006). The importance of 
the site is probably due to its location in the heparin and C-reactive protein (CRP) binding site 
of Factor H. The sequencing of the SCR 7 domain in ARMD patients' has revealed more than 
2wfold higher frequency of the mutation than in the normal control groups (Zipfel et aI, 2006). 
2.3 Role of Complement in IschemialReperfusion (IIR) Injury 
Ischemia/reperfusion (IIR) injury is a complication induced and/or amplified by several factors 
and is known to significantly affect the physiological recovery of the organ being exposed both 
experimentally and clinically (Inal et ai, 2003). Vascularized organs such as the heart, kidney 
and intestine are mainly susceptible to IIR injury (Daemen et ai, 1999). 
IIR injury triggered by revascularization surgery and organ transplantation may account for 
delayed graft recovery, and associated morbidity and mortality (Hughes et ai, 1996; Zhou et ai, 
2000). The multiple factors involved in IIR injury include inflammatory molecules, free 
radicals, and hyperactivation of the complement system (Zhou et ai, 2000; De Vries l et aI, 
2003; Sacks et ai, 2003; Mollnes and Fiane, 2003; Mollnes and Kirschfink, 2006). There is 
strong correlation between deregulation of complement and the severity of ischemia 
independent of the organ source (Mollnes and Fiane, 2003). However, the driving force, within 
the three major pathways of complement activation, seems to vary depending on the type of 
organ being exposed to the injury. According to Sacks et al (2003), the CP drives IIR injury in 
the heart, lungs, skeletal muscle and intestine. 
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For example, it has been reported that mice defective in IgG and IgM production as a 
consequence of deficiency of the complement receptors (CRs) 1 (CRI = CD35) and 2 (CR2 = 
CD21), are protected from intestinal IIR injury; 
Furthermore, treatment of rabbit and pig cardiac IIR injury models with C l-Inh ameliorated 
myocardial IIR injury. In addition, CI-Inb has been shown to reduce IIR injury in sheep after 
lung transplantation suggesting the crucial role of the c1assical complement pathway in these 
various injury models (Sacks et aI, 2003). 
2.3.1 Role of Complement in Renal IschemiaiReperfusion Injury 
The kidneys are among the most susceptible organs to ischemialreperfusion (IIR)-induced 
injury. Specifically, the tubular cells are highly susceptible to IIR injury. Due to the lack of 
oxygen supply during the ischemia time, the injured tubular epithelial cells are able to locally 
activate the complement pathway through a poorJy understood mechanism (Inal et aI, 2003). 
However, the alternative pathway of complement activation has been reported to be 
predominantly responsible for the IIR injury in the kidneys (Sacks et aI, 2003; Stahl et aI, 
2003). The continuous local production and activation of complement and the lethal MAC 
generation in the renal tubules overwhelm the natural complement inhibitors and ultimately 
destroy the renal tubules irreversibly. 
The tubular collapse is amplified due to the fact that the tubular epithelial cells are able to 
provide all the necessary complement activation ingredients when injured (Inal et ai, 2003). 
The main factors involved in renal ischemialreperfusion injury are the complement (mainly 
through its alternative cascade), inflammatory chemicals (predominantly derived from 
activated complement components cleavage) and the highly reactive free radicals mainly 
generated during reperfusion time. Supportive evidence to the involvement of these variables 
comes from a number of studies that have shown the effects of the direct inhibition of 
complement using anti-complement proteins (Wen et ai, 2004; Yamada et aI, 2004), 
monoclonal antibodies (Williams et ai, 1997; De Vries l et ai, 2003; Quigg, 2003; DiLilIo et aI, 
2006; Mollnes and Kirschfink, 2006), complement-inhibitor expressing transgenic animals 
(Schiller et aI, 2001), and certain complement component knock out animals (Zhou et ai, 2000; 
Lien et ai, 2003; Stahl et aI, 2003; Thurman et aI, 2003; Yamada et ai, 2004; Thurman et ai, 
2006). All these studies illustrated the essential role of complement inhibition and its possible 
benefits in the clinic. 
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Furthermore, the role of free radicals in renal IIR injury has been demonstrated in various 
studies and is exclusively described in the literature (Rhoden et aI, 2002; Fujii et aI, 2003; 
Kielar et aI, 2003; Singh and Chopra, 2004; Rodriguez-Reynoso et aI, 2004). A brief overview 
ofthe different inhibitors and their mechanism ofaction follow. 
2.3.1.1 Therapeutic Role of anti-complement Molecules in Renal IIR Injury 
Although the kidney is considered to be resistant to anti-complement therapy following 
ischemia/reperfusion (IIR) injury (Park et aI, 2001; Inal et aI, 2003), inhibition of the 
alternative complement pathway at different stages ofcomplement synthesis has been shown to 
curb the persistence of IfR-induced renal injury. For example, De Vries2 et al (2003) 
demonstrated the prevention of renal IIR injury using lysophosphatidic acid (LP A). LPA is a 
multifunctional molecule with anti-apoptotic, anti-inflammatory and anti-complement 
properties. The anti-apoptotic activity is due to its ability to inhibit activation of caspase-7, an 
apoptosis pathway molecule, following renal I/R injury. Its anti-inflammatory activity is the 
result ofthe inhibition of tumor necrosis factor-a (TNF-a) and inhibition ofneutrophils. LPA 
has the ability to dose dependently inhibit the complement components C3, C6 and C9 (De 
Vries2 et aI, 2003). LPA has been shown to immensely ameliorate IfR-induced renal injury in 
mice (De Vries2 et aI, 2003). In another study, the same authors demonstrated significant 
protection from renal I/R injury by inhibition of the complement component CS using anti-CS 
monoclonal antibody termed as BBS.1. Besides its effective complement inhibitory activity, 
BBS.l has also been shown to inhibit the aggregation of inflammatory cells (neutrophils) and 
the MAC-induced late apoptosis in murine model (De Vries2 et aI, 2003). 
Cobra venom factor (CVF), a controversial complement regulator (Park et aI, 2001; Yamada et 
aI, 2004 Vs Mollnes and Kirschfink, 2006; Lachmann, 2006) has also been shown to improve 
I/R-induced renal injury in CDSSICDS9 double knock out mice but failed to provide any 
therapeutic value in wild type mice (Yamada et ai, 2004). Meanwhile, the soluble form ofCrry 
was reported to play negligible therapeutic role in renal I/R injury (Park et aI, 2001). However, 
the membrane bound form of the protein was shown to abrogate I/R-induced renal injury 
(Schiller et aI, 2001) supporting the role of complement in renal IIR injury. 
Other soluble or membrane bound forms of complement inhibitors with beneficial role in 
attenuating renal IIR injury might emerge in the future. For example, the newly identified 
complement inhibitory activity of the herbal formulation Curcumin (Kulkarni et ai, 200S), 
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together with its anti-inflammatory property, may in the future playa role in the prevention of 
I/R-induced renal injury. 
2.3.1.2 Genetic Engineering Tools to Inhibit Complement 
Major advances in molecular biology and genetic engineering have allowed researchers to 
further understand the mechanisms of different diseases. For example, the use of transgenic 
animals expressing critical molecules, and the use of gene-knock out animal models, have 
contributed vast knowledge to the field of science in general, and transplantation medicine and 
immunobiology in particular. Brief overviews of these approaches follow. 
2.3.1.2.1 Complement Inhibition using Transgenic Animals 
The local expression of Crry, an active murine C3 convertase inhibitor, in the glomerular and 
tubular membranes of the kidney has been shown to completely abrogate IIR-induced renal 
injury (Schiller et aI, 2001) compared to the markedly elevated tubular damage in the wild type 
mice, suggesting the injurious role of complement and the therapeutic value of complement 
inhibition in I/R-induced renal injury. 
2.3.1.2.2 Complement Inhibition using Knock Out Animals 
A number of studies have supported the damaging role of complement in IIR-induced renal 
injury. These studies have developed novel techniques to understand the contribution of each 
complement component using target specific knock out technology. For example, the novel 
and classically cited (above 90 citations) work by Zhou et al (2000) have meticulously studied 
the effect of C3, C4, C5 or C6 deficiency in the genesis of renal IIR injury. In their study, the 
•deficiency of C3, C5 or C6 was protective from IIR-induced renal injury in mice, suggesting 
the crucial role of the alternative complement pathway in general and the membrane attack 
complex (MAC) in particular. However, the lack of C4 did not provide any degree of 
protection suggesting the insignificant role of the classical complement pathway in renal IIR 
injury (Zhou et aI, 2000). Moreover, the replacement with human C6 in the C6-deficient mice 
rendered the susceptibility to a degree of the wild type mice suggesting further the independent 
role of C6 in renal IIR injury (Zhou et aI, 2000). Furthermore, Thurman and his colleagues 
(2003) also demonstrated the critical role of the alternative complement pathway by using 
Factor B deficient mice. In the absence of Factor B gene, the animals were partially protected 
from IIR-induced renal damage compared to the increased tubular injury in the Factor B 
sufficient mice (Thurman et aI, 2003). 
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Recently, Thurman et al (2006) have further demonstrated the involvement of the alternative 
pathway by showing the increased susceptibility of Crry heterozygous knockout mice to renal 
l/R injury. 
In addition to the critical role of the alternative complement pathway in renal IIR injury, the 
contribution of the lectin pathway ofcomplement activation has also been demonstrated by the 
direct relationship of the mannan-binding lectin (MBL) gene knockout mice, the consequent 
diminishing of C3 deposition, and the subsequent protection from l/R-induced renal injury 
(Moller-Kristensen et ai, 2005) indicating the role of complement inhibition in conferring 
resistance to renal IIR injury. Similarly, Yamada et al (2004) evaluated the roles of the natural 
complement regulators, CD55 and CD59 in renal IIR injury. Although the deficiency of CD55 
exposed the animals to a greater degree of l/R injury, the lack of CD59 did not affect the 
degree ofinjury. Interestingly, the simultaneous lack ofboth genes rendered the animals highly 
susceptible to the injury, suggesting their additive role in providing protection against renal IIR 
injury (Yamada et ai, 2004). 
Lien et al (2003) have extensively reviewed the effect of 16 independent knock out genes in 
the genesis of IIR-induced renal injury. For example, the lack of the Na+/Ca2+ exchanger 
(NCX) gene (NCX1) provided protection by regulating the accumulation of intracellular Ca2+, 
known to be involved in hypoxia-induced renal injury (Matsumura et ai, 2002; Yamashita et ai, 
2003). The deficiency of caspase-l, a member of the cysteine proteases involved in activating 
lethal cytokines, offered significant functional and structural protection from tubular damage as 
well as reduced the influx of neutrophils by inhibiting the activation of the proinflammatory 
molecule interleukin-18 (IL-18) (Melnikov et aI, 2001). Furthermore, the lack of the growth 
factor midikine has been reported to protect renal IIR injury by inhibiting the activity of lethal 
chemokines (Lien et aI, 2003). Intercellular adhesion molecule-l (ICAM-l) deficiency also 
reduced renal IIR injury and improved survival in mice by preventing the adhesion and 
aggregation of neutrophils to the renal tubular epithelial cells (Kelly et aI, 1996). 
In conclusion, there is overwhelming evidence that the complement cascade plays a damaging 
role in ischemia/reperfusion injuries. For example, different pharmacological agents that 
directly or indirectly regulate the complement cascade have been shown to attenuate IIR injury 
in dogs, mice and rats (Stahl et aI, 2003; Kitada et aI, 2002; Yagmurdur et ai, 2003). 
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In addition, transgenic animals expressing complement control proteins (Schiller et ai, 2001; 
Knight et ai, 2005) or critical complement component knock out animals (Zhou et ai, 2000; 
Stahl et ai, 2003; Thurman et ai, 2003; Thurman et ai, 2006) have strongly suggested the role 
of the complement cascade in I/R injury and provided further insights to the design of target­
specific therapeutics. 
THEREFORE IT WAS HYPOTHESIZED THAT INHIBITION OF EXCESSIVE COMPLEMENT SYNTHESIS IN 
THE RENAL SYSTEM FOLLOWING ISCHEMIAlREPERFUSION (IIR) INJURY MIGHT BE A FEASIBLE 
APPROACH TO AMELIORATE ISCHEMIC DAMAGE. BASED ON THIS HYPOTHESIS, THE THERAPEUTIC 
ROLE OF A COMPLEMENT INHIBITOR, THE VACCINIA VIRUS COMPLEMENT CONTROL PROTEIN 
(VCP), WAS ELUCIDATED FOLLOWING ISCHEMIAlREPERFUSION-INDUCED RENAL INJURY IN RATS. 
The vaccinia virus complement control protein (VCP) was isolated from vaccinia virus 
infected cells (Kotwal and Moss, 1988). It has structuml and/or functional homology to 
members of the regulators of complement activation (RCA) family (Smith et aI, 2000). VCP 
regulates both the classical and the alternative pathways of complement activation through its 
ability to block the activated C3 and C4 early complement components from stimulating 
further complement components including the formation of the membrane attack complex 
(MAC, C5b-9) (Kotwal, 1997). This terminal complement component and the C3 are believed 
to be injurious in renal I/R injury (Zhou et aI, 2000). 
2.3.1.3 Anti-inflammatory Agents in RenalllR Injury 
Although inflammation may be a direct result of complement activation and cleavage, which 
genemtes powerful pro inflammatory peptides such as C3a, C4a and C5a, or may be it is 
initiated through the accumulation of free radicals following reperfusion injury, it is still 
considered as an important independent factor in I/R-induced renal injury. Its direct inhibition 
has been accounted to reduced tissue injury. For example, the anti-inflammatory drug, 
FR167653, has been shown to ameliorate renal I/R injury in dogs. FR167653 works by 
inhibiting the pro inflammatory chemicals IL-lf3 and TNF-a. (Kitada et ai, 2002). Furthermore, 
the anti-inflammatory property of heparin, apart from its anticoagulant activity, has been 
shown to reduce the deposition of IgM and C3 as evaluated by immunostaining (Yagmurdur et 
ai, 2003). The heparin treated rats displayed lower lipid peroxidation and serum creatinine than 
the untreated I/R injury group. The electron microscopic study also revealed an increased 
proximal and distal tubule injury in the histology of the untreated group suggesting further the 
anti-inflammatory action of heparin and its potential benefits in limiting I/R-induced renal 
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injury (Yagmurdur et ai, 2003). Moreover, the inhibition of the inflammatory cyclooxygenase 
(COX) enzymes 1 and 2 using indomethacin or rofecoxib drugs provided significant 
improvement in renal structure and function following IIR injury (Feitoza et aI, 2005). 
2.3.1.4 Free Radical Scavengers 
The role of free radicals in the pathogenesis of renal IIR injury has been extensively 
documented. The use of natural and synthetic free radical scavengers in renal IIR injury animal 
models have identified a number of promising inhibitors that can limit the progression of renal 
IIR injury. For example, treatment with L-carnosine, an antioxidant and free radical scavenging 
peptide, prior to ischemic injury has been shown to dose dependently reduce the levels of 
plasma creatinine and BUN compared to the untreated control group (Fujii et aI, 2003). 
Moreover, the histopathologic findings revealed a decreased medullary congestion and necrosis 
of the tubular epithelial cells in the rats which received treatment. Meanwhile, pretreatment of 
rats with the grapefruit derived bioflavonoid herb, naringin, protected the animals from renal 
IIR injury as evaluated by serum creatinine, BUN and creatinine clearance measurements 
(Singh and Chopra, 2004). The histopathologic results also supported the protective role of 
naringin as revealed by decreased tubular cell swelling, tubular dilation, tubular epithelial cell 
necrosis, interstitial edema and deposition of hyaline casts (markers of renal failure) in the 
treated animals. The protective effect of naringin was thought to be due to its antioxidant and 
free radical scavenging properties (Singh and Chopra, 2004). In addition to the aforementioned 
studies, the therapeutic role of mehitonin, a multifunctional hormone secreted by the pineal 
gland in the brain, was also evaluated in renal IIR injury. This free radical scavenging molecule 
improved both renal structure (by limiting the degree of tubular damage by about 50%), and 
function. Moreover, treatment with melatonin has improved the survival rate by 30% compared 
to the untreated group (Rodriguez-Reynoso et aI, 2004). 
In conclusion, a vast number of studies have demonstrated the therapeutic potential of blocking 
complement (mainly the alternative pathway), inflammation and/or free radicals as promising 
approach in preventing the ischemialreperfusion-induced renal injury. Figure-l (shown above) 
is reproduced from Mollnes et al (2002) to summarize the initiation, convergence and 
divergence of the 3 known complement activation pathways and the possible therapeutic 
intervention spots from complement mediated tissue injury (Mollnes et ai, 2002). 
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3.1 INTRODUCTION 
Vaccinia virus complement control protein (YCP) inhibits both the classical and the alternative 
pathways of complement activation and enables the vaccinia virus to evade host immune 
. defense. Proficient downmodulation of complement activation decisively depends on the 
competence of the inhibitory protein to efficiently bind the activated third (C3b) and fourth 
(C4b) host complement components. Incorporating the resourceful information obtained from 
sequence alignment with homologous orthopoxviral proteins such as the highly efficient 
human complement inhibitor, the smallpox inhibitor of complement enzymes (SPICE), and 
host complement inhibitors such as membrane cofactor protein (MCP) and soluble complement 
receptor type-l (sCRl), crystallographic structure of the recombinant VCP (rVCP) (Murthy et 
ai, 2001) and molecular modeling exercises (Liszewski et aI, 2000; Murthy et aI, 2001; Ganesh 
et ai, 2004), putative sites have been identified on the yeast cell expressed rVCP (Smith et aI, 
2000) as contact sites for C3b/C4b. Site-specific mutagenesis studies substituted amino acid (s) 
in the postulated sites. 
The aim of this study was to characterize the complement inhibitory activities of the generated 
mutant proteins in comparison to rVCP and the natural VCP isolated from vaccinia virus 
infected cells. The activities were compared for both the classical and the alternative pathways 
by employing antibody mediated and zymosan-induced in vitro assays respectively. 
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3.2 MATERIAL AND METHODS 
3.2.1 Identification of Critical Amino Acids for VCP Mutagenesis 
Based on a number of independent observations, putative amino acids have been identified in 
the rVCP sequence as critical sites to enhance its complement inhibitory activity. Alignment of 
amino acid sequence with SPICE, crystallized structure ofrVCP and computer based modeling 
exercises have deduced the C3b/C4b contact points in the rVCP sequence as described below. 
3.2.1.1 Sequence Alignment 
The conceptually translated amino acid sequence of recombinant VCP (rVCP) was aligned 
with the amino acid sequence of serine protease inhibitor of complement enzymes (SPICE) 
searched using the NCBI protein-protein blast (blastp) search tool. The blast alignment 
revealed 95% identity with the D 15L protein (known as SPICE) of the Variola virus Congo­
1965 strain (Mas sung et aI, 1996) as shown in Figure-l below. The two proteins were then 
aligned using the blast 2 sequences (bI2seq) tool and the differences are displayed as shown in 
Figure-I. The difference was mainly in SCR-2 (41.7%) and minimal in SCR-I (0%) suggesting 
the role of the former SCR in offering SPICE a differential advantage in inactivating human 
complement about 100-fold more than rVCP (Rosengard et aI, 2002). Therefore, SCR-2 was a 
fine candidate for mutagenesis studies. 
;:. 	 rVCP CCTIPSRPINMKFKNSVETDANANYNIGDTIEYLCLPGYRKQKMGPIYAKCTGTGWTLFN 60 

SPICE 60 

rVCP QCIKRRCPSPRDIDNGQLDIGGVDFGSSITYSCNSGYHLIGESKSYCELGSTGSMVWNPE 120 

SPICE •••••••••••••••• H ••••••••••••••••••.• Y •••• Y•••• K •••••••..•• K 120 

rVCP APICESVKCQSPPSISNGRHNGYEDFYTDGSVVTYSCNSGYSLIGNSGVLCSGGEWSDPP 180 

SPICE ..•....... L .....•....•.N ....•......•.••..................N.. 180 

rVCP TCQIVKCPHPTISNGYLSSGFKRSYSYNDNVDFKCKYGYKLXXXXXXXXXPGNTWKPELP 240 

SPICE ............ L .................... T.......... L ..........Q.... 240 

rVCP KCVR 244 

SPICE 244 

Figure 1: Amino acid sequence alignment ofrVCP (WR strain) with SPICE (Congo-1965 
strain) revealing 12 amino acid differences. 
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3.2.1.2 Modeling Studies 
Computer based are backbone pharmacognosy computational 
chemistry due to their ability to provide information regarding the physicochemical 
of molecules 	 known structures, and rational prediction unknown structures 
and hence better insights to the 	 Here, the Swiss-Model 
program (www.expasy.org) was to the space filling of rVCP, rVCPEl and 
rVCPH98y, E 102K, E 1 (abbreviated in thesis as hrVCPs) as displayed in 
2 (A-C). Figure was generously modeled by Dieter Blaas (University Vienna, 
Austria) using "GRASP software. The Discovery Studio Viewer Pro (OS Viewer pro; 
Accelrys Inc., San USA) software package was used to view and edit the modeled 
structures. OS viewer Pro is user-friendly tool to sketch modifY 
molecular structures. 
3.2.1.3 Crystallography 
Determining 	 crystal structure a protein provides original information about structural 
helical or coiled) the protein, hidden/exposed and therefore their 
importance in mutagenesis 	 The crystal structure of 
rVCP was determined at 2.lAo (Murthy et ai, 2001). This information was crucial 
identifYing critical amino acids in rVCP for mutagenesis studies. 
3 Cloning 	 hrVCPs 
cloning hrVCPs into pPIC9 expression vector the transformation 115 Pichia 
pastoris yeast cells was recently published (Ghebremariam3 et ai, 2005) (These experiments 
were performed Odutayo 0. Odunuga as part postdoctoral research as 
in the the thesis). The cells putative to the gene 
were (Figure 3) AOX-l universal {Invitrogen 
and the actual recombinant clones were for studies. 
conditions of PCR used in the ...... " ... 7<.1"1 in Table and B 
below. amplified products (15 ~l each) were resolved in a 1.2% agarose in a horizontal 
system using the conducting Tris-Acetate (TAE) (Appendix A) at 70V 2 
molecular weight marker Life WI, USA) (Appendix B) 
was as a standard marker. 
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Table lA: Components of the AOX-l PCR perfonned on putative recombinant yeast cells 
Component Stock concentration Final concentration 
"Primers 50pmoJ/~1 lpmol 
dNTPs 200mM 40mM 
MgCh 25mM 1.5mM 
Reaction buffer lOX IX 
Taq polymerase 5U/~1 1.25U 
DNA Single colony -
#Primers used in the 5'~ 3' orientation are: the forward (GACTGGTICCAATIGACAAGC) 
and the reverse (GCAAATGGCATICTGACATCC). The reaction mix was in 25~J and the 
samples were amplified using the PCRSprint (ThermoHybaid) PCR machine. The conditions 
of the reaction are shown in Table lB . 
Table IB: Amplification conditions of the AOX-I PCR perfonned on putative recombinant P. 
pas/oris colonies 
Step Temperature (0C) Time (min) Cycle 
Initial denaturation 94 2 1 
Denaturation 94 1 30 
Primer annealing 55 1 30 
Extension 72 1.3 30 
Final extension 72 5 1 
3.2.3 Production ofrVCPlhrVCPs in Flask 
The recombinant proteins (VCPEl08K and rVCPH98Y, EI02K, E120K) were produced by 
inoculating positively identified single colonies from regenerated dextrose base (RDB) plates 
(Appendix A) into 10ml of buffered minimal glycerol medium (BMGY) (Appendix A) at 30°C 
at 200rpm for 24 hours in a shaker incubator. This starter culture was further inoculated into 
490ml of BMGY until the OD6oo spectrophotometric reading reached above 2. The growth 
media was clarified by centrifugation at 4000g for 4 minutes and the harvested cells were 
induced with l25ml of buffered minimal methanol medium (BMMY) (Appendix A) containing 
4% filter sterilized methanol (Merck Chemicals) for a period of 96 hours . The supernatant 
containing secreted protein(s) was harvested by centrifugation at 13200 rpm for 10 minutes. 
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Twenty fll of each sample was mixed with 8)l1 of loading buffer mix (Appendix A) and 23)l1 of 
the sample mix was SDS-PAGE analysed at 110 volts for 2 hours (Figure 4A). The gel was 
coomassie blue stained (Appendix A for staining solution) for 30 minutes and destained 
(Appendix A for destaining solution) for 4S minutes. The samples which showed a band at the 
size of the standard VCP (rVCP) were fi lter sterilized using either O.22)lm syringe filters 
(Millipore products) or O.4S)lm filter units (Adcock Ingram), diluted in binding buffer (SOmM 
sodium acetate, pH S.S; sometimes pH 7.0) (Amersham Pharmacia Biotech cue card) and 
accommodated into a sample loop. The HiTrap heparin columns (3 X Sml connected in series 
to make a ISml column) were equilibrated with S-column volume (SCV; 1 CV = Sml) of filter 
sterilized and theoretically degassed distilled water and then with the binding buffer (Appendix 
A) prior to the injection of the sample accommodated in the sample loop (Amersham 
Pharmacia Biotech). The sample was then injected at a flow rate of ImVmin in a low-pressure 
AKTA prime chromatographer (Amersham Pharmacia Biotech) with the aid of the built-in 
peristaltic pump. The flow-through (unbound) sample was collected through the outlet valve 
and the bound protein was eluted at a linear NaCI gradient of 0 (binding buffer) to 100% (1 M 
NaCI prepared in binding buffer) and collected in a series of fraction tubes (3mlltube). The 
peak fractions were SDS-PAGE analysed and those containing pure hrVCPE 1 08K or hrvCPH98Y, 
EI02K, E120K were pooled, concentrated and SDS-PAGE analysed (Figure 4B) prior to 
biological activity test. 
For large scale VCP purification, the high-pressure liquid chromatography (HPLC) technique 
was applied in a lOS explorer (Amersham Pharmacia Biotech) using the UNICORN 4.10 
software package (Amersham Biosciences, Uppsala, Sweden). This explorer purifies large 
sample volume of up to SOOml and tolerates a flow rate elevation of 1 Omllmin due to the higher 
column pressure limit (up to 2SMPa) compared to the AKTA prime (lMPa). The property of 
the HiTrap heparin column allows the chromatographic techniques to separate VCP based on 
the principles of affinity (to heparin) and ionic interaction (cation-exchange) with the 
negatively charged heparin matrix. 
3.2.4 Production ofrVCP/hrVCP in Fermentor 
Large-scale production of different recombinant proteins applying the process of fermentation 
is a widely employed procedure in various bioteclmology and pharmaceutical laboratories. 
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The use of fermentors for industrial scale protein production has a clear and unambiguous 
advantage over the condition- and scale-limited production of foreign proteins in flasks. 
Fermentors provide a tight regulation of different parameters such as temperature, pH, 
agitation and the level of dissolved oxygen in the culture. These factors, alone or in 
combination, have significant effect on the expressed protein and on the expression system. 
Here, a series of fermentation experiments (over 20 fermentations ' with a number of 
modifications) were undertaken to optimize the production of the recombinant VCP (rVCP) 
using a 14-liter BioFlo 110 Benchtop Fermentor (New Brunswick Scientific Co, Inc., New 
Jersey, USA) (Appendix B). Some of the fermentation trials are described below. 
3.2.4.1 Fermentation-l 
Single colony putative to express the VCP gene was initially inoculated into I-liter of BMGY 
and then into 16-liter at 30°C at 200 rpm in a shaker incubator until the 00600 
spectrophotometric reading reached above 2. Pre-induction sample was taken and the cells 
were harvested by centrifugation at 10000 rpm for 10 minutes. The cell pellet from the 16-liter 
culture was inoculated into 4-liter of BMMY containing 0.5% methanol in the fermentor, 
where as the pellet from the I-liter was inoculated into 250ml of BMMY (0.5% methanol) in 
the flask as an external control. The initial fermentation parameters used in this experiment are 
shown in Table 2A below. 
Table 2A: Parameters used in Fermentation-I 
Parameter Value Setpoint (Low - High) Control 
Temperature (0C) 30 30 (29.5 - 30.5) Auto 
Agitation (rpm) 200 200 (150 - 250) Auto 
pH 5.77 0 Off 
~issolved oxygen (%) 0 0 Off 
After 24 hours of induction, a final concentration of 2% methanol was added to the fermentor 
and to the control flask, and a further 1% after 48 hours of induction. Samples were taken 
every 24 hours (for 72 hours) from the flask and only at 72 hours from the fermentor (due to 
the difficulty in sampling at this stage). The samples were SOS-PAGE analysed (at 70V for 2 
hours) in a 4-12% pre-cast gel as shown in Figure-5. 
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3.2.4.2 Fermentation-2 
Based on the outcome of the first fermentation trial; that is, growing the cells in flasks and 
inducing them in the fermentor, the present experiment attempted growing the cells in the 
fermentor and inducing them in the same fermentor after a short "starvation period" in order to 
allow the cells to switch from glycerol (in the BMGY) to the methanol (in the BMMY) as a 
source of carbon. Here, a single colony from YPD plate (Appendix A) was inoculated into 
100mi of BMGY at 30°C at 200 rpm in a shaker incubator. After 48 hours, the inoculum was 
inoculated into 5-liter of BMGY in the fermentor. The 24 hours post-inoculation readout is 
displayed in Table 2B. 
Table 2B: Parameters used in Fermentation-2 
Parameter Value Setpoint (Low - Higb) Control 
Temperature (0C) 29.9 30 (29.5 - 30.5) Auto 
* Agitation (rpm) 200 205 (200 - 350) Dissolved oxygen 
Pump C (%) 0 40 "Off/On 
pH 6.14 6.10 (5.0 - 6.5) Auto 
Dissolved oxygen (%) 18.6 20 (20 - 30) Auto 
Footnote: *the cascade of the agitation was changed from "Auto" (in Fennentation-l) to 
"Dissolved oxygen" (d02) that means when the level of oxygen in the culture drops, the 
agitation automatically increases to unifonnly distribute the available oxygen throughout the 
culture. 
#switched on when the cells needed additional carbon source as described below. 
After -29 hours of growth, the OD6oo reading started to drop (2.124 to 1.8) suggesting cell 
death and therefore I-liter of 50% glycerol was fed through an external pump (pump C) at a 
rate of 165mVhour. Consequently, the cell growth started to improve (OD6oo rose to 2.024). 
After -35 hours of growth, I-liter of the culture was centrifuged at 3500g for 45 minutes and 
the cells were resuspended in 250ml of BMMY containing 4% methanol. This induction phase 
took place in a shaker incubator (control). The remaining cells in the fennentor were starved 
for 30 minutes in order to allow exhaustion of the glycerol in the culture and then fed with 
50ml of filter-sterilized methanol over a period of 24 hours. Following the start of the 
induction phase, industrial oxygen was pumped from an externally connected cylinder (Afrox, 
Cape Town, South Africa) in order to increase the supply of oxygen and hence the efficiency 
of methanol metabolism. 
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However, as a result of high cell yield, large amount of foam was produced in the system and 
significantly blocked the exit of air, as a result the fermentor was turned off and the supernatant 
(~5-liter) was harvested (at 90 hours instead of 96 hours post-induction as planned initially) by 
centrifugation at 3500g for 45 minutes. Finally, the sample was filter-sterilized and then 
concentrated using the process of ultrafiltration as described below. 
3.2.4.2.1 Concentration by Ultrafiltration 
The process of ultrafiltration allows fast and effective concentration and partial purification of 
large volume samples compared to the small volume centricon, centriprep or amicon filters 
(Millipore). In this experiment, peristaltic pump assisted pellicon XL filter device (Millipore) 
with a nominal molecular weight cut-off IOkDa was used to concentrate the 5 -liter supernatant 
harvested from the fermentor into a volume of 500 ml (lOX) within few minutes. Because the 
cassette has a molecular weight (MW) cut-off 10kDa, any material with MW less than 10kDa 
is collected through the "permate" tube while the molecules above 1 OkDa are collected through 
the "retinate" tube. Therefore, the rVCP (28.8kDa) was collected through the "retinate" 
partially purified by the size-exclusion nature of the device. Sixteen ~l of the concentrated 
sample was mixed with 7Jll of loading buffer and then analysed by SDS-PAGE in a 12% 
resolving gel. 
3.2.4.3 Fermentation-3 
In order to avoid the foaming problem encountered in the previous fermentation, antifoam-204 
was purchased from Sigma-Aldrich and Iml was added for every 5-liter culture. In this 
experiment, 5-liter of BMGY was first poured into the fermentor in order to adjust the 
temperature of the media to 30°C prior to inoculating the starter culture. High-purity nitrogen 
was then pumped (~lOOkPa) into the fermentor in order to calibrate the amount of dissolved 
oxygen (d02) in the media so that the d02 displayed in the screen panel reflects valid readings. 
The starter culture (125ml) was then inoculated into the fermentor. The initial fermentation 
readout is shown in Table 2C below. 
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Table 2C: Parameters used in Fermentation-3 
Parameter Value Setpoint (Low - High) Control 
Temperature (C) 30.2 30 (29.5 - 30.5) Auto 
Agitation (rpm) 212 500 (300 - 550) Dissolved oxygen 
Pump C (%) 0 100 Off/On 
pH 6.13 5.00 (5.0 - 6.5) Auto 
Dissolved oxygen (%) 46.6 30 (25 - 35) Auto 
*after -20 hours, pump C was turned on and the cells were fed with 500ml mixture of 50% 
sterile glycerol, basal salts (Appendix A) and PTMI trace salts (Appendix A) at a rate of 
40mJlhour. 
Meanwhile, -25ml of the culture was pumped out of the fermentor and was incubated in the 
shaker incubator as a control (for contamination). After 45 hours of growth in the fermentor, 
high cell mass was formed (00600 was 3.0 compared to 2.4 in the flask) and the cells were 
harvested by centrifugation at 4000g for 5 minutes. The cells were then induced in 114 volume 
of buffered methanol (Appendix A) and incubated in the shaker incubator for 48 hours. Finally, 
the supernatant was harvested by centrifugation at 4500 rpm for 20 minutes and the sample 
was SDS-PAGE analysed. 
A number of subsequent fermentation trials were attempted to produce significant and 
relatively pure rVCP. The parameters that were continuously modified in order to optimize the 
process of fermentation were the agitation, pH, fed-batch (amount and composition), and 
dissolved oxygen. Moreover, a synthetic media, composed of basal salts and PTM 1 trace salts, 
was used as a growth media in one instance, independent of the complex BMGY. Among the 
promising trials was the production of rVCP using the parameters described in Fermentation-4 
Table 20 below. 
3.2.4.4 Fermentation-4 
Single colony putative to express the rVCP gene was inoculated into 500ml ofBMGY at 30°C 
at 200 rpm in a shaker incubator until the 00600 spectrophotometric reading reached above 2. 
The starter culture was then inoculated into 8-liter of BMGY in the fermentor. The 
fermentation parameters used in this experiment are shown in Table 20 below. 
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Table 2D: 
30 
Parameter 
Temperature (0C) 
*Agitation (rpm) 
Pump C (%) 
**pH 
Dissolved oxygen (%) 
30 (29.5 30.5) 
400 400 800) 
0 
5.9 5.5 (5.0 
19.7 
Footnote: the cells continue to consume 
speed of agitation increases towards 
oxygen. 
**as the cells metabolise the 
acidify the media and causes a drop 
the external peristaltic to 
Midrand, South Africa) the 
#after 20 hours of growth, 1 of 
##the source of the dissolved 
"VI'''''',"''I (Merck Saarchem, 
air. An oil-free Bambi 
amlospm~nc air and feeds the 
was supplied from an 
Control 

Auto 

Dissolved oxygen 

OfflOn 
Auto 
dividing), the 
to the 'scarcity' of 
by-products such as C02, which 
automatically activates 
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The samples were SDS-PAGE analysed and those containing a band at the size of the standard 
VCP were confirmed by western blotting (Figure 6B) as described below. The rVCPlhrVCP 
containing samples were purified using the procedure described above. The purified proteins 
were then dialysed (Spectropore membrane tubing) against phosphate buffered saline (PBS, pH 
7.2) and the protein concentration was estimated using the Biorad microplate assay protocol as 
described below. 
3.2.5 Estimation of Protein Concentration 
The concentration of the purified proteins was estimated using the bovine serum albumin 
(BSA) standards (Pierce Laboratories; Rockford, Illinois, USA) and the Bio-Rad DC protein 
assay reagents in a 96-well microplate assay. This colorimetric assay is based on the principle 
of the Lowry assay and involves the initial reaction of the protein (standard or sample) with the 
supplied alkaline cooper tartrate solution (reagent A). This reduction reaction (Cu2+ to Cu +) 
further reacts with specific amino acids constituting the protein and upon the addition of Folin 
reagent (reagent B), blue color, equivalent to the protein concentration, develops and this can 
be measured spectrophotometrically or using a microplate reader (Caprette, 1997). 
In this experiment, 51-11 of the samples or standard was mixed with 25 1-11 of the supplied reagent 
A, mixed well and then 2001-11 of reagent B was added into each well. The mixture was 
incubated at room temperature for 5 minutes and the protein concentration was measured at 
595nm using microplate reader (anthos 2010, Salzburg, Austria). Finally, the quantified pure 
recombinant VCP was monitored for bacterial endotoxins using the QCL-1000 Chromogenic 
Limulus Amebocyte Lysate (LAL) quantitative assay (BioWhittaker, Walkersville, MD) prior 
to biological use. 
3.2.6 Screening for Endotoxin 
Bacterial endotoxins are usually active contaminants of genomic DNA, plasmid and proteins in 
solutions. These toxins also known as lipopolysaccharides (LPSs) are often derived from gram­
negative bacteria (Velez et ai, 2006). Vaccines or any other therapeutic materials need to be 
monitored for endotoxins prior to their in vivo use as they may cause septic shock, hypotension 
and multiple organ dysfunction syndrome (Perrella et ai, 1996). 
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The Chromogenic Limulus Amebocyte Lysate (LAL) test is a widely used enzymatic assay for 
the quantification of endotoxins and applies the catalysis of a proenzyme into its active form by 
bacterial endotoxins resulting to the development of a yellow color proportional to the 
concentration of endotoxin present in the sample (BioWhittaker Manual). In this experiment, 
the microplate assay method (BioWhittaker Manual) was used. Initially, a 96-well plate and all 
the reagents were pre-warmed at 37°C. Fifty III of blank (endotoxin free water), standard or 
sample was added into each well and then 50lll of the supplied LAL was added into each well 
and mixed prior to 10 minutes incubation at room temperature. The supplied substrate solution 
(1001l!) preheated to 37°C was added into each well, mixed and incubated for 6 minutes at 
37°C. The reaction was then stopped by adding 100111 of stop reagent (10% SDS) and the 
endotoxin concentration was measured at 405 nm using a microplate reader. 
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Production of YCP from natural infection 
3.2.7 Tissue Culture Experiments 
When the vaccinia virus infects mammalian cells such as the African green monkey kidney 
(BSC-I) cells, the vaccinia virus complement control protein (VCP) is majorly secreted from 
the infected cells to the media (Kotwal and Moss, 1988). In this experiment, the natural VCP 
was produced by infecting BSC-I cells at a titer of 3x I 06 cells with the laboratory adapted 
vaccinia virus vGKS strain (Kotwal and Abrahams, 2004) at a multiplicity of infection (MOl) 
of 1 in a serum-free minimal essential medium (MEM) Earle's Base (Highveld Biological, 
Lyndhurst, South Africa) containing I X triple antibiotics (Penicillin, Streptomycin and 
Fungizone, Highveld Biological) for 48 hours. The produced VCP was confirmed by western 
blotting as shown in Figure 6B. The western blot protocol used in this experiment was as 
described below. 
3.2.7.1 Western Blot 
The natural VCP and the hrVCP were SDS-PAGE (Appendix A) analysed and confirmed by 
western blotting (Figure 6B). In this experiment, the resolved samples were transferred 
(Appendix A) from the gel into an lmmobilon-P (PVDF) membrane with a pore size ofO.4S).lm 
(Millipore Corporation, Bedford, MA) at a constant current of 0.14A0 for 1.3 hours. The 
membrane was then removed and stained with Ponceau S (Appendix A) stain for 1-2 minutes 
in order to assess the success of the transfer. The membrane was rinsed with TBS (Appendix 
A) prior to blocking with freshly prepared S% blocking solution (Appendix A) at 4°C 
overnight. The blocking solution was discarded and the membrane was incubated with 1: 1000 
diluted rabbit anti-VCP primary antibody (10mglml) (Vector Laboratories, Burlingame, CA) 
(Appendix A) for 1 hour at room temperature with continuous shaking at a rate of 100revs/min 
(Orbital Shaker S03, Stuart Scientific, United Kingdom). The membrane was washed with 
30ml of 0.1% TBS-T (Appendix A) twice for 10 minutes each. The membrane was washed 
again with 30ml of O.S% blocking solution twice for 10 minutes each and incubated with 
1: 12S00 diluted anti-mouse/anti-rabbit IgG peroxidase secondary antibody (Appendix A) 
(Roche Diagnostics, Mannheim, Germany) for 30 minutes with continuous shaking. The 
membrane was then rinsed and washed with TBS-T (30ml each) four times (IS minutes each). 
The bands were detected by adding premixed detection reagent (Appendix A) for 60 seconds. 
Finally, the blot was inserted into a film cassette and exposed for various time points and the 
X-ray film was processed by transferring it into a Developer (-2 minutes), Stopper (2% acetic 
acid) (quick dip) and a Fixer (-2 minutes). 
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Following the western blot confirmation, the supernatant containing VCP was then purified, 
concentrated, dialysed, and monitored for endotoxins as illustrated above. The production and 
passaging of BSC-I cells as well as the titration and infectivity of the vaccinia virus vGK5 
strain are described below. 
3.2.7.2 Production and Passaging of BSC-l cells 
Pre-produced stock of African green monkey kidney (BSC-I) cell line was generously 
provided by Prof. Girish J . Kotwal (Division of Medical Virology, UCT) for further cell line 
production and maintenance experiments as described below. 
The cells (_107) were inoculated into 20ml of MEM containing 10% fetal calf serum (FCS) 
2(Highveld Biological, Lyndhurst, South Africa) and I X triple antibiotics (as above) in a 75 cm 
pyrogen free sterile cell culture flask (Corning Incorporated, NY, USA) and incubated at 37°C 
in a Thermocyt incubator with 5% C02 (ESI-Flufrance, Wissous, France). At day four, the 
cells were fully confluent as revealed under 40X Olympus CK2 light microscope (Japan). 
Thereafter, the entire medium was aspirated, leaving the adhered cells behind, and the cells 
were treated (l minute) with trypsinfEDT A in order to remove any traces of anti-trypsin prior 
to partial trypsinization with 2ml of fresh beef pancreas-derived gamma irradiated 
TrypsinfEDTA (Highveld Biological, Lyndhurst, South Africa) at 37°C with occasional 
vigorous shaking for 5 minutes. All the cells were detached with the application of gentle 
mechanical force and in-and-out aspiration as confirmed under a microscope. The cells were 
resuspended in IOml of fresh MEM and transferred into I5ml tube for centrifugation at IOOg at 
20°C for 5 minutes (Heraeus Multifuge 3 L-R, Kendro Laboratory Products, Hanau, Germany). 
Finally, the supernatant was discarded and the cell pellet was resuspended in 0.5ml of 
cryoprotective medium (basal eagle ' s medium containing Hanks' BSS and 15% DMSO) 
(BioWhittaker, Walkersville, MD). The cell-suspension was aliquoted into 2ml cryovials and 
stored at -80°C and the cells were thawed and passaged when necessary. 
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3.2.7.3 Virus Titration 
The BSC-1 cells (O.Sml x 6) were plated out in 6-well plates (Coming Incorporated, NY, USA) 
until confluency (-72 hours) and each well, except the negative control, was infected with the 
pre-titrated vaccinia virus vGKS strain (initial stock kindly provided by Walter Rangel De 
10 10Campos, MSc graduate) at a titer range of 106 - plague forming units (pfu) per ml as 
follows (Kotwal and Abrahams, 2004). 
The original stock (2 x 107 pfu/ml) was diluted by mixing 11-l1 of the virus with 1 ml of fresh 
MEM (without FCS and antibiotics). A I-ll of the mix was added to the well labeled as 106, 
mixed, and lOOl-l1 of this mix was transferred into the well labeled as 107 and so on up to the 
10 10 labeled well. The cells were infected by incubating them with the different viral titers' at 
37°C for 48 hours. The supernatant was removed and the wells were stained with crystal violet 
stain (Appendix A). Subsequently, the number of plaques was counted (Figure 7A) and the 
viral titer was determined as described above. 
3.2.7.4 Confirmation ofInfectivity and Virus Production 
To confirm the infectivity of the newly produced vGKS strain, confluent 6-well plate grown 
BSC-1 cells were infected with vGKS virus at a multiplicity of infection (MOl) of 0.1 by 
adding l.S1-l1 of virus stock (3 x 104 viral particles) into 3 x 106 cells in 1ml. After 24 hours of 
infection, the entire medium was sucked out and the cells were resuspended in Iml of serum­
free MEM and incubated further at 37°C for 24 hours. After a total of 48 hours of infection, the 
supernatants were harvested and the wells were stained with crystal violet for 1 hour at room 
temperature (Figure 7B). Once the infective ability of the virus was confirmed, virus stocks 
were produced by infecting fully confluent BSC-1 cells with a viral titer of 2 x 108 pfu/ml for 
48 hours. The cell monolayer was washed twice with O.Sml of PBS (pH 7.2) and the cells were 
detached using a cell scraper. The cell suspension was harvested and freeze-thawed between 
-80°C and 37°C three times followed by sonication using an ultra sonic cell disrupter (VirTis, 
NY, USA) for 30 seconds on ice. This step was done in order to destabilize the cell membrane 
and release the internalized viral particles. The supernatant was clarified by centrifuging at 
4000g for S minutes and the viral particles were aliquated in eppendorftubes and stored at 
-80°C for further use. 
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3.2.8 Inhibition of Complement In Vitro 
The bioactivity of VCP, rVCP, hrVCPE I 08K and hrvcpH98y, E 1 02K, E 120K was tested for the 
classical pathway and that of rVCP, hrVCPEI08K and hrVCPH98y, EI02K, EI20K for the 
alternative pathway of complement activation in microplate based in vitro assays. For the 
classical pathway, the ability of normal human serum to lyse 95% of sensitized sheep red blood 
cells (ssRBCs) (Diamedix Corporation; Miami, Florida, USA) was first tested in serum assay. 
3.2.8.1 Serum Assay 
The level and potency of circulating complement in human blood varies from one individual to 
another. Therefore, before using any given serum as a source of complement in assays 
measuring classical complement inhibition, its ability to lyse 95% of ssRBCs need to be 
confirmed by serial dilutions. In this experiment, three sterile eppendorf tubes were labeled as 
1:30, 1 :60 and 1 :90, and 75/l1 of ssRBCs suspension was added into each tube. Ten /ll of the 
supplied gelatin-veronal-buffer (GVB) was added into each tube and mixed well. Normal 
human serum was thawed from -80°C and diluted 1 :30, I :60 and 1 :90. Fifteen /ll of each 
dilution was added into the respective tube and the samples were incubated at 37°C for 1 hour 
prior to centrifugation at 7000 rpm for 30 seconds. Finally, 75/l1 of each sample was 
transferred into a well in a 96-well plate. The absorbance, proportional to the percentage of 
lysis, was measured at 405nm measurement filter and the dilution that yielded 95% lysis was 
used for the subsequent hemolysis assay as illustrated below. 
3.2.8.2 Modulation of Classical Complement Pathway 
The efficiencies of the natural VCP, rVCP, hrVCPEI08K and hrVCPH98y, EI02K, E120K to 
modulate the antigen-antibody triggered classical complement activation was demonstrated by 
incubating the respective protein with IgG-sensitized sheep RBCs prior to activation of the 
pathway using human serum at a dilution established by the serum assay. We have recently 
published the details of the assay (Ghebremariam3 et aI, 2005). In this experiment, 75/l1 of 
sensitized sheep red blood cells (ssRBCs) suspended in GVB were transferred into clean 
eppendorf tubes and then different amounts of each protein (20 - 100ng) were added to the 
respectively labeled tubes. Finally, 15/l1 of I :60 diluted human serum (determined using serum 
assay as described above) was added into each tube except the negative control. The samples 
were incubated at 37°C for I hour, centrifuged at 7000 rpm for 30 seconds and 75/l1 of the 
supernatant was transferred into each well of a 96-well plate. 
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The absorbance, proportional to the percentage of lysis, was measured at 405nm and was 
subtracted from 100% to calculate the percentage of inhibition. The result was standardized in 
the background of the negative control in order to account the complement independent 
spontaneous lysis of the cells. The inhibition of lysis by the various VCPs and comparison of 
their potency in modulating the classical pathway of complement activation is shown in Figure 
8 A-C. 
3.2.8.3 Modulation of the Alternative Complement Pathway 
The alternative component of the complement pathway is an active defense tool against 
microbial infections during childhood. However, excessive activation of the alternative 
pathway can result in a number of disorders as described in the literature review. In this 
experiment, the alternative pathway was selectively activated in normal human serum using 
zymosan (Fearon and Austen, 1977; Kazatchkine et aI, 1979; Fishelson et aI, 1984; Mahesh et 
aI, 1999) and then used the "Quidel Bb Fragment Enzyme Immunoassay" kit (Quidel 
Corporation, San Diego, USA) to quantify the abilities of the VCPs to regulate the activated 
pathway. This assay, modified for the first time for this purpose, was published recently 
(Ghebremariam3 et aI, 2005). The avidity of the different VCPs in modulating the alternative 
pathway of complement activation is shown in Figure 9. 
Briefly, the alternative complement pathway was selectively activated using zymosan, a 
component of the yeast cell wall. Each recombinant protein was preincubated with human 
serum and the mix was then incubated with 12.5Jlg of double-sonicated zymosan at 37°C for 1 
hour. Subsequently, 10JlI of each mix was transferred into clean eppendorf tubes and 90JlI of 
the supplied complement specimen diluent (Quidel corporation) (Appendix A) was added in 
order to make 1: 10 dilution. Prior to the addition of samples, each well in the 8-well strip was 
washed with 200Jll of IX wash buffer (Appendix A) three times (1 minute each). The samples 
(lOOJlI each) were added into the prewashed wells coated with mouse anti-human Bb antibody 
and incubated for 30 minutes at room temperature in order to allow the capture of the 
generated Bb fragments by the monoclonal antibody. The samples were then discarded and the 
wells were washed 5X using a multi-channel pipetter (1 minute per wash). Horseradish 
peroxidase (HRP)-coupled goat anti-human Bb (50Jl\) was added and incubated for 30 minutes 
to detect the bound Bb. The conjugate was then discarded and each weIl was washed 5X as 
described above. The color was developed by adding 100/-L1 freshly prepared substrate solution 
(Appendix A) and incubated at room temperature for 30 minutes. 
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Finally, 50).tI stop solution (contains 250mM oxalic acid as described in the insert provided) 
was to stop the reaction and the absorbance of the developed equivalent to 
concentration of Bb was measured at 405nm measurement filter. In this 
naIve serum and serum sample preincubated with equivalent amount of zymosan (in the 
"'R''''''_'' of the protein) were used as negative and positive controls respectively. The kit is 
normally used to assess the activation of Factor B in patients' sera. In the present study, we 
have tuned the protocol in order to evaluate the ability of a complement inhibitor to regulate 
alternative complement pathway by selectively activating the alternative pathway in normal 
human serum. 
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3.3 RESULTS 
3.3.l Modeling Studies 
The computer-based modeling exercises (using the Swiss-Model and "GRASP" programs) 
revealed the surface potentials of rVCP, hrVCPE1 08K and hrvCPH98Y, EI02K, E120K (Figure 
2A-D). The study showed that the substitution of the amino acid glutamic acid (E) to lysine (K) 
at position 108 (E 108K) has minimized the acidity of rVCP (Figure 2A and 2D) in the SCR-2 
as shown in red and subsequently increased the overall positive charge of the protein as 
displayed in blue color (Figure 2B and 2D). This single amino acid substitution has minimally 
reduced the overall hydrophobicity (water solubility) of the protein as glutamic acid has a 
hydrophobicity of -3.5 while lysine has a slightly reduced Water solubility (-3.9). 
A B 
Figure 2A and B: CPK (space filling) display style of rVCP (A) and hrVCPE1 08K (8) models 
showing a single amino acid change (EI08K) in the SCR-2. Note: the red colors indicate 
acidic amino acids while the blue color designates basic amino acid (Modeled using the Swiss­
Model software, and edited using DS ViewerPro software package). 
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The substitution of the amino acids histidine (H) to its SPICE and MCP analog tyrosine (Y) at 
position 98 ~H98Y); glutamic acid (E) to lysine (K) at position 102 (E I 02K) and the 
substitution of glutamic acid to its SPICE and sCRI homologs at position 120 (EI20K) has 
immensely increased the basic (positive) amino acid content of the modified protein 
(hrVCPH98Y, EI02K, E120K) as shown in Figure 2C and 20 below. 
C 
hrVCPH98Y, EI02K, E120K 
Figure 2C: CPK (space filling) display style of hrVCPH98Y, EI02K, E120K based on the 
crystal structure of rVCP (protein databank ID 1 G40). The blue colors indicate the basic amino 
acids substituted in the rVCP (Figure 2A) to generate this modified protein (Modeled using the 
Swiss-Model software and edited using DS ViewerPro software package). 
In addition to my modeling studies (Figure 2A - 2C) using the Swiss-Model program, Figure 
2D was kindly drawn by Dieter Blaas a/the University a/Vienna, Austria using the "GRASP" 
sajiware package. This modeling shows the sites and proximity of the modified amino acids in 
the single (E108K) and triple (H98Y, EI02K, E120K) mutant proteins (Figure 20). 
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Figure 2D: Surface potential and line drawings of rVep, hrVCPE108K and hrVCPH98Y, E102K, 
E120K displaying the sites of the mutated amino acids (shown in green clusters) and the effect 
of the amino acid change(s) in the charge distribution of the protein. Blue color indicates basic 
amino acids while red color shows acidic amino acids. (This was kindly modeled by Dieter 
Blaas of the University of Vienna, Austria using the "GRASP" software package). 
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3.3.2 Screening ofrVCPlhrVCP putative clones 
The transformed recombinant GS 115 yeast clones were PCR-screened for the integration of the 
hrvCPE1 08K and hrVCPH98Y, EI02K, El20K DNA in their genome. As shown in Figure-3 
below, the recombinant clones (Figure-3 lanes 4-7) showed a major band running at the size of 
the positive control (AOX-lIrVCP; 1222bp) suggesting size of the rVCP gene (732bp) flanked 
by the alcohol oxidase-l (AOX-I) gene sequence (490bp), the gene where the rVCP is cloned 
down-stream to. These actual recombinant clones were used for subsequent protein production 
experiments. 
2S00bp --. 
2000bp --. 
lS00bp --. 
IOOObp --. 
1 2 3 4 5 6 7 
Figure-3: Confirmation of putative rVCPlhrVCPs recombinant yeast clones in a 1.2% agarose 
gel electrophoresis. Lane-I: lkb+ MW marker; lane-2: rVCP/AOX-I and 2 control (l222bp 
and 2200bp respectively); lane-3: negative (H20) control; lanes-4 and 5: rVCP genes (1222bp 
each) representing colonies 1 and 2; lane-6: hrvCPH98Y, EI02K, El20K gene; lane-7: 
hrVCPEI08K gene. The up-arrows, inside the gel, show a second band (~2200bp) in each of the 
lanes suggesting the presence of the yeast's own alcohol oxidase gene (AOX-2; 2200bp). 
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3.3.3 Production ofrVCPlhrVCPs in Flask 
The rVCPIhrVCP proteins were produced using the protocol described above. The pre and post 
induction samples were SDS-PAGE analysed (Figure 4A) and the samples containing a band at 
the size of standard rVCP were filter sterilized, concentrated and then purified using heparin 
column chromatography. The purified samples were then SDS-PAGE analysed (Figure 4B) 
and the pure fractions were concentrated and dialysed prior to their use in the in vitro assays 
described below. 
B 
35kDa 
25kDa 
15kDa 
lOkDa 
35 kD .. 
25kDa 
1 2 3 4 
1 2 3 4 5 
Figure 4: SDS-PAGE (12%) analysis of recombinant VCPs produced in flask. (A): lane-2: 
standard rVCP; lane-3: unpurified supernatant of rVCP; lane-4: unpurified supernatant of 
hrVCPEI08K; lane-5: unpurified supernatant of hrVCPH98Y, EI02K, E120K. (B): heparin­
column purified samples of rVCP (lane-2); hrVCPE1 08K (lane-3) and hrVCPH98Y, E I 02K, 
E120K (lane-4). Lane-l is a broad range molecular weight marker (Promega). (Figure 4B is 
published in the Ann. N.Y Acad Sci 1056: 113-122 (2005) ; page-116 Ghebremariam3 et al). 
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3.3.4 Production ofrVCp/hrVCPH98Y, EI02K, E120K in Fennentor 
The production of recombinant VCPs appear to greatly vary from the flask to the fermentor 
even when using a split of the same colony (Figure 5). This could be due to the differences in 
the major variables in the flask and the fermentor. For example, temperature, pH, agitation and 
the level of oxygen available in the system are significant contributors of foreign protein 
production in Pichia pas/oris yeast expression system. The appearance of abundantly secreted 
proteins as shown in Figure-5 (lanes 5-7) may be due to the effect of methanol toxicity causing 
the release of endogenous yeast proteins. 
45kDa 
30kDa 
1 2 3 4 5 6 7 
Figure 5: Coomassie-stained SDS-PAGE (4-12% precast gel) analysis of recombinant VCP. 
Lane-I: molecular weight marker; lane-2: standard recombinant VCP (28.8 kDa); lane-3: 
preinduction sample; lane-4: 72 hours postinduction (fermentor); lanes 5-7: 24, 48, 72 hours 
postinduction samples (flask). 
However, following the second fermentation approach (growing and inducing the recombinant 
yeast cells in the same fennentor as described in "SECTION 3.2.4.2"), there was no band at the 
size of the standard VCP in any of the lanes (data not shown). The absence of VCP 
corresponding band in the fermentor sample may be due to the inhibition of methanol by 
glycerol (Invitrogen Life Technology, 2002) as the cells were induced after a short 'starvation 
period' without clarifying the growth media and therefore, this may not be an efficient 
mechanism to exhaust the glycerol (without killing the cells) supplied with the complex growth 
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medium. However, following extensive optimization trials in the flask and fermentor, the 
production of recombinant VCP was significantly improved as shown by SDS-PAGE analysis 
(Figure 6A) and western blotting (Figure 6B). Moreover, the western blotting (protocol 
described above) result also confirmed the ability of the anti-rVCP (rabbit anti-VCP) antibody 
to recognize the triple mutant (hrvCPH98Y, E102K, E120K) (Figure 6B lanes 2-5) and the 
vaccinia virus-infected mammalian cell secreted natural VCP (Iane-6) as well as their equal 
mobility despite their functional differences (Figure 8 and 9). Furthermore, optimization of the 
protein production simplifies the challenges of purification. 
3SkDa 
2SkDa 
1 2 3 8 9 104 5 6 7 

28kDa 
Figure 6B: *in lanes 4 and 5, 
in addition to the hrVCP bands, 
the size of the major bands 
(arrows) (~35kDa estimate) and 
their recognition by the rabbit 
anti-VCP antibody suggest the 
co-production of unprocessed 
(uncleaved) VCP with the 
signal sequence in the 
fermentor. However, the 
suggestion needs to be 
confirmed by Edman 
degradation (N-terminal protein 
sequencing) of the proteins. 
1 2 3 4 5 6 
Figure 6: Analysis of recombinant VCPs (A): SDS-PAGE (12%) showing lane-I: broad range 
molecular weight marker; lanes 2 and 10: standard rVCP (arrows); lane-3: preinduction sample 
(colony-I, flask); lane-4: 72 hours postinduction (colony-I, flask); lane-5: preinduction sample 
(colony-2, flask); lane-6: 72 hours postinduction (colony-2, flask); lane-7: preinduction sample 
(colony-I, fermentor); lane-8: 72 hours postinduction (colony-I, fermentor); lane-9: 96 hours 
postinduction (colon~-I, fermentor). (B): western blotting of lane-I: rVCP standard (28.8 
kDa); lanes 2 and 3: rVCPH98Y, E102K, EI20K 24 and 48 hours postinduction (flask); *Ianes 
4 and 5: hrVCPH98Y, E102K, EI20K 24 and 48 hours postinduction (fermentor); lane-6: natural 
VCP produced from infection of mammalian cells. 
63 

3.3.5 Production ofVCP from natural infection 
The tissue culture based production of VCP is usually guaranteed as long as the virus used in 
the experiment is infective enough (high titers). Our comparative experiments have shown that 
the VCP produced from vaccinia virus Lister strain (242 amino acids long) infected cells runs 
at a higher molecular weight than the VCP produced from vaccinia virus vGK5 strain (244 
amino acids). Despite its fewer number of amino acids, the lower mobility was found to be due 
to its two novel glycosylation sites (Odunuga et aI, 2005). 
The production of VCP from vGK5 strain is confirmed by western blot as shown in Figure-6B 
above. The virus titration (plaques shown in the wells) and confirmation of infectivity are 
shown in Figure 7 A and 7B respectively. 
NEGATIVE 
Figure 7A: Six-well based quantitative viral assay showing titration (quantification) of 
vaccinia virus vGK5 strain (dots showing viral plaques) at the dilutions shown. This titration 
assay shows a viral titer of 2XI08 virus particles/ml (arrows). Uninfected BSC-l cells are 
shown as "NEGATIVE' control. 
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Figure 7B: Six-well based qualitative viral assay displaying the ability of the quantified vGK5 
strain to infect mammalian (BSC-l) cells (monolayer peeled-off) at a titer of 3 X 104. The 
uninfected (negative) control is shown by an intact monolayer of cells (arrow). 
3.3.6 Inhibition of Complement In Vitro 
The abilities of the recombinant VCPs (rVCp/hrvcPElOSKlhrvcPH9SY, El02K, E120K) to 
inhibit either of the two major pathways of complement activation appear to vary significantly. 
3.3.6.1 Classical Complement Pathway Inhibition 
Using antibody-sensitized sheep red cells, the efficacies of the rVCP, hrVCPE 1OSK and 
hrVCPH9SY, El02K, E120K were detennined. This assay involves the fonnation of antigen­
antibody complex and measures the resultant lysis of the red cells bearing the complex. We 
have recently published (GhebremariamJ et aI, 2005) the outcomes of the classical complement 
inhibition by the different VCPs in a series of dilutions. The single mutant hrVCPE 1OSK has 
been found to possess approximately 25-fold increased activity (ranging from 19.7 to 33.7­
fold) while the triple mutant revealed about 100-fold (91.S to ll6-fold) increased activity than 
rVCP in inhibiting the classical pathway of complement activation (Figure SA-C). In a separate 
experiment, we have also shown the ability of the natural VCP to be about SO-fold more active 
than the rVCP in inhibiting the classical complement pathway (Odunuga et ai, unpublished 
data). 
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Figure 8: Comparative in vitro analysis of classical complement pathway inhibition at various 
dilutions. (A): R,ercentages of classical pathway inhibition by rYCP (diamonds), hrVCPE1 08K 
(squares) and hr CPH98Y, EI02K, El20K (triangles) at the indicated amounts of the proteins. 
(B): comparison ofrYCP, hrVCPE108K and hrvcPH98Y, EI02K, El20K potency at the indicated 
amounts of the proteins. Experiments were performed in duplicates and the bars indicate 
standard errors of sample mean. (Figure 8 is published in the Ann. N. Y Acad. Sci 1056: 113­
122 (2005); page-II 7 Ghebremariam3 et al). 
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3.3.6.2 Alternative Complement Pathway Inhibition 
In addition to the comparative analysis of the classical complement pathway, the activities of 
the different recombinant VCPs (rVCp/hrvcPEI08KJhrvcPH98Y, EI02K, E120K) were also 
compared for the alternative pathway of complement activation by measuring an alternative 
pathway specific breakdown product. We have published this novel assay and its feasibility in 
measuring the degree of inhibition by complement control proteins (Ghebremariam3 et ai , 
2005). Our findings have shown that the recombinant VCP with single amino acid substitution 
(hrvCPEI08K) possessed almost 55-fold increased ability, and the triple mutant (hrvCPH98Y, 
EI02K, E120K) revealed almost 100-fold increased activity. The inhibitory concentrations at 
50% (ICso) were 32ng and 16ng respectively, compared to the weaker inhibition by rVCP (ICso 
value of 1760ng) as shown in Figure-9 below . 
Inhibition of AP by rVCP/hrVCPs 
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100 
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Recombinant VCPs 
Figure 9: comparison of rVCP, hrVCPEI08K and hrVCPH98Y, EI02K, El20K in inhibiting the 
alternative pathway of comR,lement activation showing -55-fold and - IOO-fold increased 
activity by nrVCPEI08K and hr CPH98Y, EI02K, El20K respectively. (Figure 9 is published in 
the Ann. N. Y Acad. Sci 1056: 113-122 (2005); page-118 Ghebremariam3 et at). 
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The observed increase in the inhibitory of both the classical and the alternative 
pathways of complement activation following one and three amino acid substitution(s) suggest 
that the putative amino acids contact with C3b/C4b complement components and 
allowed the modified to block complement activation. 
Moreover, we have identified a new nl1T"TnJP heparin binding site of the K-X-K type (Smith et 
ai, 2000) in the mutant E 120K created by the substitution of 
glutamic 02K) (Ghebremariam3 et ai, 2005). 
Therefore, the nmnbc;r in the recombinant VCP has 
from four (in rVCP) et to 
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3.4 DISCUSSION 
classic observation that rabbit kidney (RK-I cells infected with wild-type vaccinia virus 
Western Reserve (WR) majorly secrete a polypeptide of approximately 35kDa; tog;etner 
with the of the polypeptide led to the discovery of vaccinia 
virus complement control protein (YCP) (Kotwal and Moss, 1988). The search for 
homologs in the protein database has revealed the hit (38%) to human complement-4b 
binding protein (C4b-BP) (Kotwal Moss, 1988). It was therefore observation U\l'r"f"h,3,. 
with 	 the homology search in the databank that brought the stories of human proteins, 
and mimicry of poxviral proteins together. 
Consequently, the of as a complement inhibitory protein and as a factor 
(in host defense) were established (Kotwal et ai, 1990; 
et ai, I number of poxviral complement inhibitory proteins has been 
increasing. The sequencing variola genome (Massung et aI, 1996), the in vivo cowpox 
work (Miller et aI, 1997) and the monkeypox YCP homolog DNA sequencing (Uvarova and 
Shchelkunov, 2001) to identification of IMP and 
respectively. These poxviral proteins, known as complement regulatory proteins (CRPs), share 
significant structural and/or functional homology with the human regulators of complement 
activation (RCA) family. These poxviral CRPs, with the exception IMP, have 
expressed as recombinant proteins (Smith et 2000; Rosengard et ai, 2002; SfYroera et aI, 
2005; et ai, 2006) and demonstrated their identity, 
inhibitory activity and heparin binding among and in reference to some 
members of RCA family (Rosengard et ai, 2002; SfYroera et aI, 2005; Liszewski et aI, 
2006). deduced amino acid sequence alignment of the recombinant poxviral CRPs 
above identity et aI, 2006) the paradigm conservation of 
complement inhibitors the evolution of poxviruses (Ciulla et aI, 2005). the 
remarkable identity, efficiency in inhibiting either pathways of complement 
their contribution as cofactors and their 
substantially (Rosengard et ai, 2002; SfYroera et 2005; Liszewski et 2006). For 
the amino acid (I 1-12 acids) and seem to have 
endowed SPICE with the ability to inhibit human complement 100 to 1OOO-foid more 
than VCP (Rosengard et 2002; SfYroera et aI, 2005) suggesting their ultimate 
role in complement inactivation (Rosengard et 2002; Ganesh et aI, 2004; Ghebremariam3 et 
ai, 2005; SfYroera et aI, 2005; Liszewski et ai, 2006). 
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However, not all the amino acid differences are equally critical, as some of the residues are 
located in that are inferred not to make significant contact with human complement 
C3b/C4b (Murthy et ai, 2001; Rosengard et 2002; Ganesh et aI, 2004). 
Moreover, point mutation studies in MCP, a of the RCA family sharing 35% amino 
acid identity with (Sfyroera et 2005), have shown that some residues at specific 
positions are necessary activity others are important for C3b and/or C4b 
(Liszewski et ai, 2000) suggesting the explicit role of individual amino acid residues. 
Other studies have speculated that the amino acid differences between VCP SPICE in 
module 2 (SCR-2) are critical in offering SPICE an increased C3b/C4b cofactor activity 
(Murthy et aI, 2001; Rosengard et aI, 2002; Ganesh et aI, 2004; et 2005). 
Sfyroera et al (2005) published a study addressing the importance of individual amino acid 
residue and entire module differences between VCP and The study evaluated the 
significance the amino acid differences at positions 77, 103, 108 and 120, all located 
L>~j'''-'''' (a module that above 40% VCP/SPICE acid 
individually or in various combinations. They also elucidated the effects of double amino acid 
substitutions in SCR-2 to the SPICE homologs (EI08K, E120K), triple amino acid 
substitutions in VCP or in VCP multiple amino acid substitutions in VCP SCR­
SCR-3/4 and finally VCP et aI, 2005) [only 
second to Rosengard et al (2002)]. The modeling plasmon 
resonance (SPR)-based binding assays and functional studies that were employed in the 
by Sfyroera et al (2005) addressed a number essential questions and supported our 
concentration in amino acid differences localized in SCR-2 (H98, £108, E]20). 
The novel work by Sfyroera et al (2005) showed that generated recombinant SPICE was 
about 75- and 1000- folds more potent than recombinant (rVCP) inhibiting the 
classical and the alternative pathways complement activation respectively, when using 
human sera as a source of complement. work supported the previously documented 
(Rosengard et aI, 2002) potency of recombinant over rVCP with some discrepancies 
(-to-fold) that may have risen from the differences in the assays Interestingly, the single 
amino residue substitutions in VCP to the SPICE analog significantly enhanced 
function the recombinant proteins inhibiting at least the alternative complement pathway 
et 2005). the amino substitutions in rVCP at position 
77 (Q77H) , 98 (H98Y), 103 (St03Y), 108 (E1 and 120 (E1 have upregulated the 
ability the individual modified rVCPs by 11-, 28-, 24-, 1 and folds in inhibiting the 
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complement pathway respectively (SfYroera et ai, 2005). Moreover, modified 
generated from amino substitutions in SCR-2 and to their 
homologs been found to be increasingly associated with Factor I in degrading C3b to its 
inactive components (SfYroera et aI, 2005). 
t
Our studies have demonstrated that acid substitution in rVCP at position 108 
from glutamic acid (E) to lysine (K) to match its SPICE analog 08K) the ability 
of modified protein, that we named "humanized recombinant 
rvCPE108K) n, by about and folds in inhibiting the classical and the alternative 
pathways of complement activation respectively (Ghebremariam3 et ai, 2005), again 
confirming the crucial role the residue in human C3b/C4b interaction. Additionally, with the 
guidance of sequence alignment (Liszewski et aI, 2000; Rosengard et ai, 2002), crystallography 
(Murthy et ai, 2001) and computer modeling studies et ai, 2004), we a 
modified recombinant protein with three amino acid substitutions in the rVCP (H98, 
20). The inclusion tyrosine (Y) at position 98 appears to have contributed to the 
in cofactor activity in MCP, as substitution by (Y98A) has diminished 
MCP's C4b cofactor activity to less than 40% (Liszewski et ai, 2000). Moreover, its 
conservation in and the from modeling studies predicting that the residue at 
this position is surface~exposed (Liszewski et ai, 2000; Ganesh et ai, 2004) makes it a suitable 
candidate for mutagenesis studies. In addition, the H98Y targeted mutation in rVCP has been 
shown (SfYroera et aI, 2005) to enhance the ability of the modified protein to inhibit the 
alternative complement activation by about 28-fold indicating the residues genuine role. 
Furthermore, the amino acid residue at position 102 is a critical site for C3b/C4b binding and 
C3b/C4b cofactor activities as its substitution in MCP affected the complement binding and 
cofactor activities for both the classical and the alternative complement pathways et 
2000). Moreover, MCP and VCP modeling studies have proposed that position-l02 is 
and to influence complement activity et ai, 
2000; Murthy et aI, 2001; Ganesh et 2004) it as one of the critical sites for 
interaction with E102K an additional 
heparin-binding of the Previously, Smith et al (2000) have four 
putative (KIR-X-KlR) heparin~binding sites in rVCP amino 
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this new site has nwnber of putative heparin-binding from one to 
two in SCR-2 and to five in the whole protein (Ghebremariam3 et 2005). The third amino 
residue that we considered modification was glutamic at position 120 (E120) 
to its and SPICE homolog 20K). This amino acid substitution has been shown to 
C3b binding and of secreted CR I (Krych et 1991) and the C4b 
,",V1U.... "Vl activity of et ai, 2000) making it an residue for modification. 
Moreover, the residue at this position is predicted to in VCP and MCP 
potentials. To confirm this, site-directed amino acid residue to 
analog (E120K) shown to be the most critical singie amino acid 
substitution to bridge the between SPICE and VCP in inhibiting the alternative 
complement pathway (Sryroera et ai, 2005). This single amino has bestowed on 
modified rVCP an S7-fold activity in regulating the alternative pathway (Sryroera 
et ai, 2005). We demonstrated the modified VCP triple amino acid residue 
substitutions which we named recombinant £102K, E120K)" 
to closeness to um.an'·comJ:Hernelll specific sequence, was 
IOO-fold more active than regulating both the 
pathways of complement activation (Ghebremariam3 et 2005) indicating a 
synergistic/additive effect of the individual amino acid potency. these were not the 
ultimate amino acid residues in responsible for the 100-1 OOO-foid increased potency 
to rVCP. Our amino acid KI02 exists in 02 making it difficult 
to the specific role of this residue. In addition, et al (2005) reported that 
two amino acid I'p"1I"n1P "...."'..""',,.....,'u at positions 1OS in the rVCP sequence 
to SPICE homolog OSK, E120K), a SPICE-like been achieved 
inhibiting the alternative pathway complement activation the 
mediated degradation ofC3b cofactor activity). 
(Ghebremariam3 et ai, 2005) and the Sryroera et al (2005) studies confirm that not all 
amino acid differences hpt'''lp,>n and VCP are equally crucial in interacting complement. 
differences the alternative pathway activity of the single mutant 
may be largely (yeast vs. 
probably due to the ITTP'"P"{,P''' in the mechanism of "">1"11'\"'<'" activation 
vs. LPS), measurements of alternative pathway corno()nems (Factor Bb vs. 
different substrates used in developing the reactions. 
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I 
8 
In conclusion, we modified the in vitro activity of the recombinant VCP 
inhibiting both the classical and the alternative pathways of complement activation 
9). Our modeling studies (Figure 2A-D) have demonstrated that the substituted amino 
acids have increased the overall positive charge (basic amino acid content) of the modified 
proteins compared to rVCP. This is true in the modeling studies with various amino acid 
substitution(s) in the rVCP '''/rn..r<> et aI, 2005). 
Although, there was no noticeable difference in the heparin-binding abilities of rVCP and 
hrVCPH98Y, 02K, E120K, the newly created putative heparin-binding in the latter protein 
may have some in vivo retention advantage for the humanized recombinant VCP. It has 
previously reported that the binding ability of VCP is responsible for its sustained 
bioavailability and for blocking the of inflammatory cells to the of 
injury (Kotwal, 2000; Hicks et ai, 2002; Jha et aI, 2003). The efficient increase in the in vitro 
complement inhibitory activity the humanized rVCP ChrvcPH98Y, E102K, 20K) has 
encouraged us to elucidate its in vivo role in modulating ischemialreperfusion (IIR)-induced 
injury, a complication known to cause excessive complement activation as described in 
"CHAPTER 4" of the 
CHAPTER 4 

EVALUATION OF THE IN VIVO ROLE OF VACCINIA VIRUS 

COMPLEMENT CONTROL PROTEIN (Vep) FOLLOWING 

RENAL ISCHEMIAIREPERFUSION INJURY 
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4.1 INTRODUCTION 
Renal transplantation is performed in most major centres throughout world. During the 
transplant procedure there is an ischemia reperfusion (UR) injury that accounts for a delayed 
physiological recovery of the graft. This surgically biologically induced injury results in 
inflammatory response that involves activation of the complement system. The alternative 
pathway complement activation through Factor B, C3 or the membrane attack 
(MAC; C5b-9) components has shown to the predominant route of complement 
activation one of the major causes of tissue injury renal UR injury (Zhou et ai, 2000; 
Sacks et ai, 2003; Thurman et ai, 2003; Thurman et ai, 2006). The vaccinia virus 
control protein (VCP) regulates both the classical and alternative complement 
activation by preventing the formation ofC3b, a complement component where both pathways 
aim of the study was to investigate the of the VCP produced from vaccinia virus 
infected cells (VCP), the recombinant VCP (rVCP) and humanized recombinant VCP 
(hrVCP) collectively and independently on injury of the kidney. A number of procedures 
involving techniques were attempted in order to develop a feasible renal IIR injury 
model. were found to be candid approaches in provoking renal UR 
injury in rat models. In the model (unilateral injury), IIR injury was induced by 
subjecting Evans rats to 60 minutes ischemia of the right kidney followed by hours 
reperfusion time. animals were randomly allocated to receive VCP produced from natural 
infection and cell hrVCP combination or phosphate buffered saline (PBS) 
or sham group. the second model (bilateral UR injury), the IIR injury was induced by 
subjecting Long Evans rats to laparotomy, mobilization of both kidneys and of the 
renal arteries for 60 minutes followed by 24 hours rats were randomly 
allocated to receive natural VCP, hrVCP or or sham groups. In both models, blood 
samples were collected at various intervals for BUN and creatinine studies, and kidneys 
harvested histopathological and immunohistochemical studies. 
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4.2 MATERIALS and METHODS 
4.2.1 Expression of recombinant vep (hrVCPH98y, EI02K, E120K) 

The PCR-based mutagenesis and cloning of the humanized recombinant VCP (hrVCP) in the 

Pichia pas/oris yeast expression system was described previously (Ghebremariam3 et aI, 2005). 

The expression of two alcohol oxidase genes (AOX-I and AOX-2) allows the recombinant 

yeast clone to metabolize methanol faster (Mut+) than the mere AOX-I expressing clones 

(Mue) upon induction with methanol. 

4.2.2 Screening of recombinant clones 

Selective plates such as the minimal methanol histidine (MMH) medium (Appendix A) are 

often used to screen for putative yeast transformants. However, they do not differentiate the 

actual recombinants from those harboring the Ppic9 vector (Appendix B) without the gene of 

interest. Therefore, it usually needs to be confirmed by PCR. The putative recombinant clones 

were screened using the forward (5'- GACTGGITCCAAITGACAAGC - 3') and the reverse 

(5' - GCAAATGGCAITCTGACATCC - 3') AOX-l universal primers (Invitrogen life 

technologies) and the amplified products were analysed in a 1.2% agarose gel (Figure I). The 

hrvcPH98Y, E 102K, E 120K gene-expressing recombinant clones were used for subsequent 

protein production experiments. 

The recombinant protein was expressed by inoculating positively identified colonies into 30ml 
of buffered minimal glycerol complex medium (BMGY) at 30°C at 200 rpm for 48 hours and 
then further inoculated into 970ml of BMGY until the OD600 read above 2. The cells were 
harvested by centrifugation at 4000g for 4 minutes, rinsed twice with distilled water and 
resuspended in 250ml of buffered minimal methanol complex medium (BMMY) containing 
HPLC grade methanol at a final concentration of 4% for 96 hours. 
1500bp 
1000bp 
1 2 3 4 5 
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Figure 1: Agarose gel 
electrophoresis (1.2%) of 
recombinant Pichia pas/oris yeast 
genomic DNA performed using 
AOX-I universal primers. Lane-I : 
lkb+ MW marker; lane-2: negative 
(H20 control); lane-3 : rVCP/AOX-1 
gene control amplified from Ppic9 
vector (I 222bp ); lanes 4 & 5: 
hrVCP genes amplified from Ppic9 
(1222bp each) . Note: AOX-2 genes 
(2200bp) indicated by upper arrows 
(lanes 4&5). 
The samples were SDS-PAGE analysed and those expressing a band at the size of the standard 
recombinant VCP (rVCP) were purified using a series of HiTrap heparin columns 
(Ghebremariam
3 
et ai, 2005). The purified fractions were then SDS-PAGE (12%) analysed 
(Figure 2A) and confirmed by western blotting as described above. 
4.2.2.1 Western Blot 
The purified natural VCP and the hrVCP were SDS-PAGE (Appendix A) analysed and 
confirmed by western blotting (Figure 2B) . This experiment was performed using the protocol 
described in the previous chapter. 
4.2.3 Tissue Culture Experiments 
4.2.3.1 Production of VCP from natural infection 
The natural VCP was produced in tissue culture by infecting BSC-l cells with vaccinia virus 
vGK5 strain as described in "CHAPTER 3". The post-infection supernatant containing secreted 
VCP was purified from the medium under similar conditions to the hrVCPH98Y, E 1 02K, E 120K 
containing supernatant (Figure 2A) as described above. The fractions containing pure VCP and 
hrVCPH98Y, E I 02K, E 120K were confirmed by western blotting (Figure 2B) and then pooled 
and dialysed against distilled water. The protein concentration was estimated using the BioRad 
assay as described earlier. The dialysed protein was lyophilized and resuspended in phosphate 
buffered saline (PBS; pH 7.2). The final protein was then monitored for bacterial endotoxins 
using the QCL-lOOO Chromogenic Limulus Amebocyte Lysate (LAL) quantitative assay 
(BioWhittaker, Walkersville, MD) described above. 
A 
R 
35kDa 
25kDa 
1 2 3 
M 1 2 3 
Figure-2: A) SDS-PAGE analysis (12%) & B) Western blotting of rVCP (lane-I); hrVCPH98Y, EI02K, EI20K 
(lane-2) and natural VCP (lane-3). Lane-M (Fig. 2A) is molecular weight marker. 
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In Vitro Complement Inhibition 
biological ability ofVCP and hrVCPH98Y, E120K to inhibit the classical and/or the 
alternative complement pathway(s) was evaluated 96-well based in vitro assays 
(Ghebremariam3 et ai, 2005). 
4.2.4.1 Serum Assay 
This assay demonstrates the ability of a serum to 95% sensitized sheep red blood 
cells (ssRBCs). Because not every individual has same level of circulating complement, the 
amount serum responsible to lyse 95% ssRBCs needs to be detennined when sera 
from different sources and even when using serum the same source for an extended 
period of time. In assay, the in "SECTION 3.2.8.1" was reproduced. 
4.2.4.2 Inhibition ofthe Classical Complement Pathway 
The abilities of VCP and hrvCPH98Y, EI02K, 20K to block complement mediated lysis of 
sheep red (Diamedix Corporation, Miami, USA) were tested by pre incubating the IgG­
sensitized red cells with and "',..~'''''~ .... the antigen-antibody dependent 
classical pathway using human serum as a source complement as demonstrated earlier 
(Kotwal et 1990, Ghebremariam3 et ai, 2005). The experiment was perfonned using the 
protocol ti"'<:l"rll"ll'ti 
4.2.4.3 Inhibition of the Alternative Complement Pathway 
The hrVCPH98Y, 02K, E120K was evaluated its ability to inhibit the alternative 
complement pathway by measuring a cleavage product of an alternative pathway specific 
enzyme, Bb (Quidel Corporation; San Diego, CA, USA) as described previously 
(Ghebremariam3 et ai, 2005). The details the procedure used in this experiment are 
described in the previous chapter. 
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Animal Experiments 
4.2.5 Procedure-l 
Four male Long rats 147-1S7g were used in study. The animals were 
caged under standard conditions including a regular light and dark cycle with unlimited access 
to rat chow water prior to the start the experiment. The research protocol was approved 
by the University of Cape Town animal research ethics committee. 
4.2.5.1 IschemialReperfusion Injury 
UHIUIUI., were with a combination of diethyl ether and ketamine 
hydrochloride (lOOmg/kg, im). abdomen was cleaned with a cleaning solution and shaved 
with surgical blade. Laparotomy was performed by midline incision both kidneys were 
dissected. The animals were catheterized and baseline blood and urine were collected prior to 
was induced by both and left arteries 
(bilateral clamping) with non-traumatic vascular clamps 4S minutes. The flow of blood was 
reestablished by removing the clamps and the abdominal cavity was closed with 4-0 prolene 
blue monofilament polypropylene suture (Ethicon, In addition to the baseline, blood 
samples were collected at start reperfusion and 2 hours of 
blood flow until sacrifice. Blood urine samples were collected urea 
studies (serum) and analysis (urine). kidneys were harvested and fixed in 
10% formalin histopathological studies. 
4.2.5.2 Administration of rVCP 
In the VCP recipient group, the recombinant VCP (rVCP) was administered both intravenously 
(IV) and intraperitoneally (IP) one animal. In order to potentially prevent or at least 
minimize ischemia, an IP injection of 2Smg/kg was administered two hours before the 
laparotomy. Moreover, an IP injection of 30mg/kg was given just after closing the abdominal 
wall. Furthermore, IS minutes before clamping, a bolus IV dose of Smg/kg was administered 
through the vein. Subsequently, rVCP was IV (1 IS 
the (that is 30 minutes applying the clamps), just removing 
the and every IS minutes 2 hours in order to increase the bioavailability the 
protein. 
order to comparatively the most suitable route of administration and possibly cut 
down the tedious and vUf,,""S'US IV rVCP was administered (n 1) only IP in 
the same interval and at the same to the IP route of first animal. Blood and urine 
",",1I,'V"-" were at the same In one animal, phosphate buffered saline (PBS, 
pH 7.2) was administered both IV and IP at equivalent intervals to the administration of 
rVCP in the first animaL In procedure, one animal was included as a sham control in order 
to understand the of anesthesia and surgical procedure~induced stress in blood 
biochemistry. In this animal, the kidneys were similarly isolated, however, no were 
applied and animal did not any ml!~ctlon. 
4.2.5.3 Blood Urea Nitrogen (BUN) Assay 
The blood samples were allowed to clot at room temperature overnight. The serum was 
separated by centrifuging at 3000 rpm minutes and kept at until use. samples 
were thawed once prior to study. Here, the Kinetic UV method was used to 
measure the serum levels. One reagent tablet was first dissolved in I of supplied 
(Boehringer, Mannheim). After 15 minutes, 10).11 serum or standard (precinorm U at 
50mg/dl) was added to every ml of the solution and mixed gently. Finally, two 
were taken at 340nm at 30 seconds (AI) and 3 minutes (A2) after the addition of the sample or 
standard and the concentration urea was calculated as: 
Where: AI & A2 are sample and 
are standard absorbance at 30 sec 
& 3 min. respectively 
Creatinine Assay 
The blood samples were separated as described above in the BUN assay and 50).11 of each 
serum was diluted (l: 1) with distilled water. Two hundred ).11 of sodium was 
and mixed well. Thereafter, 200).11 of sulphuric acid was added, mixed and centrifuged at 3000 
rpm for 15 Following the spinning, 200).11 each supernatant was transferred into a 
eppendorf tube and was mixed with 200).11 picric acid in to down 
other metabolities and separate them from interfering with the creatinine readout (Sharpe, 
1925). Finally, 200).11 of NaOH (0.75 M) was added and incubated for 20 minutes at room 
temperature. The was taken at run. 
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was done using the HiTachi U-2000 spectrophotometer and two and 
a positive control with known creatinine concentration were used to justifY and calculate the 
concentration of creatinine in the sample. The creatinine concentration was calculated as 
follows. 
C (mg/dl) = 

Standard absorbance* 

=~==== 
*N.B: The "standard absorbance" was the averaged result of two independent 
absorbencies. 
""....",..,.,.., Urinalysis 
In order to confirm the previously suggested hypothesis (Jha et ai, 2003) of the rapid exclusion 
of VCP from circulation and to clarifY the presence of high molecular weight proteins 
following ischemiaJreperfusion injury, urine samples (from baseline and sacrifice) were 
comparatively elucidated via SDS-PAGE. The samples were kept at 4°C and then 20f.li of each 
sample was transferred into clean eppendorf tubes and centrifuged at 7000 rpm for 5 minutes. 
The supernatant was separated and 16.51l1 was mixed with 6.51l1 ofloading buffer mix and then 
analysed by SDS-PAGE (Figure 3). 
4.2.6 Procedure-2 
Seven male Long rats weighing 240-274g were used the The animals were 
housed under standard temperature and pressure including a regular light and dark cycle 
with free access to rat chow and water 24 hours prior to the procedure and then access to 
water for the duration of the experiment. 
4.2.6.1 IschemialReperfusion Injury 
The animals were initially anesthetized with a combination of diethyl ether inhalation and 
ketamine hydrochloride (lOOmg/kg, im) (Centaur Labs). The abdominal was cleaned 
with a surgical detergent and laparotomy was performed by midline incision. With the 
exception of sham control, acute renal failure was induced by removal of the right kidney 
(right nephrectomy) followed by 45 minutes occlusion of the left renal pedicle (artery and 
vein). 
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this procedure, the animals were allowed to stabilize following the nephrectomy prior to the 
contralateral clamping. The perfusion of blood was reestablished by removing the vascular 
clamps and the abdominal cavity was with black-braided 5-0 Sharpoint precut 
suture (Sharpoint, USA). In addition to baseline, blood samples were collected at the time 
reperfusion, then every 2 hours until sacrifice or the completion of experiment The 
right kidney (trimmed for identification) was pre-fixed in 10% formalin and left kidney was 
harvested during sacrifice and fixed likewise. 
4.2.6.2 Administration of rVCP 
The recombinant vep (rVeP) was administered both (IV) and intraperotoneally 
(IP) in two of rVep A dose of 8mglkg was injected IV (through the renal 
vein), 60 minutes before applying the clamps and 30 minutes after clamping (although the 
renal vein was clamped during this administration, the first blood that flows following 
reperfusion was expected to immediately transport the protein once the blood flow was re­
established). An IP dose 30mglkg was 2 hours the start of the 
experiment, the establishment of blood then 4 hours until 
sacrifice or the completion of experiment. two vehicle control animals, normal saline 
(0.9%) (Adcock Ingram, Johannesburg, South Africa) was administered both IV and at 
equivalent to administration of rVeP. Moreover, in order to observe the effect of a 
non-complement inhibitor on ischemiaireperfusion one was administered 
(IV IP) with bovine serum albumin (BSA) at equivalent intervals to the administration 
rVep and normal saline. BSA was chosen due to the easier availability of the protein. 
In addition to the aforementioned control animals, one animal was used as a nephrectomy 
control without contralateral clamping. From this model, it was expected to draw on 
the ability of a single intact kidney to clear metabolic the degree of stress and 
discomfort by nephrectomy, and most importantly to evaluate the effect proteins; 
complement inhibitor and non-inhibitor, in renal ischemiaireperfusion injury. A sham control 
was included to understand the anesthesia and the stress by 
lengthy In this a similar procedure was followed to dissect the 
kidneys. However, neither nor clamping was applied and the did not 
injection the course of the study. The body temperature the animals was 
maintained by covering with a regulated warming blanket. 
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4.2.6.3 Blood Urea Nitrogen (BUN) Assay (method adapted from the MPR2 Urea Kinetic UV 
method supplied insert) 
The blood samples were allowed to clot at room temperature 2 hours and serum was 
separated spinning at 3000 rpm for and stored at until use. In 
biochemical experiment, the Kinetic UV method was 
in the serum This method applies the urea in sample into 
(NH4+) by the help the catalytic urease and then the generated NH4+ 
undergoes an oxidation reaction with alpha-ketoglutarate and the coenzyme nicotinamide 
adenine dinucleotide (NADH) in the presence of glutamate dehydrogenase (GLDH) to yield 
glutamate and NAD+ which is proportional to the ('...rl('p:nTr~lTl of urea in sample. The 
chemical is displayed as follows: 
"N.B: The chemical representation of the reaction was reproduced from the MPR2 Urea Kinetic UV method 
insert (Boehringer, Mannheim). 
The amount of incubation and measurement was 
to the one explained under "procedure-J " above. 
4.2.6.4 Creatinine Assay 
The same batch of serum (to the ones used for BUN assay), all other required solutions as 
well as the amount of sample used, of incubation, standards and absorbance measurement 

filter described above for creatinine were used this set of experiment. 

4.2.6.5 Histopathological Study 

Both kidneys each animal were sectioned longitudinally and then dehydrated, cleared, 

wax impregnated and embedded in paraffin. The sections were cut 1-2J.tm sections and 
stained with Hematoxylin and (H & E) stain. A blinded pathologist evaluated the 
sections. 
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4.2.7 Procedure-3 
Six male Long rats weighing 156-176g were used in this study. The animals were caged 
under conditions including a regular (l2-hour) and dark (12- hour) cycle with 
access to rat chow and water prior to experiment. The animals were "Tt'",.tl'·rt from 
the day before the procedure. 
4.2.7.1IschemialReperfusion Injury 
The animals were with a combination of inhalation and ketamine 
hydrochloride (lOOmg/kg, im). The abdominal area was sterilized with a cleaning solution and 
was shaved to expose the abdominal skin. Laparotomy was performed by midline incision and 
both kidneys were isolated. The animals were randomly allocated to receive rVCP, normal 
saline or sham controls (n = 2 each). Baseline blood was collected prior to induction 
which was provoked by flow of blood in both the right and renal 
arteries for minutes. The flow of blood was reestablished by removing the clamps and the 
abdominal cavity (skin and muscle layer) was closed with 4-0 and 6-0 prolene blue 
monofilament polypropylene sutures. The animals were then stabilized and returned to their 
In the sham both the were dissected similarly without the application of 
clamps. Blood were collected 8 hourly for hours the kidneys were harvested 
histopathological study. 
4.2.7.2 Administration of rVCP 
To further elucidate other potential route of rVCP administration, the rVCP was injected 
subcutaneously (SC) at 30mg/kg 2 hours the surgical procedure and then every 4 hours 
for the duration of the study period. Normal (0.9%) was administered to the (saline) 
pnnrr", animals at equivalent to administration ofrVCP. No injection was given to 
the sham group during the study period. 
4.2.7.3 Blood Nitrogen (BUN) Assay 
BUN was np,'1"A.'t'n,·rt as demonstrated 
4.2.7.4 Analysis of serum Complement 
In order to evaluate efficacy of rVCP administration SC and the expected subsequent 
complement inhibition, level of (classical) complement was semi-quantified 
indirectly by hemolysis assay. dilution of serum to 95% of the 
"n...u,., ......"'... sheep red blood cells (ssRBCs) was determined serum assay as described above. 
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Once serum dilution was determined, 75111 of the were mixed with lO1l1 of the 
supplied GVB buffer 151li of serum from rVCP, saline or sham control rats 
after 24 hours IIR injury. the complement such as VCP the 
level complement is expected to be minimal and tt'lp,rpTnrp of the ssRBCs would 
lysed. reaction mix was incubated at 37°C for I hour and spun at 7000 rpm for 30 
seconds. Seventy-five III of each was transferred into a 96-well microplate. 
absorbance was measured at 405nm and the percentage of lysis, proportional to level 
'V"'V"". was calculated compared among the groups. of were 
incubated without serum as a negative control and human serum at a dilution known to lyse 
95% of ssRBCs was used as a positive controL 
Histopathological Study (protocol from Marilyn Tyler's adapted Department of 
Surgery, Groote Schuur VeT) 
The kidneys were sectioned 10ngitudinal1y and then fixed III 10% formalin, dehydrated, 
cleared, wax impregnated and embedded in paraffin. The were cut in 1-21lm sections 
on a sliding microtome Microtome sliding 2000R), floated onto microscopic slides and 
with Hematoxylin and Eosin (H E) as briefly described below. 
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4.2.8 Procedure-4 
Eighteen male Long rats 18g were in this study. The animals were 
housed under temperature and pressure (STP) including a regular light and dark cycle 
with free access to rat and water. 
4.2.8.1 IscbemialReperfusion Injury 
The animals were anesthetized with ketamine hydrochloride (IOOmgikg, im). The abdominal 
cavity was cleaned with plasmalyte B cleaning solution and shaved with gamma radiation 
surgical blade (Paramount Surgimed Ltd). Laparotomy was performed by midline 
incision and the right kidney was dissected under surgical microscope. blood was 
collected from the inferior vena cava and ischemia was induced by clamping 
artery with clamps for 60 minutes. The perfusion of blood was 
reestablished by the clamp, and the abdominal wall was closed with 4-0 prolene blue 
monofilament polypropylene continuous suture (Ethicon, PA). The animals were randomly 
allocated to receive VCP or (n 6 each). Similarly, in the sham group (n 6), the right 
kidney was dissected, however, no clamp was applied. At the end of the hours experiment, 
the animals were f'lVE'I"!H'P"'"''''W''''''''' and blood was collected from the aorta for biochemical 
kidneys (left right) were for histopathological and 
immunohistochemical studies. 
4.2.8.2 Administration ofVCP/hrvcPH98Y, EI02K, E120K 
In the VCP recipient group, a combination of the natural infection derived VCP and the newly 
characterized recombinant VCP (hrvCPH98Y, EI02K, E120K; abbreviated in the text as hrVCP) 
was administered both intravenously (IV) and intraperitoneally (IP). Due to its efficient in vitro 
complement inhibitory activity (Ghebremariam3 et ai, 2005), lower doses the hrVCP were 
administered in this model compared to the amount of rVCP used the previous procedures. 
The hrVCP was initially administered IP at 3mgikg, 2hours before the laparotomy. 
Subsequently, 5 minutes before clamping, 15 minutes before and 5 minutes after releasing the 
clamps, an IV of 600llgikg was through the dorsal To maintain 
bioavailability of the protein in circulation, an amount of 3mgikg was given IP every 4 hours 
until the completion of the study. The control group received similar volumes of phosphate 
buffered saline (PBS) at equivalent intervals to the administration ofVCPI hrVcPH98Y, EI02K, 
E120K. 
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In this model, the normal administration was replaced by PBS because it was found that 
an..",'""" study has shown the perfusion of rat kidney with normal saline causes increased 
and functional damage compared to a similar perfusion with PBS (Hughes et aI, 
1996). sham group did not receive any injection during the entire study period. 
4.2.8.3 Blood Urea Nitrogen (BUN) Assay 
Despite its susceptibility to exogenous factors such as protein-rich diet in one extreme 
starvation on the other, BUN is routinely to assess renal function. In this 
the serum of urea from the baseline following the IIR injury were 
compared. Blood samples were allowed to clot for 45 minutes at room temperature and were 
centrifuged at 2500 rpm for 30 minutes. The concentration of urea was estimated using the 
Urease-UV Kinetic enzymatic assay kit (Kat Medical, Gauteng, South Africa) following the 
procedure inserted (Kat Medical). 
4.2.8.4 Creatinine Assay 
Serum samples obtained using the procedure described above were analysed for creatinine 
concentration (Merck Chemicals, Gauteng, South Africa) using the HiTachi U-2000 
spectrophotometer (HiTachi, Japan) and the mean concentration was compared among the 
4.2.8.5 Histopatbological Study (protocol adapted from Marilyn Tyler's adapted protocol, lpn:~rtnlp.nt of 
Groote Schuur Hospital (GSH), VCT) 
The harvested kidneys were sectioned longitudinally before fixing them in 10% formalin 
(prepared in PBS). The sections were cleared and wax 
impregnated; Leica 1020 Germany), embedded in wax, and 
cut in 1-21lm sections on a sliding microtome (Leica Microtome sliding 2000R). The sections 
were floated onto slides and fixed at prior to Hematoxylin and (H & 
stain. The were initially cleared in xylol for 3 and then twice for I 
prior to hydration in a series of 96%, 70% alcohol for 1 minute 
were rinsed with water for 1 minute and then hematoxylin ~ ....,,.~'~ 
seCtiOIIS were then rinsed in running tap water for 1 minute and dipped in acid alcohol for 10 
prior to rinsing with blue water for 1 minute and in tap water for 
another minute. The sections were counterstained with (l %) for 2 minutes and 
before dehydrating them in 70%, 96% and absolute alcohol respectively. The sections were 
finally cleared with xylol and covered with Canada balsam cover slip prior to examination. 
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The histology was interpreted by a pathologist blinded to the treatment that the animals 
received and the of injury was scored (Figure 8). 
4.2.8.6 Immunohistochemical (The VCP immunostaining was performed by Amod p, Kulkarni 
using protocols modified from Marilyn Department of Surgery, GSH, VeT and Amod P. Kulkarni's; 
Division of Medical Virology, protocols the proteolytic enzyme retrieval and 
the C3 staining was peiformed by Heather !isley, chief medical technologist in the Division of Anatomical 
Pathology, VCT) 
The paraffin embedded tissue sections (mounted on APES coated were immunostained 
VCP and the complement component C3. For the VCP (Figure 9), sections 
were at 60°C about 1 hour prior to in xylol for 20 minutes (4 """"UF.""', 
5 minutes each) and then rehydrated from absolute alcohol to 96% (2 changes, 2 minutes each) 
and quick rinsed in Afterwards, the tissue's own (endogenous) peroxidase activity was 
inhibited using 2% commercially available H20 2, diluted in distilled for 5 minutes and 
rinsed in both the cooker and the proteolytic 
a11<15"'11 retrieval methods were the method, the citrate buffer 
6.0) was initially boiled and slides were in the buffer. l'",n,li'pr was switched 
on and the boiling pressure was maintained for 2 minutes to 'cook' the tissue releasing 
the pressure the process conduction. Alternatively, in the proteolytic enzyme 
method, the were with the proteolytic enzyme 
(DakoCytomation, Denmark) for 8 minutes. slides were to tap water 
for 10 minutes and then rinsed in PBS-T(ween 20) (Appendix A) for 5 minutes. The sections 
were blocked with 1 :20 diluted normal goat serum (DakoCytomation, Denmark) for 10 
minutes and then incubated with chicken anti-VCP primary antibody (1: 150) at 4°C overnight. 
controls, no primary antibody was added. The slides were rinsed with 
for 10 minutes prior to 50 minutes incubation with 1:350 diluted goat anti-chicken secondary 
antibody Laboratories, Burlingame, CA). The slides were quick rinsed with and 
then incubated for 30 with 1:400 diluted avidin (Dako AlS, Denmark) and rinsed again 
with PBS-T to 5 minutes incubation with the chromogenic substrate 
diaminobenzidine (DAB) (Novocastra) and then with PBS and water enhancing 
the color with 1% copper sulphate solution for 5 minutes. sections were counter 
with hematoxylin 30 with blue water for 
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Finally, the were rinsed with tap water for 5 minutes, (in a of 70%, 
96% and absolute alcohol), xylol and then mounted in Entellan (Marienfeld, Germany). 
specificity and the degree of antibody staining were interpreted by a pathologist and 
scored semi-quantitatively. 
4.2.8.7 Complement Component C3 staining 
the complement staining, APES slides were used. The were xylol dewaxed 
and rehydrated prior to treatment with protease (5mg/ml) at 37°C 30 minutes. slides 
were rinsed with PBS for 5 minutes and blocked endogenous activity 
1% H202 for minutes then in water and PBS sequentially. The were 
blocked 1:3 diluted normal serum 20 minutes. the serum was 
drained off the slides were incubated with 1 :700 diluted rabbit anti-human polyclonal C3 
antibody (Dako NS, Denmark) 45 minutes and then washed with for 5 minutes prior 
to incubation with 1: 160 diluted anti-rabbit peroxidase conjugated secondary antibody. 
slides were washed with PBS for 10 minutes and the color was developed for 2 
using DAB. slides were and was enhanced with sulphate 
solution (1 %) 5 followed by a wash with distilled water and counterstaining 
with Mayer's hematoxylin 30 Finally, the sections were with 
water for 30 seconds and dehydrated, cleared and mounted immunohistochemical 
examination. Here, the uninjured (left) kidney of each group mounted on the same was 
used as a the C3 in right were 
compared among 10). Rabbit anti-human po\yclonal antibody 
NS, with cross-reactivity to rat C3 was as a antibody and 
the staining was performed in department of anatomical pathology, UCT. 
Statistical Analysis 
creatinine concentration results are demonstrated as mean ± SEM n independent 
experiments. Microsoft was used to plot the creatinine 
4.2.9 Procedure-5 
male (LE) rats 422 479g were used in this study. The animals 
were housed under standard conditions (temperature, and humidity) including a 
regular light (l2-hour) and dark (12-hour) cycle with free access to rat chow and distilled 
water. The modified protocol was amended by the University Cape Town anima! research 
ethics committee. 
4.2.9.1 IschemiaJReperfusion Injury 
on the invasive applied to establish ischemia/reperfusion-induced 
acute rena! failure, the optimization procedure was finally refined in my own hands. In order to 
stimulate an ischemia model with both structural and functional feasibility, the following 
procedure was applied this experiment. The animals were anesthetized with forane 
(isoflurane) (Abbott Laboratories S.A. (pty) Ltd) and abdominal cavity was 
with a solution. The abdominal was exposed and laparotomy was 
performed by midline incision. Both kidneys were carefully dissected under surgical 
microscope and baseline blood was collected from the inferior vena cava. Acute renal failure 
was by ceasing the flow of blood confirmed by visual inspection of the kidneys) 
in both right and left arteries 60 minutes followed 24 hours The abdominal 
cavity was closed with ethilon blue monofilament polyamide 6 
suture (Ethicon, Johnson&Johnson, PA). The animals were allowed to recover the 
surgical procedure and were administered with 1001-11 of the 
(300J.!g/ml) (Schering-Plough R C UK) intramuscularly (1M), to 
minimize the degree pain and discomfort provoked by the procedure. The renal failure was 
induced in VCP, the hrVCPH98Y, E102K, E120K recipients (n = 3 each) and the PBS 
vehicle control (n = 4). In sham group (n = 4), both kidneys were similarly 
isolated without the application of vascular clamps. After 24 hours, animals were 
overanesthetized and blood was collected from the aorta for BUN and creatinine ".IAYl"". The 
were harvested for histopathological and immunohistochemical studies. 
4.2.9.2 Administration of VCP/hrVCPH98Y, EI02K, E120K 
Based on the promising therapeutic role of proteins, it was decided to elucidate the 
therapeutic potential of protein independently. animals received the yeast-cell 
humanized recombinant VCP, with three critical amino acid differences to the rVCP, 
(hrVCPH98Y, 02K, 20K) and the animals were administered with the 
mammalian cell derived natural VCP. 
On the of the previous partial protection outcomes, doses (to assess 
whether the amount of protein was a limiting was administered both 
intravenously (IV) and (IP). Two hours before laparotomy, an dose 
4mglkg was administered initially. effectively down the of complement, an IV 
(dorsal vein) dose of Imglkg was then injected 5 minutes before applying the clamps, 
minutes after clamping and 5 minutes after releasing clamps. Due to slow absorption 
and hence relatively delayed elimination the body, the IP dose was administered 
sparingly 4 hours for 24 hours study period. vehicle control group received the 
same volumes of PBS at equivalent intervals to the ofVCP. The did 
not any injection during study 
4.2.9.3 Blood Urea Nitrogen (BUN) Assay 
serum urea nitrogen concentration was comparatively estimated between the baseline level 
and following IIR injury. The blood were allowed to clot 2 at room 
temperature and sera was separated by centrifugation at 3000g for 30 minutes. This 
was performed using the Urease-UV Kinetic kit following the procedure 
provided as described above. 
4.2.9.4 Creatinine Assay 

The serum creatinine concentration was estimated using the procedure described above and 

was repeated in an independent laboratory (The National Health Laboratory (NHLS), 

Clinical laboratory, GSH, UCT) an automated technique. 
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4.2.9.5 Histopathological Study 
was performed the protocol adapted from Marilyn Tyler's (Department 
of Surgery, VCT) adapted protocol. The formalin (10%) fixed kidney tissues were 
dehydrated immersing them in an increasing percentage of ethanol, the dehydrated sections 
were then xylol cleared and wax impregnated; TP 120 processor, Nussloch, Germany). 
tissues were then embedded in liquefied paraffin wax (55-60°C), cut in 1 
on a sliding microtome (Leica Microtome sliding 2000R). The sections were mounted 
onto microscopic slides and heat fixed at 55°C incubator. H E protocol was as 
demonstrated under procedure-4 above. The histology was examined and interpreted by a 
pathologist blinded to treatment that the animals received and the of injury was 
scored. 
Immunohistochemical Study 
To assess the density and distribution of the complement component C3, the paraffin 
embedded tissue sections mounted on APES coated slides were immunostained as described 
under procedure-4 above. this experiment, only the proteolytic enzyme retrieval 
method was used. The degree distribution antibody LUIUIU5 was 
interpreted by a blinded pathologist and graded semi-quantitatively. 
Statistical Analysis 
The BUN results are "',",l11V'''''<l as mean ± SEM of n 
independent experiments. The values were subjected to one-way analysis of variance 
(ANOVA). ANOV A, developed by Sir Ronald Fisher in the 19th century, is a scientifically 
valid statistical method of perfonning multiple r{'\rnn~irl and a 
differential over pairwise comparisons employed by Student's t-test when """"uU"F. 
with multiple groups at a (Durrheim, 2002). In experiment, analysis was 
both the "STATISTICA" "R" software "STATISTICA" was 
when there was homogeneity of variance in "R" was used when of 
was needed. Both programs were kindly run by Dawit Y. Ghebrehiwet, 
10),,),rt)'I'''''''''''lo/Zoology, 
4.3. RESULTS 

4.3.1 Procedure-l 
4.3.1.1 Mortality 
The small of the animals, frequent bleeding (bled up to 4 times 500-700f.L1 time), 
unavoidable surgical the possible triggered by the anesthesia as well as the 
accounted for deterioration of the animals' health. As a result, the 
experiment was humanely terminated sacrificing the animals between 5 hours 20 minutes 
and 8 hours and 30 minutes post-reperfusion. 
4.3.1.2 Serum Creatinine and BUN 

Due to fewer number of animals used in this experiment, the short survival of the animals, 

and the extreme fluctuation in the biochemical data analysed, there was statistically 

insignificant (extremely variance) levels of BUN and creatinine within and the 
Therefore, serum urea and concentration results were based on 
null hypothesis (Hoffman, 2002). 
4.3.1.3 Urinalysis 
samples obtained through catheterization from the baseline and the times 
were (12%) to assess filtration of the renal system 
that could otherwise had been reabsorbed under physiological conditions. Despite the 
short survival (reperfusion injury) there was significant excretion of bulky proteins following 
the ischemiaireperfusion injury suggesting pathological changes in the renal system 
the animals exposed to I1R injury 3). The intensity of the post-reperfusion sample in 
the control slightly dense lane-6) compared to the VCP 
treated animals (Figure-4A, the therapeutic value ofVCP. Interestingly, 
post-reperfusion urine sample the sham group also displayed significantly 
banding patterns (Figure- 3B, lane-3) compared to the baseline protein bands (Figure-3B lane­
2) suggesting the possible reperfusion injury due to stress, anesthesia and dehydration-induced 
hypovolemic shock. 
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Figure 3 (A&B): SDS-PAGE analysis of urine samples A) pre (lanes 1 & 3) and post IIR injury (Janes 
2 & 4) of VCP treated rats. Pre (Iane-S) and post (lane-6) I/R injury of PBS group. B) Standard VCP 
(28.8 kDa) indicated by arrow (Iane-l); baseline control from sham 'injured' (lane-2) and sampled at 
sacrifice (after - 8 hours) (lane-3) . 
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Procedure-2 
4.3.2.1 Creatinine and BUN 
animals were kept lying on the (OR) (the animals were needed to be 
sedated due to the IV catheterization) for duration of the experiment or until death . 
..,au",,,,",, significant swelling the due to insufficient circulation. In addition, the 
animals were frequently bled biochemical studies. Consequently, the rVCP treated, one (of 
two) PBS control, nephrectomy control and even the sham control animals died between 5 
hours 35 minutes and 17 hours 30 minutes. Neither the BUN nor serum creatinine levels 
had significantly deviated from the baseline values in animals. 
One of the saline group animals survived 23 hours post reperfusion and therefore the BSA 
administered animal was for In two animals, the 
significantly from 21.5mgldl baseline in the BSA group to 121.4 mgldl at 
and from 18.68mgldl baseline the saline group to 192.40mgldl at sacrifice suggesting a 
significant accumulation the nitrogenous waste following the induced ischemia/reperfusion 
injury. However, there was no significant difference in the creatinine levels. 
4.3.2.2 Renal Histopathology 
animals that died hours nn..OL~''''n,~""" did not show histologic 
changes, in the 'injured' kidneys', mild apoptosis some ('Arlt1pnC~ltI 
chromatin that are markers of early cell damage. However, the saline control and the BSA 
'treated' animals displayed extensive tubular necrosis. Surprisingly, the BSA 'treated' rat 
showed even more pathologic than the saline control vehicle (data not shown) 
suggesting that administration of bovine serum albumin (BSA) did not only to provide any 
protection but contributed further and unanticipated damage possibly by the 
plasma volume and therefore reperfusion injury. 
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Procedure-3 
4.3.3.1 Blood Urea Nitrogen 
Surprisingly, the BUN levels post ischemialreperfusion injury was unequivocally lower than 
the corresponding baseline samples in 5/6 (83.3%) of the animals' suggestion either decreased 
urea production by the liver or starvation. rule out the first possibility, liver tissues from 
group were H & E stained and interpreted by an expert. liver histology revealed 
normal cytology and tissue architecture (data not shown). It is very likely that 
possibility, starvation, was the reason as the animals were from the day before 
I"Yt"iPl"lm.;>nt to avoid factors such as diet influencing the outcome. Moreover, pre 
weighing animals a significant drop in body weight (the 
was 18 grams animal). 
4.3.3.2 Complement Analysis 
serum complement level before foHowing ischemia reperfusion injury was analysed. 
All ""'1'""""" showed similar \."U","1'. complement (classical component) 
the injury or lack of injury and despite er.., ..... "_,,, of rVCP that Injury 
did not hyperactivation of classical component of complement pathway and the 
administered rVCP did not inhibit the classical pathway of complement activation suggesting 
that subcutaneous (SC) route is not an effective route for systemic delivery. This was in 
agreement to previously outcomes Comm. Smith, University 
KY, USA). because renal injury predominantly 
involves alternative complement this observation only 
importance. 
4.3.3.3 Renal Histopathology 
The minutes bilateral clamping approach did not induce a fine ischemialreperfusion injury 
model in own hands. The histology only focal necrotic changes and was not 
to compare effect of 
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4.3.4 Procedure-4 
4.3.4.1 Serum Creatinine and BUN 
As shown in Figure 4 below, there was considerable difference (1.2-fold ± 0.127) in the serum 
creatinine levels between the untreated injured (PBS) group and the VCP/hrVCP treatment 
group, suggesting that the VCP improved renal function and enabled the renal system to 
excrete the metabolic waste better than the equally injured animals in the untreated group. The 
sham group displayed the lowest serum creatinine levels as expected. However, there was no 
statistically significant difference in the serum urea and creatinine levels among any of the 
groups. 
Comparison of serum creatinine conc. following I/R 
injury 
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Figure-4: Mean Serum creatinine concentration after 24hrs I/R injury. Bars represent standard 
errors of sample mean (mean ± SEM). 
Interestingly, one additional, bilaterally clamped, animal showed a 2.9-fold rise in serum 
creatinine and a 25.3-fold rise in serum BUN levels after 24 hours of IIR injury compared to its 
baseline concentrations suggesting that acute renal failure (ARF) was induced in this animal. 
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4.3.4.2 Renal Histopathology 
Figure 5, 6 and 7 show the representative renal histologies of the sham, VCP and PBS groups 
respectively. In the sham group, the tissue displayed normal glomerular (not shown in Figure) 
and tubular histology (Figure 5A & B) in both kidneys. In the VCP group (Figure 6B), focal 
necrosis of the tubular epithelial cells was observed in 5/6 (83%) of the animals compared to 
the markedly elevated and diffuse necrosis of the tubular epithelium in the PBS group (Figure 
7B). The uninjured kidneys were stained for intra-group comparison (Figure 6A for the VCP & 
Figure 7 A for the PBS group). The representative right kidneys from each group are displayed 
for simultaneous comparisons (Figure 8 A-C). 
A B 
Figure 5: H & E stained left (A) and right (B) kidney histology displaying normal tubular 
epithelial cells following sham 'injury' (photographs taken at 40X objective magnification at 
different contrast of visible light). 
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A B 
Figure 6: H & E stained kidney histology in the vep treated group demonstrating nonnal 
tubular epithelial cell population in the left kidney (A) and focal necrosis (arrows) of tubular 
epithelial cells (B) following 24-hours ischemialreperfusion injury (40X objective 
magnification). 
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A B 
c 

Figure 7: H & E stained kidney histology in the PBS vehicle control group portraying normal 
tubular epithelial cell population in the left kidney (A) and extensive tubular epithelial cell 
necrosis in the right renal cortex (B). C) shows cortico-medullary (arrows) necrosis following 
24-hours ischemialreperfusion injury. All, except C) at lOX, were at 40X objective 
magnification. 
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A 

B c 
Figure 8: H & E stained right kidney histology: A) nonnal tubular epithelial cells (sham 
group); B) focal necrosis (arrows) of tubular epithelial cells (VCP group) and C) extensive 
tubular epithelial cell necrosis (renal cortex) (PBS group). (40X objective magnification) . 
104 

4.3.4.3 Immunohistochemistry 
The antibody staining for VCP revealed that the protein administered systemically reached the 
kidneys and was retained significantly in the renal tubules and minimally in the apical 
membranes of the renal cortical tubular cells as well as the Bowman's capsule epithelium 
(Figure 9A). This is most likely due to the heparin binding property of VCP (Smith et aI , 
2000), as the heparin like molecule, heparan sulfate proteoglycan (HSP), is an essential 
constituent of the tubular basement membrane (Lelongt et ai, 1988). Both the kidneys have 
almost equally retained the administered protein despite the level of injury to the right kidney. 
Both the PBS and the sham group (Figure 9B) did not show any VCP staining as expected. 
R 
Figure 9: Immunostaining for VCP showing A) strong tubular epithelium stain (arrows) and 
B) negatively stained section from untreated group. Magnification at 40X. 
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The C3 immunostaining for the VCP group showed minimal and extremely focal «5%) C3 
deposition in the epithelium of the injured kidney (Figure lOA). However, the PBS group 
displayed a strong tubular epithelium stain (25-50%) in the injured kidney (Figure lOB) 
suggesting high levels of C3 deposition in the renal tubules following I1R injury. The sham 
group (Figure 10C) and the left (uninjured) kidneys of the VCP and the PBS group showed 
only basal staining between the epithelia. 
A B 
C 

Figure 10: Immunostaining for C3: A) focal deposition in the tubular epithelium of the VCP 
group (arrows) & B) markedly elevated deposition in the renal tubules of the PBS group. C) 
shows basal staining between the epithelium in the sham group. Magnification at 40X. 
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4.3.5 Procedure-5 
4.3.5.1 Blood Urea Nitrogen (BUN) 
As shown in Figure II A below, there were substantial differences (3.7-fold) in the serum BUN 
levels between the natural YCP treatment group and the untreated injured (PBS) group 
suggesting the effective therapeutic potential of YCP. Moreover, there was about 1.73-fold 
lower accumulation of urea in the yeast cell derived humanized recombinant YCP (hrYCP) 
treated animals compared to the PBS group suggesting further the therapeutic value of the 
modified recombinant protein. 
Comparison of serum Urea concentration following I/R injury 
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Figure l1A: Mean Serum Urea concentration following 24 hours bilateral I1R injury (Note: a 3.7-fold 
and 1.73-fold rise in the PBS group compared to the VCP and the hrVCP treatment groups respectively. 
The Sham group showed almost intact urea concentrations. Bars represent standard errors of sample 
mean (mean ± SEM). 
Moreover, a powerful statistical method was used to analyse the significance of the differences 
in serum urea concentration among the different groups. The natural YCP treated animals 
(p<0.05) and the sham controls (p<O.OI) showed statistically significant difference compared 
to the PBS group (Figure 11 B) suggesting the therapeutic potential of the natural YCP. Despite 
the noticeable differences in the mean values, treatment with hrYCP did not show statistically 
significant improvement (p>0.05) in clearing urea from the circulation in comparison to the 
PBS group as shown in Table 1 below. 
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Figure lIB: Comparison of serum urea concentration at baseline ( open boxes) and following 
24 hours ischemialreperfusion injury (grid boxes) of the VCP, hrVCP, PBS and the Sham 
groups. The boxes show the mean value ± standard error and the whiskers display the mean ± 
standard deviation. The analysis was performed by Dawit Y Ghebrehiwet, Department of 
Zoology, VCT using the "R" software package. 
Group VCP hrVCP PBS Sham 
VCP - 0.555049 0.026913 0.639774 
hrVCP 0.555049 - 0.248003 0.096248 
PBS 0.026913 0.248003 - 0.002569 
Sham 0.639774 0.096248 0.002569 -
Table 1: Analysis of varIance followed by the Tukey HSD test. The statistically significant 
differences in urea concentration (p<0.05) are displayed in boldface type. 
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4.3.5.2 Serum Creatinine Concentration 
The creatinine study also showed noticeable rise in the PBS group suggesting the failure of the 
kidneys to excrete the metabolic waste. However, following treatment with the natural VCP or 
the humanized recombinant VCP (hrVCP), the levels of serum creatinine dropped by about 
8.S-fold and 11.6-fold respectively (Figure 12A). However, the ANOVA did not detect 
statistical significance at a p value below 0.05 among the treatment (VCP/hrVCP) and the PBS 
group (Figure 12B). 
Comparison of serum Creatinine concentration following I/R 
injury 
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Figure 12A: Mean Serum Creatinine concentration after 24 hours IschemialReperfusion (I/R) 
injury (Note: -8.S-fold and 11.6-fold increase in the PBS group compared to the VCP and the 
hrVCP treatment groups respectively. The sham group showed normal creatinine 
concentration. Bars represent standard errors of sample mean (mean ± SEM). 
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Figure 12B: Comparison of serum creatinine concentration displaying the baseline (open 
boxes) and after 24 hours ischemiaireperfusion injury (grid boxes) of the YCP, hrYCP, PBS 
and the Sham groups. The boxes show the mean values ± standard error and the whiskers show 
the mean ± standard deviation. The analysis was performed by Dawit Y Ghebrehiwet, 
Department o/Zoology, UeT using the "R" software package. 
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4.3.5.3 Renal Histopathology 
The interpretation of the renal histologies by a blinded pathologist revealed that all the PBS 
group experienced severe and diffuse tubular necrosis (3+ to 4+) in the cortex and partly 
involving the medulla following the ischemiafreperfusion injury (Figure 13D). The severity of 
injury was equivalent in both kidneys suggesting that acute renal failure was induced. 
However, following treatment with VCP or hrVCP, the necrosis was correspondingly focal (1 + 
to 2+) and limited to the cortex (Figure l3B&C) indicating the beneficial role of intervention 
with VCP/hrVCP. The sham group showed normal renal architecture (0 injury score) in both 
kidneys (Figure 13A). 
A B 
C D 

Figure 13: H & E stained renal histology showing A) normal tubular epithelial cells following 
sham 'injury ', B) focal necrosis (arrows) of tubular epithelial cells following natural VCP 
treatment, C) focal necrosis (arrows) of tubular epithelial cells following recombinant VCP 
(hrVCP) treatment and D) diffuse necrosis of tubular epithelial cells in the PBS group 
following 24-hours ischemiafreperfusion (1IR) injury. (Representative fields of the Sham, VCP, 
hrVCP and the PBS groups are shown) (40X objective magnification). 
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4.3.5.4 Early Migration of Inflammatory Cells 
Interestingly, the H&E stained kidney sections of the PBS group showed aggregation of few 
neutrophils suggesting early migration of inflammatory cells (Figure 14). However, there were 
no neutrophils in the Sham or the VCPIhrVCP groups indicating that VCPIhrVCP inhibited 
migration of inflammatory cells to the site of injury following 24 hours ischemialreperfusion 
Injury. 
Figure 14: H & E staining showing recruitment of inflammatory cells (neutrophils) 
following renal IIR injury in the PBS group (arrows) 
(40X objective magnification). 
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4.3.5.5 Immunohistochemistry 
In accordance with the previous findings (Figure 10) and the literature described above, there 
was a direct relationship between C3 deposition and tubular injury. The PBS group showed 
extensive C3 deposition in the renal tubules following 24 hours I1R injury (Figure 15D). 
However, the VCP/hrVCP treatment has abrogated the local C3 deposition (Figure 15B&C). 
The sham group displayed only basal levels of C3 between the epithelia (Figure 15A). 
A B 
C D 

Figure 15: Immunostaining for complement component C3: A) basal staining between the 
epithelia in the sham group; B) minimal deposition in the tubules of the natural VCP treatment 
group (arrows), C) focal deposition in the tubule of the recombinant VCP (hrVCP) treatment 
group (arrows) D) markedly elevated C3 deposition in the renal tubules of the PBS group. 
(40X objective magnification). 
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Summary of the IIR injury techniques employed in the different procedures 
described above 
Procedure Ischemia 
induced by 
Duration of 
Ischemia (min) 
Remarks 
1 Bilateral clamping 
(n = 4) 
45 Animals too small, 
mUltiple bleeding 
caused dehydration 
and rapid deterioration 
of their well-being. 
Animals did not 
survive for 24 hrs 
2 Right nephrectomy 
followed by left 
clamping 
(n = 7) 
45 Animals were under 
continuous anesthesia 
and lying on the OR 
table for prolonged 
period of time. 
Animals did not 
survive for 24 hrs. 
BSA did not have any 
protective role. 
3 Bilateral clamping 
(n = 6) 
45 rVCP administered 
subcutaneously (SC) 
did not inhibit the 
level of circulating 
complement as 
evaluated by 
hemolysis assay 
4 Unilateral clamping 
(n = 19) 
60 The VCPlhrVCP 
combination delivered 
both IV and IP has 
improved kidney 
structure. 
No significant 
differences in the 
serum BUN and 
Creatinine probably 
due to the 
compensatory effect 
of the contralateral 
kidney. 
5 Bilateral clamping 
(n = 14) 
60 The VCPlhrVCP 
treated animals 
showed significant 
structural and 
functional integrity 
compared to the PBS 
group 
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4.4 DISCUSSION 
The direct and indirect involvement of the complement system in a number of animal models 
that mimic human diseases has been strongly implicated. Among the spectrum of diseases, it is 
worth acknowledging the role of complement in atherosclerosis (Thorbjornsdottir2 et aI, 2006), 
head injury (Reynolds et ai, 2004), traumatic brain injury (Hicks et ai, 2002), xenorejection 
(Kahn et ai, 2003; Ghebremariam I et ai, 2005; Ghebremariam2 et aI, 2005), cardiopulmonary 
bypass (Mollnes and Kirschfink, 2006), the recently established recurrent miscarriage (Girardi 
et ai, 2006) and ischemialreperfusion (l1R) injury. 
The role of the complement cascade in renal IIR injury has been repeatedly demonstrated and 
inhibition of the complement system at C3 or C5 level or knocking out Factor B, C3 or C6 
complement components in mice (Zhou et ai, 2000; Thurman et ai, 2003; Thurman et ai, 2006) 
have been shown to protect the animals from renal IIR injury suggesting the critical role of the 
complement cascade in general and the alternative complement pathway in particular in the 
pathophysiology of IIR injury. In this study, we evaluated the roles of the complement 
inhibitors, vaccinia virus infected-mammalian cells derived natural VCP and the recently 
generated humanized recombinant VCP (hrVCP), in modulating renal IIR injury. Previous 
studies have demonstrated the interrelationship between C3 deposition and tissue injury (Stahl 
et ai, 2003; Anderson et ai, 2003). Moreover, 50% reduction in renal IIR injury in C3-deficient 
mice have been reported (Zhou et ai, 2000). It was therefore important to investigate the 
significance and implication ofC3 inhibition by VCP in IIR injury animal model. Recombinant 
VCP (rVCP) has been previously shown (Anderson et ai, 2003) to reduce C3 deposition in 
guinea pig hearts and its subsequent contTibution to prolonged graft survival in a guinea pig-to­
rat cardiac xenotransplantation model. In this study, we report the relationship between C3 
deposition and renal tubular damage and the significant reduction in C3 deposition and 
consequent contribution in conferring partial protection of the VCPlhrVCP treated rats from 
IIR-induced renal injury. There was a significant reduction in the degree of necrosis of tubular 
epithelial cells following treatment. The inhibition of C3 may either be directly protective or 
indirectly either by preventing the assembly of the detrimental membrane attack complex 
(MAC) on tubular cells (Zhou et aI, 2000) or by retaining the heparin like molecule, heparan 
sulfate proteoglycan (HSP), in the tubular basement membrane (TBM). HSP, like heparin, 
might have complement inhibitory activity and therefore maintenance of HSP in the TBM 
using heparin-binding proteins such as VCP may prevent local complement activation and 
hence tubular collapse. 
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For example, Yagmurdur et al (2003) have demonstrated the therapeutic potential of heparin 
following renal IIR injury and was accounted to its complement inhibitory activity and not to 
the anticoagulant property of heparin. 
The lack of complete protection may either be due to the retrospectively speculative lower dose 
of VCPlhrVCP administered or may be due to partial role of complement in renal I1R injury. 
Therefore, to rule out the first assumption, further studies may be needed to elucidate the role 
ofVCPlhrVCP at higher doses and probably more frequent administration of the proteins. 
Even under physiological conditions, VCP has been previously suggested to be speedily 
eliminated from circulation as a result of its smaller size and charge distribution (lha et aI, 
2003). Our immunohistochemical staining results for VCP indicate a strong and specific 
staining of the renal tubules (Figure 9A), where C3 deposited in the PBS group, and some 
staining on the apical membranes of the renal cortical tubular cells as well as in the Bowman' s 
capsule epithelium. Based on this results and observations, we also strengthen the previous 
hypothesis that the fate of the systemically administered soluble VCP may be rapid exclusion 
from circulation mainly when maiming the renal system itself. Therefore, we suggest coupling 
of the protein with some molecules that do not regress its function. However, the size of the 
conjugating molecule needs to be taken into account as a large (160 kDa) complement inhibitor 
was shown not to improve renal I/R injury (Park et aI, 2001) probably because of its size and 
therefore lack of bioavailability in and around the tubules (Thurman et aI, 2003; Thurman et aI, 
2006). It is also advisable if VCP can be coupled with other compounds such as free radical 
scavengers that have healing potentials (Fujii et aI, 2003; Rodriguez-Reynoso et aI, 2004; 
Singh and Chopra, 2004) for a synergistic effect in the treatment of renal IIR injury while 
preventing the rapid elimination of the protein from circulation. 
Interestingly, Park et al (2001) queried the advantage of inhibiting the complement system in 
ameliorating renal ischemiaireperfusion injury following the evaluation of the role of soluble 
Crry in mice prior to I/R-induced renal injury and their article quoted Stein l and colleagues 
(1985) work as they did not achieve any therapeutic value following the abrogation of 
complement using the glycoprotein cobra venom factor (CVF). However, Riedemann and 
Ward (2003) referenced the same work by Stein2 et al (1985) as a therapeutic gain following 
the abrogation of C3 using CVF. It appears that there is a controversial report on the same 
work. 
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Unfortunately, I was not able to access the original article by Stein et al (1985) and therefore 
can support neither of the reports. Meanwhile, Yamada et al (2004) evaluated the therapeutic 
role of CVF in wild type and CD551CD59 double knock out mice following renal 
ischemia/reperfusion injury and demonstrated that CVF partially protected the highly 
susceptible CD551CD59 deficient mice to a degree of res istancel susceptibility of the wild type 
mice. However, CVF did not offer significant protection in the wild type animals suggesting 
the limited potential of the glycoprotein. Conversely, a recent report (Mollnes and Kirschfink, 
2006) described CVF as "potent complement activator " rather than "complement inhibitor " 
likewise; Lachmann (2006) described CVF as an alternative complement pathway activator. 
Therefore the inability of the glycoprotein to reduce tubular necrosis following VR-induced 
renal injury, at least in wild type rats, may be accounted to its bulky size (149 kDa) and 
therefore limited bioavailability where required, and probably due to its controversial 
biological effect. 
In the unilateral IIR injury model, we did not perceive any evidence of exogenous cells such as 
neutrophil recruitment to the site of injury in any of the groups. However, in the bilateral VR 
injury model, there was early migration of neutrophils to the site injury in the untreated injured 
(PBS) group suggesting the severity of the induced injury in the latter model. 
In conclusion, the lack of significant elevation in BUN and creatinine levels in the unilateral 
VR injury model, relative to the structural damage, may be due to the compensatory ability of 
the intact contralateral kidney to excrete metabolic wastes. Subclinically, this model implies 
that in conditions where BUN and creatinine are used as surrogate markers of renal function 
the patient may be misdiagnosed due to the masking ofthe injured kidney by the compensatory 
effect of the contralateral kidney to expel the metabolic wastes from circulation. However, the 
ability of the kidneys to excrete these metabolic wastes was significantly compromised in the 
untreated (PBS) group of the bilateral IIR injury model. Therefore, this model may be relevant 
to a clinical condition reflecting reduced excretion of metabolic wastes as a result of tubular 
damage. Overall, the natural VCP showed a better preservation of kidney structure and 
function than the hrVCP following renal VR injury. 
It is also sensible to establish different animal models where the renal IIR injury is induced by 
various independent causes such as drug, surgical procedure or sepsis in order to verify if the 
alternative complement pathway remains the driving force despite the etiology of the injury. 
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CHAPTER 5: PROJECT SUMIvIARY 

The first two chapters of the thesis explored the genesis of poxviruses and their set of proteins 
known as complement regulatory proteins (CRPs) with emphasis on the vaccinia virus 
complement control protein (VCP). HistoricalIy, it is the significant amino acid homology 
(38%) ofVCP to the human complement-4b binding protein (C4b-BP) that caught the minds of 
researchers. Subsequently, the mimicry of poxviral proteins to host complement control 
proteins was elucidated in some other members of the poxviruses. 
For about 18 years folIowing its identification, a vast number of researches have been done to 
understand and exploit the potential benefits of VCP. A cluster of the work cited in this section 
include identification of the abilities of VCP to inhibit the classical and the alternative 
pathways of complement activation, its heparin binding property, its cloning and expression in 
Pichia pastoris yeast system, its crystal structure and modeling studies as welI as its robustness 
to a handful of adverse conditions. The present work has characterized the functions of two 
modified proteins with single and triple amino acid changes in the recombinant VCP (rVCP) 
sequence ("CHAPTER 3"). The proteins, named hrVCPEI08K and hrvCPH98y, EI02K, E120K; 
inhibited both the classical and the alternative complement pathways better than rVCP with the 
latter protein displaying up to lOO-fold increased activity in inhibiting both pathways 
independently. Moreover, the modeling study revealed significant increase in the net positive 
charge of the modified proteins. In addition to the enhanced in vitro activity, the in vivo role of 
hrvCPH98Y, EI02K, E120K (abbreviated as hrVCP) was evaluated in a rat ischemia/reperfusion 
(I/R) injury model ("CHAPTER 4"). 
Both the unilateral and the bilateral IIR injury models established in this project have indicated 
the beneficial roles of the natural VCP produced from vaccinia virus-infected celIs and the 
yeast cells expressed hrVCP in conferring partial protection from I/R-induced renal injury. The 
serum profile of the VCP/hrVCP treated animals showed low levels of the nitrogenous wastes 
(urea and creatinine) compared to the accumulated levels in the phosphate buffered saline 
(PBS) administered group. Similarly, the histological study showed partial damage of the 
tubular epithelial celIs compared to the extensive necrosis in the PBS group. Moreover, the 
immunohistochemical study revealed focal levels of the injurious complement component (C3) 
in the renal tubules of the VCPlhrVCP groups compared to the diffuse C3 staining in the PBS 
group. 
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RECOMMENDATION 

This project addressed various research queries from different angles. The first part of the work 
has tried to optimise the production of recombinant VCP both in the flask and fermentor. The 
work carried out a battery of fermentation trials with various modifications to the levels of 
dissolved oxygen (d02), pH and agitation. However, this work has only solved the puzzle of 
optimisation in part and therefore future work needs to continue the process of optimisation for 
consistent and large-scale production of VCP. The up-coming work needs to give particular 
emphasis to the pH, agitation and the level of d02 supplied, as they appear to be the most 
critical variables even when changed subtly. Moreover, it might be essential to compare and 
contrast the production of VCP using both synthetic and complex media in the fermentor. 
Furthermore, it is advisable to use self-autoclavable fermentors to minimize the risk of 
contamination and also it is important to incorporate proper cooling system (rather than a 
chiller) in order to cope with the load of heat generated during the growth phase. 
The second part of the work has established two animal models of renal ischemiaJreperfusion 
(l/R) injury that mimic clinical condition. The work has addressed the beneficial role of 
complement inhibition using VCP/hrVCP in minimizing renal l/R injury. However, the work 
was done in small animals (rats) -and fewer in number. Therefore, future work may need to 
expand the findings in large number of animals. Moreover, despite their equivalent in vitro 
activity in inhibiting human complement, the natural VCP showed relatively better ability in 
preserving the rat kidneys than the humanized recombinant VCP (hrVCP) suggesting that 
'humanizing' VCP may have increased the specie-distance from the rodent model used here 
and therefore its therapeutic potential may need to be evaluated in higher-order animals 
preferably non-human primates. The future work may also need to evaluate the role of VCP at 
higher doses and probably more frequent injections to elucidate if it is possible to achieve dose 
dependent additional protection. Meanwhile, it may be worthy to couple VCP with a free 
radical scavenger to investigate if there is a synergistic effect in diminishing l/R-induced renal 
injury while delaying the rapid elimination of, the otherwise small, VCP from circulation. 
However, the total size after conjugation has to be taken into account as the protein needs to be 
available in and around the tubules to prevent necrotic damage. 
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The last part of my work (not included in the thesis due to the lack of direct relevance to the 
scope ofmy proposed project) has started the long and obscured immunogenicity study of VCP 
using sera from smallpox vaccinated and unvaccinated (or unaware of their vaccination) 
subjects. Although very preliminary, the findings indicated the presence of antibodies in 
human sera reactive to VCP despite the status of vaccination suggesting that the administration 
of VCP in humans may cause some immune reaction and therefore should initially be 
performed under close clinical scrutiny or it might be pertinent to perform simple skin allergy 
test in order to grasp the immediate effect of VCP administration in humans before proceeding 
to clinical trails. However, the immunogenic potential of VCP need to be first confirmed by 
screening large number of vaccinated and unvaccinated individuals (preferably individuals 
born after the global eradication of smallpox) both by ELISA and western blot. 
Moreover, the anti-VCP antibody raised in rabbits (rabbit anti-VCP) had also been shown to 
significantly react to the vaccinia virus total protein in the absence of VCP and following 
preadsorption with VCP at various dilutions, suggesting some sort of cross-reactivity. Future 
work may need to screen different batches of rabbit anti-VCPs and may need to expand the 
work by immunizing rabbits with VCP, monitoring the generation of antibodies, and then 
challenging the animals with vaccinia virus to elucidate if there is in vivo cross-reactivity and 
hence cross-protection against poxviral challenge compared to unimmunized controls. 
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APPENDIX A 

MEDIA, BUFFERS, AND SOLUTIONS 

MEDIA 
MMH: 
For II: 

Dissolve 15g agar in 700ml water & autoclave 

Cool to -50°C and add: 

100miiOX YNB (dissolve 13.4g in 100mi water & filter sterilize) 

2ml 500X biotin (dissolve 0.02g D-biotin in 100mi water & filter sterilize) 

100ml methanol (10%, filter sterilized) 

Adjust volume with distilled water 

Pour & store plates at 4°C 

YPD: 
For 500ml: 
5 g yeast extract 
109 peptone 
109 agar 
Dissolve in -300ml distilled water & autoclave 
Add 100mi filter sterilized glucose [20%(w/v)] 
Adjust volume with distilled water 
Pour & store plates at 4°C 
RDB: 
For 250ml: 

Composition-l (prewarmed to 45°C): 

Dissolve 5g (w/v) dextrose in 25ml water & filter sterilize 

Add: 

25ml filter sterilized lOX YNB 

0.5ml 500X filter sterilized biotin 

2.5ml IOOX amino acids (O.5g each of glutamic acid, lysine, leucine, isoleucine & methionine 

in lOOml of distilled water. Filter sterilize) 

20ml autoclaved water 
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Composition-2: 

Dissolve 46.5g of sorbitol & 5g of agar in 175ml water 

Autoclave 

Cool down & mix to composition-l (above) 

Pour & store plates at 4°C. 

BMGY: 
For 11: 

Dissolve 109 yeast extract & 20g peptone in ~600ml water 

Autoclave, cool to ~450C 

Add: 

100ml autoclaved phosphate buffer (lM; pH 6.0) (dissolve ~780ml of 1M KH2P04 and mix 

with ~120ml 1M K2HP04 adjust pH to 6.0 with KOH & adjust volume with distilled water) 

100ml autoclaved glycerol (l 0%) 

100ml filter sterilized YNB (lOX) 

2ml filter sterilized 500X biotin 

Adjust volume with distilled water 

BMMY (4%): 

For 11: 

Dissolve 109 yeast extract & 20g peptone in ~600ml water 

Autoclave, cool to -45°C 

Add: 

100mi autoclaved phosphate buffer (lM; pH 6.0) as above 

100m I filter sterilized methanol (4%) 

100mi filter sterilized YNB (lOX) 

2ml filter sterilized 500X biotin 

Adjust volume with distilled water 

Buffered Methanol: 
For 11: 

96.5ml phosphate buffer (pH 6.0) 

38.5ml filter sterile absolute methanol 

Adjust volume with distilled water 

124 
Basal 
11: 
40g glycerol 
dipotassium sulphate (K2S04) 
sulphate heptahydrate (MgS04.7H20) 
4. J potassium hydroxide (KOH) 
27ml Phosphoric acid (85%) H3P04 
O.9g Calcium sulphate (CaS04) 
sterilize store at 4°C 
PTMI Trace Salts: 

For 11: 

Add: 

cupric sulphate (CuS04.5H20) 
0.08g sodium iodide (NaI) 
manganous sulphate monohydrate (MnS04.H20) 
boric (H3B03) 
Na2Mo04.2H20 
0.5g cobalt chloride (CoCh) 
20g zinc chloride (ZnCh) 
65g ferrious sulphate (FeS02.H20) 
3Aml 500x biotin 
Sml sulphuric (H2S04) 
Filter sterilize store at 4°C 
BUFFERS & SOLUTIONS 

Tris-Acetate EDTA (TAE) Electrophoresis buffer: 

For 11: 

Dissolve 48.4g Tris-base in 11.42ml gla::.:ial acetic acid 
Add 20ml EDTA (0.5M; pH 8.0) 
Adjust volume with distilled water 
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SDS-PAGE "'-'''..... n • .:;. Buffer Mix: 

Mix 2 volumes of supplied loading buffer (Invitrogen) with 1 volume of2-mereaptethanol 

Coomassie Staining Solution: 

Dissolve 1 Coomassie R-2S0 in 227m! methanol 

Add 227ml of distilled water mix 

Add 46m! glacial acid 

Filter before use 

Destaining Solution: 

For 280ml: 

90m! absolute methanol 

30ml acid 

160ml distilled water 

Chromatography Buffer: 

SOmM sodium acetate 

Adjust to pH 

SDS-PAGE Resolving (12%): 
2.Sml distilled water 
3ml 30% acryJamide & O.8g mix) 
1.9ml I.SM Tris-base (PH 8.8) 

7SJ.LI SDS (10%) 

7SJ.Ll APS (10%) 

SJ.LI TEMED 

SDS-PAGE Stacking (5%): 
2m! distilled water 
aery!amide (as above) 
37SJ.LIIM (pH 6.8) 
30J.LI (10%) 
30J.Li (10%) 
SJ.LI 
Western Blot Transfer Buffer: 
For II: 

Dissolve S.8g Tris-base & 2.93g glycine in water 

Add 200ml absolute methanol 

Adjust volume with distilled water 

Store at 4°C 

Ponceau S Stain: 

For 100ml: 

Dissolve 0.1 g ponceau S in I % glacial acetic acid 

Cover the bottle with aluminium foil & store at room temperature. 

Tris-Buffered Saline (TBS): 
For 11 
Dissolve 7.S6g Tris-base & Ilg NaCI 
Adjust volume with distilled water & store at room temperature. 
TBS-T (0.1 %): 
For SOOml: 
Mix 449.Sml TBS (from above) with O.Sml Tween-20 
Store at room temperature 
Western Blot Blocking Solution (5%): 
For 100ml: 
Dissolve Sg non-fat milk in TBS (above) 

Adjust volume with TBS 

Western Blot Blocking Solution (0.5%): 

For 100ml: 

Dissolve O.Sg non-fat milk in TBS (above) 

Adjust volume with TBS 

Primary (Rabbit anti-yeP) dilution (1:1000): 

Mix lOml ofO.S% blocking solution (above) with 1O~1 of rabbit anti-VCP 
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Secondary (donkey anti-rabbit) dilution (1:12500): 

Mix 12.Sml ofO.S% blocking solution (above) with 11-11 of POD-linked donkey anti-rabbit 

Detection Reagent Mix: Mix the supplied solution B to solution A at a ratio of 1: 100 in a dark 

room. 

Crystal Violet Stain: 

For 100ml: 

10ml crystal violet stock solution 

10mi formaldehyde stock solution 

80ml distilled water 

Complement Specimen Diluent: 

"Contains PBS, 0.05% Tween-20, 2.5% protein stabilizers, 0.035% Pro Clin 300. " (Quidel 

Corporation Insert) 

Quidel Wash Buffer (IX): 

"Contains PBS, 0.05% Tween-20, 0.01% thimerosal. "(Quidel Corporation Insert) 

Quidel Substrate Solution: 

Mix S0l-11 ofthe supplied substrate concentrate with 1 ml of substrate diluent (supplied) 

ELISA Blocking Solution: 

For 100ml: 

Mix O.Sg BSA with O.Sml Tween-20 

Adjust volume with PBS (pH 7.2) 

ELISA Wash Buffer: 

For 100ml: 

Mix 1001-11 ofTween-20 with PBS (pH 7.2) 

PBS-T (0.1 %): 

For 100ml: 

Mix 1001-11 ofTween-20 with PBS (pH 7.2) 
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APPENDIXB 

4-20% Tris-GJycine 
S~PAGEgel 
Figure: Protein Molecular Weight Marker (Reproducedfrom www.promega.comfor the sole 
purpose ofdemonstration). 
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O,l%agarc<~ 
Figure: Molecular Weight Marker (lkb) (Reproducedfrom '------~~,....~~~J the 
sole purpose ofdemonstration). 
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• Mu/ti-Languag9 Primary 
Control Unit IPCU) controls 
and displays up to 32-process 
parameters. S·imultaneousl\' 
handlBS up to four vessels 
pHfd02 CootroUer regulates 
a pH probe and a DO probe 
Power Controller regulates 
tempeTature, agitation and 
up to five pumps 
Levll4s/Foam Controll9r 
regulates antifoam, as well as 
media addition/ll.>m0V31 
Rotam9.ter for manual 
9as flow control 
Pump MOdule has four independent 
pumps for acid/base, antifoam, liquid 
addition/rem0V31. One module may 
be shall.>d by multiple vessels 
Direct Driv9 
Condenser 0 
StGrilll Samplllr 
Autoclavablll V9SSel 
Stand is provided with 
heat-blanketed vessels. 
H~tBlanket 
with two viewing 
windows provides 
precise temperatu Il.> 
control for single­
walled vessels 
Figure: BioFlo 110 Benchtop Fermentor (Reproducedfrom www. e n z yme . ucd .ie/Sc i ence/ 
Equipmentl{ermentor for the sole purpose ofdemonstration). 
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pPIC9 Stu I 
8..0 kb! 
Figure: pPIC9 vector Map (Reproducedfrom www.invitrogen.com/or the sole purpose 0/ 
demonstration). 
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